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Abstract 
Influenza virus remains a public health burden. Each year millions of people are 
infected and potentially thousands succumb to illness. In recent years the efficacy of the 
live-attenuated influenza vaccine (LAIV) has been substantially lower than the traditional 
inactivated influenza virus (IIV) vaccine, primarily due to the vaccine components’ 
inability to efficiently replicate in the human nasal epithelium. The influenza 
Hemagglutinin (HA) receptor lies at the heart of this issue. When LAIVs are grown in 
eggs for production, The HA receptor of LAIV is mutated resulting amino acid changes 
involving critical residues in and around the HA receptor binding site. These HA 
receptor mutations lead to a dramatic change in the receptor-ligand binding profile, 
decreased replication at higher temperatures, decreased host innate immune responses 
to the virus and a reduced ability to infect cells present in the human nasal epithelium. 
All of these side effects of egg adaptation can decrease LAIV effectiveness and will 
persist until the process of manufacturing vaccine is significantly changed.  
 In recent years, the neuraminidase (NA) of human H3N2 viruses gained an n-
linked glycosylation site which affected the function and antigenicity of the protein. This 
n-linked glycosylation on the human H3N2 NA is situated directly over the active site of 
the NA protein. The research herein demonstrates that this n-linked glycosylation 
decreases enzymatic activity by nearly 50%, decreases infectious virus production in 
viral growth assays, and inhibited the binding of active site-specific anti-NA antibodies. 
This fitness trade off, enzymatic activity and viral replication for immune evasion, is now 
seen in virtually all human H3N2 viruses. The once promising universal vaccine epitope 
found in the active site of human H3N2 NAs is now rendered useless by this universal 
H3N2 NA glycosylation. This dissertation serves to further our understanding of vaccine 
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efficacy and influenza virus evolution. Together these studies demonstrate that the HA 
and NA proteins of the LAIV and seasonal human influenza A viruses are major 
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General Influenza Virus Biology 
Influenza viruses are members of the Orthomyxoviridae family of viruses; a 
family that to date includes four genera of influenza viruses (A, B, C and D)[1, 2]. 
Influenza A viruses (IAV), the focus of this dissertation, are a major public health 
concern primary because of hospitalizations, economic loss and death due to IAV 
infection [3].  
 The influenza A genome consists of eight separate, self-replicating segments. 
The genome is a negative sense single stranded ribonucleic acid (RNA) genome. Each 
segment encodes for at least one protein, and some segments (matrix, non-structural, 
polymerase basic 1) encode for multiple spice variants. Together, the IAV genome 
encodes for 10-14 proteins depending on the specific subtype [1, 4-8]. The IAV particle 
is enveloped, with the membrane being derived from the host cell during viral budding. 
IAV particles are either spherical or membranous depending on the subtype. The IAV 
viral envelope is studded with viral proteins, two of which are heavily glycosylated. 
These proteins, hemagglutinin (HA), neuraminidase (NA) and matrix protein 2 (M2) 
function in entry, attachment and uncoating of the genome. Within the viral envelope, 
IAV matrix protein 1 (M1) coats the luminal surface of the viral lipid membrane (Figure 
1.1) [9-14]. The core of the virion contains the eight self-replicating segments. Each viral 
genomic segment is coated in viral nucleoprotein (NP) and is anchored at the 5’ and 3’ 
end by the polymerase complex (vRNP). The IAV polymerase complex is a heterotrimer 
complex consisting of the polymerase acidic (PA), polymerase basic 1 (PB1) and 
polymerase basic 2 (PB2) (Figure 1.1) [15-20]. Each polymerase unit in complex with a 
viral genomic segment replicates independently of other segments. The viral non-
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structural protein 2 (NS2) is found within the viral particle as well, and facilitates 
movement of the vRNP into and out of the host cell nucleus [19]. 
Influenza Entry into Host Cells 
 IAV primarily infects airway epithelial cells [21, 22]. The receptor for IAV, the HA 
protein, binds to sialic acid on host cells to initiate infection. Sialic acid is the last sugar 
present on host cell N-linked glycans suitable for HA receptor binding and entry. Sialic 
acid is the common name for a group of nine carbon sugars named neuraminic acid. 
The most common neuraminic acid, and the accepted HA receptor ligand is N-acetyl 
neuraminic acid (Neu5Ac). In all species infected by IAV, the HA receptor binds to two 
major types of Neu5Ac, “α2,6 SA” or “α2,3 SA”. Where α2,6 or α2,3 refers to the 
Neu5Ac carbon-carbon linkage to the penultimate sugar in the glycan, typically 
galactose [23]. The α2,6 vs α2,3 for Neu5ac linkages dictate IAV host tropism. Human 
IAVs canonically use the α2,6 sialic acid receptor ligand and avian influenza viruses 
canonically use the α2,3 sialic acid receptor ligand [21, 22, 24, 25]. The type of sialic 
acid linkage is an important barrier to infection for human or avian IAVs. Additionally, as 
discussed later, IAV HA using an α2,6 vs α2,3 Neu5ac linkage is an important 
consideration when human vaccine candidate viruses are passaged through 
embryonated hen’s eggs during vaccine manufacturing. 
 Once the HA receptor binds the sialic acid, the virus particle enters the host cell 
through the endocytic pathway or through the micropinocytosis pathway [26-28]. Within 
the endosome, the pH of endocytic vesicles drops to a pH of 5 to 5.5 [11, 26, 27, 29]. 
This pH lowering event is critical to the IAV particle to initiate a number of downstream 
effects. Influenza HA protein is a type I fusion protein with the fusion peptide (a 
hydrophobic peptide capable of inserting into the host cell membrane) buried within the 
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HA structure [27, 30-33]. Once the pH of the endosome lowers, the HA protein 
undergoes a conformational change which exposes the fusion peptide of the HA 
protein. This allows the viral membrane and the host endosome to fuse. Additionally, 
the low pH environment of the endosome allows the viral M2 protein to acidify the inside 
of the viral particle. This allows the release of vRNPs into the cytoplasm by releasing 
vRNPs that are bound to viral M1 within the viral protein [14, 28, 34-36]. Once the viral 
membrane has fused with the host endocytic vesicle and the vRNPs have released from 
the viral particle, the vRNPs are free to move about the host cell and initiate genome 
replication, transcription and ultimately translation of viral proteins (Figure 1.2). 
Influenza Genome Replication and Transcription 
 After vRNP complexes are released into the host cell cytoplasm, the vRNP 
complex must enter the nucleus to replicate and transcribe the genomic material. This is 
accomplished by utilizing the host cell importins which bind to nuclear import signals 
present on the viral nucleoprotein [37-39]. All eight segments of IAV enter the nucleus 
and begin transcription and replication of the genome.  
Influenza A genome replication is performed via a copy RNA intermediate. The 
polymerase complex accomplishes this partly due to the 5’ and 3’ end of each segment 
and numerous secondary structures to self-prime polymerase activity and induce 
production of copy vRNA. Recent studies have shown that adenine triphosphate and 
guanine triphosphate bound to the vRNA in the vRNP complex and initiate transcription 
of the copy RNA as sort of a priming event [1, 37, 40, 41]. As copy RNA is being 
transcribed, it binds to free nucleoprotein within the nucleus and the polymerase 
complex to form a new vRNP complex [1, 15, 37]. At this point, the copy RNA bound to 
vRNP can initiate transcription of vRNA, which will be packaged in the viral particles. 
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The IAV polymerase complex is an RNA dependent RNA polymerase with no 
functional proof reading exonuclease mechanism, meaning that in approximately every 
10,000 nucleotides transcribed one will be an incorrect base pair [42, 43]. Considering 
the IAV genome is approximately 13,200 nucleotides in total, each progeny virion will, 
on average, have one incorrectly copied nucleotide. While a considerable amount of 
these mutations could be deleterious, synonymous or occurring outside the open 
reading frame of each segment, a small amount of mutations will incur a fitness benefit 
to the virus. Furthermore, an infected cell can product over one million infectious 
particles, it’s clear that the process of error prone genome replication allows IAV to 
quickly adapt to new hosts and immune pressure by continually altering the amino acid 
sequence of all eight segments at random [7, 42, 43]. The vRNP complex exits the 
nucleus via binding to another viral protein, NEP, which facilitates recruitment of host 
cell exportins. Once free of the nucleus, vRNPs are moved to the plasma membrane via 
microtubules, where they are packaged in a budding influenza virus [7]. 
Influenza Particle Assembly 
Freshly transcribed viral mRNAs are produced and exported from the nucleus, 
undergoing splicing if necessary, and then bind free ribosomal units found in the host 
cell cytoplasm. Influenza A viral mRNAs are similar to host mRNAs in structure 
(containing both a 5’ cap and 3’ poly A tail) and as such the translation of protein is 
similar to translating host cell proteins. Out of the eight segments in IAV, five are 
synthesized in the cytoplasm by free ribosomes and will traffic in the cytoplasm and into 
the nucleus of the cell. The other three proteins, NA, HA and M2 are transmembrane 
proteins and require a different mechanism of translation. When a viral mRNA encoding 
an influenza transmembrane protein binds a free ribosomal subunit, the ribosome-
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mRNA complex is directed to the cellular endoplasmic reticulum (ER) as is the case for 
normal cellular transmembrane proteins. This targeting event is directed by the 
transmembrane domain, a sequence of hydrophobic amino acids, in the case of NA and 
M2 [7, 44]. The HA protein has a cleaved signal peptide that facilitates trafficking to the 
ER [7, 44]. Peptide synthesis occurs through a translocon protein in the ER membrane, 
allowing the growing peptide chain for HA, NA and M2 to enter the lumen of the ER [7].  
 Within the lumen of the ER a variety of post translational processing events take 
place for the three transmembrane proteins. The HA and NA contain a number of N-
linked glycans, which are added by host cell oligosaccharyltransferases to the amino 
acid sequence N-X-T/S in the viral protein. Where X can be any amino acid besides 
proline. These N-glycosylations are added as a high mannose residue in the ER of the 
host cell and modified as the protein travels through the Golgi complex of the cell [45, 
46], typical of normal n-linked glycosylations. Additionally, the HA and NA proteins 
exists at homotrimer and homotetramer proteins, respectively, on the influenza viral 
envelope. These are assembled within the ER and cysteine disulfide exist between 
monomers of each protein and within individual protein chains to hold the tertiary and 
quaternary structures together. The M2 protein of IAV does not have canonical N-linked 
glycosylation sites but does contain cysteine disulfide bonds [1, 7, 47, 48].  
 To assemble the influenza A particle, all components must meet at the apical 
plasma membrane. In the cytoplasm, vRNP complexes are trafficked to the apical 
plasma membrane via the host cell exocytic pathway. At the apical surface, M1 binds 
the host plasma membrane to vRNP complexes [1, 7, 49-51].  
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 Hemagglutinin, NA and M2 proteins are embedded within the apical plasma 
membrane and congregate within lipid rafts and Influenza particles are rich in 
cholesterol [52-54]. On the viral surface, the distribution of HA and NA is not completely 
random. Clusters of NA proteins surrounded by HA or single NA proteins surrounded by 
HA proteins have been observed. The significance of such is not completely understood 
but might allow the virus to efficiently move through mucin rich respiratory epithelial 
tracts [55-57]. In order to complete the influenza particle, cytoplasmic vRNPs must 
reach the apical surface and interact with the cytoplasmic tail of these three 
transmembrane influenza proteins. Particle formation and viral budding is orchestrated 
through the M2 ion channel protein, partly because M2 is a membrane bending protein. 
M2 contains an alpha helix with hydrophobic amino acids that extend into the 
hydrophobic core of the plasma membrane lipid bilayer [58, 59]. Membrane bending 
leads to membrane scission, and particle formation.  
 As the influenza particle is formed and released from the cell, the neuraminidase 
protein is required for complete viral release. Influenza HA proteins bind sialic acid 
present on both host and cell proteins, and without NA activity the viral particle will not 
effectively bud from the cell, resulting in numerous viral particles stuck to the cell 
surface. Neuraminidase activity removes sialic acid ligands from both host and viral 
glycoproteins preventing the HA protein from binding to viral particles and host cell 
glycoproteins [60, 61]. In the presence of NA inhibitor or mutant NA function, influenza 
viral particles are formed but not released from the cell surface which effectively stops 
viral spread throughout tissue [62, 63]. In the human nasal epithelium, the site of 
seasonal influenza viral replication, viral movement from cell to cell involves 
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neuraminidase cleaving decoy sialic acid receptors from mucins and viral particles 
traveling through respiratory mucins. When the viral particle reaches another epithelial 
cell, the viral life cycle is initiated once again. 
Influenza A Hemagglutinin Protein  
The IAV HA exists in nature in a at least 18 different antigenically distinct groups. 
In humans the H3 and H1 groups currently cause seasonal illness, with H2 and an 
antigenically distinct additional H1 virus previously circulating. Hemagglutinin molecules 
are further divided into clades. Influenza HA clades are proteins with minor changes in 
sequence related to a common ancestor, clades are typically noted for their antigenic 
difference or sequence differences from one another [7, 64].  
Hemagglutinin is not only a defining protein to classify influenza virus, it is the 
receptor for influenza virus and facilitates viral entry via binding to sialic acid present on 
host cells. The HA protein is a type 1 transmembrane protein, meaning the N terminus 
of the protein is on the outside of the viral particle and the C terminus is on the inside of 
the viral particle. There are two distinct regions of the HA molecule which will be 
discussed, the stalk region which contains the fusion peptide and the head region which 
contains the receptor binding domain [65, 66]. The head region is the immunodominant 
region of the HA, and the vast majority of humoral immunity produced during infection is 
directed against the HA [65, 66]. 
 The HA protein is synthesized in ribosomes bound to the ER of the host cell. 
Proteolytic cleavage of the stalk is necessary for infection, HA function and freeing the 
fusion peptide to function [67-69]. For the seasonal human influenza virus, serine 
proteases (specially tryptase-like proteases) cleave the HA to proteolytically activate it. 
This cleavage event occurs either intracellularly or through membrane bound tryptases 
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[67-69]. H3N2 influenza HA has been shown to use tryptases secreted by respiratory 
epithelial cells, which to a certain extent dictates host cell tropism [69, 70].  
During processing and export of the HA protein to the cellular surface a number 
of glycosylations are added to n-linked glycosylation sites in the HA protein. For the 
currently circulating H3N2 viruses in 2017-2018, there are seven to eight N-linked 
glycosylation sites depending on clade of HA [71, 72]. The majority of these 
glycosylation sites are present in the head of the HA molecule. When the H3N2 virus 
first emerged in the human population in 1968 there were seven n-linked glycosylations 
sites on the HA protein [7, 64]. However, only two sites were present in the head of HA. 
The other five potential glycosylation sites were present in the stalk region of the protein 
[71, 72]. As the HA protein evolves as viruses move from species to species, 
glycosylation sites are moved around the HA molecule as immune pressure mounts. 
This allows the influenza HA protein to continuously evade host immunity by shielding 
the immunodominant HA head region via N-linked glycosylation. 
 Sialic acid is the receptor for IAV, and it exists in two types. Viruses that circulate 
in avian populations such as migratory birds and domestic poultry bind to a sialic acid 
molecule in the α2,3 conformation. This nomenclature refers to the linkage of the 2nd 
carbon on sialic acid to the penultimate sugar in the carbohydrate chain, usually 
galactose. Viruses that circulate in humans bind to sialic acid in the α2,6 linkage, with 
sialic acid covalently linked to the 6th carbon which is typically galactose. This is an 
important barrier in transmission and determining host range. Swine influenza viruses 
utilize both α2,6 and α2,3 sialic acid, highlighting their importance as a vehicle to mix 
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human and avian influenza viruses [73-77]. Human seasonal influenza viruses prefer to 
bind α2,6 sialic acid. [78]. 
In recent years the composition of glycan attached to the sialic acid has come 
under focus. The Center for Functional Glycomics (CFG) routinely conducts arrays with 
influenza viruses to determine the sialic acid preference and type of glycan preferred by 
the influenza HA. There are a number of studies showing that the length, type and even 
shape of the glycan can dictate HA receptor preferences [79, 80]. Furthermore, two 
influenza viruses with a similar sialic acid binding preference can show dramatically 
different preferences for the underlying sugars in carbohydrate chains, suggesting that 
other molecules in the glycan play a role in dictating viral receptor preference [81, 82]. 
Influenza A Neuraminidase Protein  
Neuraminidase is a mushroom shaped homotetramer viral glycoprotein, of which 
9 antigenically distinct groups exist in nature. Neuraminidase is a type 2 transmembrane 
protein, meaning the C terminus of the peptide is on the outside of the viral particle, and 
the N terminus of the peptide is within the viral particle. Neuraminidase is a sialidase by 
nature, meaning it removes sialic acid by cleaving the linkage between sialic acid and 
the penultimate sugar on a carbohydrate chain [61, 83, 84]. This allows the viral particle 
to travel through respiratory mucins and prevents the HA receptor from binding to 
mucins and not the target cell. As the viral particle is being released from the infected 
cell, NA removes sialic acid from both host and viral glycoproteins. This prevents the HA 
receptor from binding to other viral particles in the vicinity or re-infecting the cell it just 
budded from [1, 61].  
 The head region of NA, which contains the catalytic enzyme region, extends 
outward from the virion surface. The catalytic site of neuraminidase is highly conserved 
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across all influenza A NA subtypes and influenza B. There are two groups of amino 
acids necessary for NA function. Amino acids that coordinate sialic acid in the enzyme 
pocket (119E, 156R, 178S, 198D/N, 222I, 227E, 274H, 277E, 294N, 425E) orient sialic 
acid inside the active site for the catalytic residues (118R, 151D, 152R, 224R, 276E, 
292R, 371R, 406Y) to perform the enzymatic reaction [83, 84]. Most circulating human 
NAs are able to effectively remove either α2,3 or α2,6 sialic acid from glycoproteins, so 
the stringent specificity seen in comparing avian and human HA receptor preference is 
not seen in NA proteins. However, both N1 and N2 show an increased reactivity 
towards α2,3 sialic acid vs α2,6 sialic acid. Human N2 NA is roughly 3 times more 
active against α2,3 vs α2,6 sialic acid [61, 85-87]. This suggests that removal of sialic 
acid attached to mucins (α2,3 linkage) is critical for viral fitness. In certain experiments, 
scanning mutagenesis revealed that changing residues involved with enzymatic function 
or coordinating the sialic acid substrate results in a significantly decreased enzyme 
function and viral replication [88, 89]. These conserved residues in all influenza A and B 
NA proteins protein allow for pan-NA inhibitors and monoclonal antibodies to target any 
accessibly residues within this sequence. Viral isolates that show resistance to chemical 
inhibitors of NA function typically show a decreased NA activity and/or viral fitness [88, 
89]. One prominent example of this is resistance seen in pre-2009 pandemic H1N1 
viruses. These isolates had substantial resistance to oseltamivir, a common NA 
inhibitor. These isolates with this NA mutation, H274Y, had decreased replication 
phenotype and a decreased enzymatic activity, highlighting the trade off in being able to 
resist inhibitors but occurring a significant fitness disadvantage [90]. Compensatory 
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mutations occurred in both the HA and NA restored some aspect of viral fitness, 
however this resistant strain was replaced with the pandemic 2009 H1N1 event [90, 91]. 
Human N2 neuraminidase proteins contain between 8 and 9 N-linked 
glycosylation sites and there are no predicted o-linked glycosylation sequences similar 
to the HA protein [61, 84]. Neuraminidase glycosylations occur in the stalk to stabilize 
the protein and the head of the protein, which are likely shielding antigenic sites [92, 
93]. The NA protein is a complex molecule and has recently re-entered the spotlight as 
an important antigen in developing universal influenza vaccines [26, 94-96]. 
Understanding how the NA protein evolves year to year will become as important as 
understanding HA mutations when designing vaccines, studying virus evolution and 
predicting pandemics. 
Balanced Activity of Influenza HA and NA Proteins  
Influenza virus fitness is a general term relating to the ability to infect, reproduce 
and spread virus to different hosts. One crucial part of this process the functional 
balance between the HA and NA proteins. Both influenza proteins interact with the 
same host molecule, sialic acid. As such, balancing the activity of each protein to this 
ligand is important in infectivity and release of progeny virions [97-99]. In broad strokes, 
an influenza particle with a balance HA/NA interaction will be able to travel through 
respiratory mucins, bind to target receptor, release from the cell at the end of the viral 
life cycle and infect other respiratory epithelial cells [56, 97, 100]. If the HA receptor 
activity is too strong in relation to NA activity, the HA protein could potentially bind too 
strongly to respiratory mucins and not reach the target cell or not be able to bud 
effectively from the cell if infection is successful [98]. Alternatively, too strong of an NA 
protein activity in relation to the HA protein could lead to destruction of the IAV receptor 
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blocking initiation of infection and entry into the host cell [97-99]. There are numerous 
factors of the HA and NA protein that dictate this fine balance. 
 Numerous experiments about HA and NA function have shown that completely 
blocking the function of either protein results in an unfit virus. Modifying the receptor 
binding site of HA, creating a functional but “dead” HA protein, produces viruses which 
cannot infect cells [101]. On the NA side of the spectrum, numerous studies have 
shown that modifying the NA protein or inhibiting activity via small molecular inhibitors 
prevents the viral particle from infecting mucin covered epithelial cells or budding 
progeny virions from the apical surface of the infected cell [102]. Small molecule 
inhibitors of NA function (e.g., Oseltamivir and Zanamivir) inhibit NA function and 
prevent the virus from releasing effectively from the cell surface. Scanning electron 
microscopy of oseltamivir treated influenza virus infections show numerous particles on 
the infected cell surface, because the NA protein is not de-sialating host and viral 
proteins on the cell surface, causing the HA protein to bind to sialic acid ligands on the 
infected cell and other viral particles [103]. 
 While these experiments show that a complete lack of either HA or NA activity 
effectively inhibit the influenza virus life cycle, there are numerous studies that show the 
HA/NA balance is more nuanced. For example, expressing NA alone or in combination 
with a functionally dead HA protein in a virus like particle (VLP) dramatically reduces the 
activity of the NA protein resulting in a 50 fold reduction in activity when testing activity 
with a bound substrate [104]. However, when NA is expressed alone enzymatic activity 
with soluble substrate is not perceptively affected. This indicates that HA plays a role in 
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anchoring the particle to a substrate or improving NA function via an unknown 
mechanism. 
 Pandemic events offer additional insights into the delicate HA/NA balance 
required for viral fitness. In many cases when an avian HA and NA, such as the 
pandemic 2009 H1N1 event or H5N1 isolated outbreaks, enter a human population 
dramatic changes in the HA and NA occur. Avian viruses use the α2,3 linkage of sialic 
acid and human viruses use a α2,6 sialic acid. Avian HA receptors often mutate to more 
efficiently use the α2,6 sialic acid receptor ligands. The NA protein also changes when 
viruses undergo species jumps. Highly pathogenic avian influenza viruses (i.e. H7N9 or 
H5N1) often have stalk deletions in the NA protein when comparing the wild aquatic bird 
virus isolates to domestic poultry isolates [105]. This suggests that the position of the 
NA enzyme due to stalk length is also critically important in determining virulence and 
fitness of influenza viruses. This short stalk found in avian H5N1 influenza prevents 
transmission between ferrets [106].  
What isn’t clear is how minor changes to the HA and NA proteins that occur in 
seasonal human influenza impact the balanced activity of HA and NA function. Human 
seasonal HA proteins are under constant immune pressure, and many of the antigenic 
epitopes that mutate season to season are near the receptor binding site of the HA 
protein [107, 108]. Similarly, the NA protein in recent H3N2 isolates has undergone 
significant changes [109]. Studying how these individual mutations impact HA and NA 
balance of human seasonal influenza viruses is crucial to understanding influenza virus 
evolution and viral fitness. 
Traditional Inactivated and Live Influenza Vaccines 
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 To prepare seasonal vaccinations, the WHO identifies candidate vaccine 
strains at the tail end of the one influenza season in preparation for the next influenza 
season. Typically conducted in February for the northern hemisphere and September in 
the southern hemisphere, vaccine strain selection is done at least 6 months before the 
start of the next season [110]. This is the first important issue with the current influenza 
vaccine preparation. Due to the high mutation rate of influenza and constant immune 
pressure from the human population, choosing a vaccine strain six months ahead of the 
influenza season is essentially a guessing game. There have been numerous accounts 
where the chosen vaccine strain no longer represents the dominant circulating virus 
strain the following influenza season [111-113].  
Vaccine preparation has not been significantly modified in the past few decades. 
The HA and NA protein from circulating strains for each subtype (H3N2, H1N1 and one 
to two influenza B strains) are combined with a helper virus, A/Puerto Rico/8/34. The 
internal segments from the helper virus are adapted for egg growth and allow sufficient 
replication of the virus eggs, whereas human viruses potentially have issues replicated 
in eggs. Combining viruses can be done via classical reassortment, which is done by 
culturing both viruses together and selecting the right reassortment, or via reverse 
genetics where cells are transfected with the correct DNA plasmids [114, 115]. The 
resulting candidate vaccine virus (CVV) contains the HA and NA of the chosen vaccine 
strain and the internal segments (PA, PB1, PB2, NP, NS and M). This vaccine virus is 
theoretically antigenically similar to the circulating viruses and should result in a high 
amount of influenza virus vaccine prepared in eggs.  
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This high growth reassortment virus is then passaged in eggs repeatedly during 
vaccine preparation. Herein lies more issues with the current vaccine preparation 
technique. First, there have been instances where the HA and NA protein could not 
grow efficiently in eggs. During the 2002-03 season a H3N2 strain was identified as the 
dominant circulating strain and selected for the following year’s influenza vaccine. This 
strain could not efficiently grow in eggs and as a result the previous year’s strain was re-
used. In this particular season, 2003-04, there was a very poor vaccine efficacy and 
nearly 85% of the isolated strains were not antigenically similar to the vaccine strain. 
Most of the viruses sequenced that year were a good match with the preferred vaccine 
strain that wasn’t used due to poor growth in eggs [116]. An additional issue with 
growing influenza viruses in embryonated hen’s eggs is that hen’s eggs contain different 
sialic acid receptors compared to the human nasal epithelium. CVVs are selected for a 
high growth phenotype which is necessary to produce large amount of vaccine antigen. 
These CVVs uniformly contain egg associated mutations in the HA protein as a result. 
Egg associated HA mutations are typically in or around the receptor binding site of the 
HA protein and the result of the human isolated virus, which uses a human α2,6 sialic 
acid receptor, growing in an avian cell culture system which only expressed the avian 
receptor α2,3 sialic acid [115, 117-121]. The issue with receptor switching and 
associated mutations is that a number of the amino acids that change during receptor 
switching and egg adaptation are located in antigenic sites [76, 115, 117, 122-124]. The 
problem arises when the vaccine virus, which effectively grows in eggs, is no longer 
antigenically matched to the selected virus strain and circulating virus strains. This was 
the case in the 2012-13 year where the H3N2 vaccine component A/Victoria/361/2011 
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gained three amino acid changes (H156Q G186V and S219Y) during egg adaptation. 
This vaccine strain was ineffective at protecting vaccine recipients from infection and as 
a result this mismatch led to a poor vaccine efficacy for the H3N2 component [118]. As 
severe influenza seasons are continuously occurring, updating our vaccine technology 
or moving towards a universal vaccine will be necessary to keep pace with IAV.  
In addition to the inactivated vaccine there is another live virus vaccine option 
currently available, the live attenuated influenza virus vaccine (LAIV). The LAIV strain is 
a live attenuated virus capable of infecting vaccine recipients and mimicking a mild 
natural infection. LAIV is produced via a reverse genetics process where the LAIV 
internal segments, which confer the temperature sensitive phenotype, are combined 
with the circulating HA and NA chosen for that vaccine season. Currently, LAIV is 
manufactured by MedImmune and indicated for individuals between 2 and 49 years of 
age. LAIV was first created by serially passaging a master donor virus, A/Ann 
Arbor/6/1960 in cooler and cooler temperatures [125-127]. This cold adapted virus can 
replicate at room temperature (25ºC), shows poor growth at physiological temperature 
(37ºC) and is attenuated in vivo replication [125, 128]. There are 6 known amino acid 
changes in the polymerase proteins (PA, PB1 and PB2) and one in the M2 matrix 
protein that contribute to this attenuation phenotype [128, 129]. The LAIV is thought to 
induce a strong mucosal immune response, stimulating production of nasal IgA and 
systemic IgG[130, 131] Additionally, unlike the inactivated flu shot, the LAIV can induce 
a CD4 T cell response which aids in protection against subsequent infection. Mucosal 
IgA, an adaptive T cell response as well as stimulating production of interferons 
mimicking natural infection are all reasons why LAIV is an attractive vaccine platform for 
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robust influenza protection [132, 133]. The LAIV vaccine has been marketed towards 
children and has proven safe in both immunocompetent and slightly 
immunocompromised child recipients, with minor virus shedding noted in both groups of 
children [134, 135].  LAIV has been heralded as an excellent vaccine to mimic natural 
infection and provide a multifaceted immune response. However, the process of 
producing the vaccine as well as year to year variation in strain selection impacts the 
vaccine production.  
Many of the issues seen in the IIV (i.e., the flu shot) are amplified when 
considering the LAIV. In order to be an effective vaccine, LAIV must sufficiently replicate 
when administered to the nasal epithelium. Receptor switching that occurs during egg 
propagation leads to the LAIV HA receptor adopting a preference for α2,3 sialic acid, 
the avian receptor. LAIV must replicate in the human nasal epithelium which expresses 
high levels of the human α2,6 sialic acid receptor. Therefore, the egg adapted LAIV 
could potentially be over attenuated by utilizing an HA receptor which has a preference 
for the avian receptor, not the human receptor. Furthermore, as discussed before, egg 
adaptation can lead to an antigenic mismatch between the vaccine virus and circulating 
human viruses. In theory, LAIV is a superior vaccine candidate when indicated. 
However, the potential for an antigenic mismatch LAIV that doesn’t replicate efficiently 









Figure 1.1: IAV Particle  
Influenza particle illustrating 8 segment negative sense RNA genome. Each genomic 
segment is covered in NP protein with a polymerase complex (PA, PB1, PB2) attached 
to each viral genome segment. Luminal side of viral membrane is coated in Matrix 
protein M1. Influenza HA and NA glycoproteins decorate outer surface of viral particle. 
M2 Ion channel embedded in viral envelope. Abbreviations: PB2 Polymerase Basic 2, 
PB1 Polymerase Basic 1, PA Polymerase Acidic, HA Hemagglutinin, NP Nucleoprotein, 
NA Neuraminidase, M Matrix, NS Non-Structural. M1 Matrix Protein 1, M2 Matrix 






























Figure 1.2: IAV Life Cycle 
 (1) Influenza particle attaches to host cell receptor containing sialic acid. (2) 
endocytosis of influenza particle. (3) After endocytosis acidification of endosome. (4) 
Fusion of viral membrane and host endosome membrane. M2 ion channel activity 
acidifies viral particle causing release of viral genome. (5) Viral genome enters nucleus 
through nuclear import signals. (6) Viral mRNA synthesized and viral genome replicated 
in nucleus. Viral mRNA leaves nucleus for translation. (7) Viral proteins translated by 
host cell ribosomes. vRNP complexes assembled with viral RNA genome and 
polymerase units. (8) Viral particle is assembled at apical surface of cellular membrane. 
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 Live Attenuated Influenza Virus (LAIV) is administered as a live virus vaccine to 
the nasal epithelium. LAIV, which is propagated in eggs, must replicate in the nasal 
epithelium to induce a protective antibody titer and cellular immune reponse. Candidate 
vaccine strains are selected based on their ability to replicate to a high titer in eggs as 
well as maintaining similar antigenicity to parental viral strains. However, the process of 
egg propagation necessary for vaccine production can lead to mutations which alter the 
antigenicity of the hemagglutinin (HA) gene and receptor tropism. In the 2012-2013 
northern hemisphere vaccine the H3N2 vaccine component contained three egg 
adaptation associated amino acid mutations in the HA gene. These mutations, H156Q, 
G186V and S219Y decreased vaccine efficacy for that season. Ferret anti-sera raised 
against the vaccine strains failed to completely neutralize circulating H3N2 viruses 
isolated in the 2013-2014 season. LAIVs were created using the wild-type (WT) parental 
HA of A/Victoria/361/2011 (WT HA LAIV), the egg adapted HA (EA HA) from the 
vaccine strain and an egg adapted virus with additional HA receptor amino acid 
changes to promote α2,3 sialic acid binding (2,3 EA HA). The WT HA LAIV preferred 
more α2,6 sialic (i.e., the human IAV receptor ligand) compared to the EA HA and 2,3 
EA HA LAIV which both demonstrated an increased preference for α2,3 sialic acid (i.e., 
the avian receptor ligand). On immortalized MDCKs, the WT HA and EA HA LAIV 
showed similar replication at 32ºC but at 37ºC the EA HA replicated significantly less. 
The 2,3 EA HA LAIV replicated poorly at both temperatures. This phenotypic difference 
was also observed on primary human nasal epithelial cells (hNECs); the WT HA LAIV, 
however, induced the higher amount of IFN-λ at both 32ºC and 37ºC compared with the 
other viruses. Finally, the WT HA LAIV infected the greatest percentage of hNEC cells 
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compared to both the EA and 2,3 EA HA LAIV including a significantly higher amount of 
ciliated epithelial cells. These results together suggest that egg adaptation of LAIV 
significantly impacts virus fitness in the human nasal epithelium, and possibly result in 
decreased vaccine efficacy overall. 
Introduction 
 Influenza A virus (IAV) is a member of the Orthomyxoviridae family of viruses. 
Each year IAVs infect between 10 and 20% of the world population, cause thousands of 
deaths and result in millions in economic loss [3]. As such, yearly vaccination is 
necessary to decrease the burden of influenza disease. There are several options 
available for annual influenza vaccination, one of which is the live, attenuated influenza 
virus (LAIV) vaccine. The LAIV is a cold-adapted, attenuated IAV. The LAIV strain used 
in the United States was first created by serially passaging of a seasonal H2N2 virus, 
A/Ann Arbor/6/1960 [125-128]. By repeatedly passaging this virus in cooler and cooler 
temperatures, the resulting virus was capable of growth at lower temperature (25ºC), 
but attenuated at 37ºC and 39ºC in animal models [138]. The attenuation phenotype of 
LAIV results in a virus that is capable of growing in the upper airway of humans, but has 
restricted, attenuated growth in the lower airway. Previous studies have mapped the 
temperature attenuation phenotype to mutations in polymerase complex (PA, PB2, PB1 
and NP) as well as the matrix protein M2 [128, 129]. The mutations result in inefficient 
viral RNA synthesis, defective particle formation, deficient replication, and a reduced 
incorporation of the viral matrix M1 protein into progeny virions [138-140]. LAIV 
produces the same amount of viral particles at 37ºC compared to a matched wild type 
(WT) virus, but the ratio of infective particles to total particles is significant lower [132].  
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The LAIV vaccine is a 6:2 reassortment virus created by combining 
hemagglutinin (HA) and neuraminidase (NA) segments from circulating seasonal 
influenza viruses with the LAIV internal segments. This recombinant LAIV is an 
attenuated replication competent antigenically similar to circulating. This results in a 
virus that can replicate and mimic mild disease in the upper airway, stimulate an innate, 
humoral and cellular immune response but cannot efficiently replicate in the lower 
airway and cause significant disease symptoms [141, 142].   
  One often overlooked aspect of the LAIV vaccine is the process of 
manufacturing the vaccine in embryonated hens’ eggs. Both the IIV and LAIV are grown 
in eggs, partially purified, then administered in their respective vaccine formulation [143, 
144]. During egg propagation and selection of a candidate vaccine virus (CVV), the viral 
HA receptor accrues a number of amino acid mutation in the HA protein [122, 124]. 
Most of these amino changes are in the receptor binding site located in the head of HA 
and the receptor binding residues in HA often overlap with antigenic regions of the HA 
head. These amino acid changes are necessary for the CVV to replicate to high enough 
titers to provide a substantial amount of vaccine antigen [123, 124]. There are many 
noted issues with egg propagated viruses undergoing drastic antigenic changes. One 
notable instance was in the 2012/13 season where the H3N2 vaccine component 
(A/Victoria/361/2011) was antigenically mismatched from circulating viruses that season 
[118]. The issue lies with the intended function of LAIV, which is to replicate and mimic 
a natural and mild influenza infection. The virus must replicate in the human nasal 
epithelium to induce a robust mucosal and systemic humoral and cellular immune 
response. While LAIV’s are historically tested for replication competence in 
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immortalized cells, very little research has been conducted on the ability of H3N2 LAIVs 
to replicate in human nasal epithelial cells and how egg adaption of the LAIV HA 
receptor impacts LAIV fitness and efficacy.  
In this study we found that egg adaptation of the H3N2 LAIV vaccine strain for 
the 2012-13 season results in sialic acid receptor changes, decreased replication 
efficiency on human nasal epithelial cells (hNECs), decreased innate immune induction 
and a decreased efficiency of infecting human nasal epithelial cells. Switching receptor 
preference by producing the LAIV vaccine in eggs could potentially have a dramatic 
effect on the replication and efficiency of the LAIV vaccine platform when administered 
to humans.  
Materials and Methods 
Cell Lines and Primary Cells 
Madin-Darby Canine Kidney Cells (MDCK) and human embryonic kidney cells 
293T (HEK293T) were maintained in complete medium (CM) consisting of Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100U/ml 
penicillin/streptomycin (Life Technologies) and 2mM Glutamax (Gibco). Human nasal 
epithelial cells (hNEC) were isolated from non-diseased donor tissue following 
endoscopic sinus surgery. Cells were grown, differentiated and maintained at the air 
liquid interface as previously described [129, 138, 145]. hNEC differentiation medium 
and maintenance medium was prepared as previously described [138, 142, 146]. hNEC 
cultures were used for low MOI growth curves only when fully differentiated. All cells 
were maintained at 37ºC in a humidified incubator supplemented with 5% CO2. hNEC 
cultures were acclimated to 32ºC for 48 hours before infection for 32ºC infections. 
Plasmids 
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 The plasmid pHH21 was used to generate full length influenza hemagglutinin 
(HA) or neuraminidase (NA) plasmids for recombinant virus production. LAIV internal 
segments from the cold adapted A/Ann Arbor/6/1960 was used as previously described 
[129, 132, 138].  Briefly, viral RNA was isolated from the 2012/2013 H3N2 northern 
hemisphere wild type strain A/Victoria/361/2011 with a Qiagen mini-vRNA isolation kit. 
Gene specific primers with cloning sites for H3N2 neuraminidase or hemagglutinin were 
used to create cDNA via a one-step RT-PCR reaction (SuperScript III-Platinum Taq mix, 
ThermoFisher Scientific). The cDNA products were cut with appropriate restriction 
enzymes, column purified (QIAquick PCR Purification kit) and ligated with restriction 
enzyme cut-pHH21 using T4-ligase (New England Biolabs, NEB). To create the 
mutated EA and 2,3 EA plasmids, site directed mutagenesis was performed on the WT 
plasmid (Agilent). Three mutations were performed on the WT plasmid (H156Q, G186V 
and S219Y) to create the EA plasmid, per the available IVR-165 sequence [147]. To 
create the 2,3 EA plasmid, two further amino acid mutations were introduced via site 
directed mutagenesis (I226Q and S228G). All plasmids were maxi prepped and sanger 
sequence verified before use in recombinant virus production. 
Recombinant Virus Production 
 Recombinant H3N2 LAIV viruses were generated using the 12-plasmids reverse 
genetics system as previously described [148, 149]. Briefly HEK293T cells were plated 
at 50% confluency 1 day before transfection in complete media. On the day of 
transfection, media was replaced with serum free Opti-MEM. HEK293Ts were then 
transfected with eight plasmids encoding full length influenza segments in the pHH21 
vector (PB2, PB1, PA, HA, NP, NA, M, NS) and four plasmids encoding the influenza 
replication proteins in the pcDNA3.1 vector (PB2, PB1, PA and NP). At one day post 
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transfection 5μg/ml N-acetyl trypsin was added to the transfection reaction. MDCK cells 
were over-laid four hours post trypsin treatment. Every 24 hours post MDCK-overlay 
virus containing supernatant was sampled for virus production. Fresh Opti-MEM with 
5μg/ml N-acetyl trypsin was added when a sample was taken. Virus from the 
transfected cell supernatants was plaque purified as described below, sequenced, and 
used to generate seed stocks by infecting MDCK cells at a MOI of 0.001. Working 
stocks were generated from sequence confirmed seed stocks by infecting MDCK cells 
at a MOI of .001 as described below. 
Virus seed and working stocks 
 For generation of recombinant virus seed stocks, 250ul of plaque picked virus 
was added to confluent MDCK cells plated in 6 well plates and infected for 1hr as 
previously described [145, 150]. The plaque pick inoculum was removed and infection 
media (IM) was added. Infection medium (IM), consisted of DMEM with .3% BSA 
(Sigma), 100U/ml pen/strep (Life Technologies), 2mM Glutamax (Gibco) and 5μg/ml N-
acetyl trypsin((Sigma)). Cells were placed in a 32ºC incubator and monitored daily for 
CPE. Seed stock was harvested between 3 and 5 days or when CPE reached 
approximately 75-80%. Seed stocks were then sequenced, and infectious virus titer 
determined via TCID50. Working stocks for each LAIV was done by infecting confluent 
MDCK cells in a T75 flask at a MOI of .001 for 1 hour at 32ºC. The inoculum was 
removed, and IM was added. Flasks were incubated at 32ºC for infection. Cells were 
monitored daily for CPE and working stock harvested when CPE reached approximately 
75-80%. Working stocks were sequenced verified and infectious virus determined via 
TCID50 as described below. 
Partially Purifying Virus Particles  
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 Virus was partially purified by ultracentrifugation over a sucrose cushion for 
glycan array. Approximately 150ml of virus was grown for partially purifying. Clarified 
virus working stock supernatant was overlaid onto a 25% sucrose-NTE (100nM NaCl 
(ThermoFisher Scientific), 10mM Tris-HCl (Promega) and 1mM EDTA (Sigma)) buffer 
pH of 7.5. Virus was centrifuged at 27,000 RPM in a SW-28 rotor in a Beckman Coulter 
Optima L90-K UltraCentrifuge for 2 hours. After the first ultracentrifugation, the 
supernatant was removed. The virus pellet was re-suspended in PBS. Pellet was further 
concentrated by ultracentrifugation in an SW-28ti rotor at 23,000 RPM for 1hr. The 
pellet was resuspended in PBS for use in labelling and glycan array 
Labeling Partially Purified Virus Particles 
 Partially purified virus particles were labeled with Alexa Fluor 488 Succinimidyl 
Ester per the manufacturer’s instructions (Thermofisher Scientific).  
Consortium for Functional Glycomics Glycan Array  
 To assess HA receptor specificity partially purified, whole virus particle labeled 
with fluorescent dye was allowed to bind to Consortium for Functional Glycomics Array 
version 5. synthetic glycan chip as previously described [79-82]. Labeled virus was 
allowed to bind to array chip for 1 hr. at room temperature, then excess was aspirated. 
Slides were washed three times before fluorescence analysis. The array chip was 
scanned with GenePix 4300A Microarray scanner then data was analyzed with GenePix 
Pro Microarray Analysis Software and processed via Excel spreadsheets as previously 
described [79-82]. Only sialic acid containing ligands were considered for analysis.  
Low-MOI Infections 
 Low-MOI growth curves were performed at a MOI of .001 in MDCK cells and .01 
in hNEC cultures. MDCK cell infections were performed as described above. After the 
infection, the inoculum was removed and the MDCK cells were washed three times with 
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PBS+. After washing IM was added and the cells were placed at 32ºC. At the indicated 
times post inoculation, IM was removed from the MDCK cells and frozen at -80ºC. Fresh 
IM was then added. For low-MOI growth curves in the presence of monoclonal 
antibodies, the indicated antibodies were added to the IM after the virus was allowed to 
attach to cells.  In low-MOI hNEC growth curves, hNECs were acclimated to 32ºC or 
37ºC for 48hrs before infection. The apical surface was washed three times with PBS 
and the basolateral media was changed at time of infection. hNEC cultures were 
inoculated at a MOI of .015. hNEC cultures were then placed in a 32ºC incubator for 2 
hours. After inoculation, the hNECs were washed three times with PBS. At the indicated 
times, 100ul of IM without N-acetyl trypsin was added to the apical surface of the 
hNECs. The hNECs were then incubated for 5 minutes at 32ºC and the IM was 
harvested and frozen at -80ºC. Basolateral media was changed every 24hrs post 
infection for the duration of the experiment.  
Basolateral IFN-λ Analysis 
 Secreted IFN-λ was quantified from basolateral samples taken during low MOI 
hNEC infections taken 24 hours post infection. The DIY Human IFN-λ I/II/III (IL-
29/28A/28B) ELISA (PBL Assay Science) was used according to manufacturers’ 
instructions. Samples were diluted 1:4 to stay within working range of the assay. Values 
of IFN-λ were adjusted by subtracting mock infected and plotted as picograms/ml. 
Plaque Assay 
 MDCK cells were grown in complete medium to 100% confluency in 6-well 
plates. Complete medium was removed, cells were washed twice with PBS containing 
2mm calcium magnesium (PBS+) and 400uL of inoculum was added. Cells were 
incubated at 32ºC for 1hour with rocking every 15 minutes. After 1hr, the virus inoculum 
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was removed and phenol-red free DMEM supplemented with3% BSA (Sigma), 100U/ml 
pen/strep (Life Technologies), 2mM Glutamax (Gibco) and 5μg/ml N-acetyl trypsin 
(Sigma) and 1% agarose was added. Cells were incubated at 32ºC for 3-5 days and 
then fixed with 4% formaldehyde. After removing the agarose, cells were stained with 
napthol-blue black. Plaque size was analyzed in Image J [151]. For recombinant virus 
production, virus plaques were picked with a pipette instead of fixing with formaldehyde 
and placed in IM and stored at -80ºC for later seed stock generation. 
TCID50 
 MDCK cells were seeded in a 96 well plate 2 days before assay and grown to 
100% confluence. Cells were washed twice with PBS+ then 180uL of IM was added to 
each well. Ten-fold serial dilutions of virus was created and then 20uL of the virus 
dilution was added to the MDCK cells. Cells were incubated for 6 days at 32ºC then 
fixed with 2% formaldehyde. After fixing, cells were stained with napthol blue-black, 
washed and virus titer was calculated. 
Flow Cytometry 
 hNECs were infected for 14 hours with the indicated LAIV at 32ºC. After infection, 
apical and basolateral surfaces were washed with PBS- twice. Cells were then 
detached with 1X TrypLE (Life Technologies) for 15 minutes at 37ºC. After, cells were 
pelleted by centrifugation. Cells were washed again with PBS- and fixed with 2% 
paraformaldehyde (Affymetrix) at room temperature for 15 minutes. Cells were 
permeabilized with .2% Tween-20 for 15 minutes at room temperature. After, cells were 
then incubated with blocking buffer (1% 2º species serum, .3% BSA in 1X PBS-). After 
blocking, cells were incubated with indicated primary antibodies, washed twice, then 
incubated with secondary antibodies. Each washing step was done with FACS buffer 
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which consisted of 0.3% BSA (Sigma) in 1X PBS-. Cells were analyzed on a BD-LSR II 
and data analyzed with FlowJo V10.5.3 software.  
Primary Antibodies 
 Primary antibodies against human beta tubulin IV (Novus Bio, clone OTI3F1) 
Alexa Fluor 488 was used at a concentration of 0.5μg/ml to identify ciliated cells in 
hNEC cultures. Goat anti-Aichi H3N2 anti-serum (BEI resources) was used to identify 
infected cells in hNEC cultures. Serum was diluted 1:500 for use in Flow Cytometry. 
Rabbit anti-M1 (Genetex, cat # GTX125928) was used at a concentration of 0.5μg/ml to 
identify infected cells in hNEC cultures via IF microscopy.  
Secondary Antibodies 
Secondary antibodies were used to detect binding of primary unconjugated 
monoclonal antibodies or poly clonal serum. Donkey anti-Goat IgG Alexa Fluor 647 was 
diluted to 0.5μg/ml in flow cytometry buffer (ThermoFisher Scientific) for Flow cytometry 
analysis. Goat anti-Rabbit IgG Alexa Fluor 647 was used at a concentration of 0.5μg/ml 
in blocking buffer (ThermoFisher Scientific) for IF microscopy. 
Statistical Analysis 
 Statistical analysis was performed using Graph Pad Prism Software (GraphPad 
v8.4.2). Viral growth was analyzed using two-way anova with a Bonferroni post test 
correction. Differences were considered significant if p <.05. Plaque size and infectivity 
in hNECs was analyzed using an unpaired t-Test. Differences were considered 
significant if p <.05. 
Results 
Egg-associated amino acid mutations that occur to human influenza isolates 
typically alter the sialic acid binding preference, due to amino acid changes in the 
receptor binding site (RBS) [116, 123, 124, 152-154]. To study the effect that egg 
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adaptation has on receptor specificity, virus replication and innate immune responses 
were analyzed against a panel of three recombinant LAIVs. All three HA proteins were 
based off of the 2012-13 northern hemisphere isolate chosen for the H3N2 vaccine 
component, A/Victoria/361/2011. The WT HA was cloned from the WT 
A/Victoria/361/2011 HA sequence.  Using the WT HA, three amino acids modifications 
were introduced according to the EA vaccine virus, IVR-165 [147]. These amino acid 
mutations were H156Q, G186V and S219Y and have been previously shown to shift 
sialic acid binding from the human α2,6 receptor to the avian α2,3 receptor [122]. Two 
additional amino acid changes were introduced into the EA HA gene to make the 2,3 EA 
HA which we believed would bind only α2,3 sialic acid. These amino acid changes, 
I226Q and S228G, have been shown to shift sialic acid binding preference from α2,6 to 
α2,3 sialic acid in other H3 proteins [74]. This third HA protein, 2,3 EA, should 
theoretically have the highest amount of α2,3 sialic acid binding out of all three HA 
proteins used. The 3D structure with highlighted amino acid changes and RBS of each 
protein is shown for the WT (Fig 2.1A), EA (Fig 2.1B) and 2,3 EA (Fig 2.1C). After 
cloning and sequence verification, the HA proteins were combined with the 
neuraminidase of A/Victoria/361/2011 and the six internal segments of the cold adapted 
A/Ann Arbor/6/64 H2N2 strain.  
 These receptor variant H3N2 LAIVs were first characterized for their sialic acid 
binding preference using a synthetic glycan array available from the Consortium for 
Functional Glycomics (v5.3 array) [155]. This array contains 156 glycans that contain 
the human α2,6 sialic acid receptor ligand, the avian α2,3 sialic acid receptor ligands, a 
mixture of each, or the non-traditional 2,8 sialic acid linkage. From this array, the sialic 
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acid ligand preference as well as subtle preferences in sugar groups within the ligand 
were determined. The WT HA LAIV, having an identical HA sequence to the circulating 
human clinical isolate, bound to a number of α2,6 and α2,3 sialic acid ligands (Fig 2.2A, 
Table 2.1). Out of the top 20 highest binding glycans, 12 glycans contained the human 
α2,6 sialic acid ligand. Seventeen out of the 20 of the highest binding glycans contain 
galactose (Gal) as the penultimate sugar (Table 2.1). The EA HA LAIV, having an HA 
protein that has an amino acid sequence of a highly egg passaged virus, also bound to 
a mixture of α2,6 and α2,3 sialic acid containing ligands. However, out of the top 20 
highest binding glycans, only 8 out of 20 contained the human α2,6 sialic acid ligand 
(Fig 2.2B, Table 2.2). There was not a significant switch in preference for other sugars 
in the carbohydrate chain, as 17 out of these 20 highest binding ligands contain 
galactose, similar to the WT HA. For the 2,3 EA out of the top 20 highest binding 
ligands, 7 out of 20 contained the human α2,6 sialic acid receptor ligand (Fig 2.2C, 
Table 2.3). The penultimate sugar for every top 20 binder was galactose for the 2,3 EA. 
However, 8/20 contained a fucose molecules attached to the synthetic glycan. From our 
glycan array analysis, we concluded that the amino acid differences between the 
different HA proteins did alter the glycan binding preference of each HA, but did not 
significantly alter the preference for other sugars in the carbohydrate ligand. The 
preference for fucosylated ligands of the 2,3 EA HA is interesting, but the relevance of 
such is unknown. Full information about all 156 sialic acid ligands used in the array can 
be found in Table 2.4 [155].  
 After determining the receptor preferences of the three LAIVs, we next tested 
how these receptor changes impacted viral replication in immortalized cells. Madin-
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Darby Canine Kidney are routinely used immortalized cells that express both α2,3 and 
α2,6 sialic acid [156]. We studied viral replication using these cells at two different 
temperatures. First at 32ºC, the average temperature of the upper airway and the 
permissive temperature to LAIV replication, both the WT and EA LAIV replicated 
similarly with no significant difference in replication kinetics or peak virus titer. However, 
the 2,3 EA HA LAIV replicated poorly at this temperature, suggesting that some aspect 
of HA function is impacted by the additions of I226Q S228G (Fig 2.3A). At 37ºC, the 
temperature of the lower airway and the non-permissive attenuating temperature for 
LAIV, the WT HA LAIV produced the highest amount of infectious virus compared to the 
EA HA LAIV and the 2,3 EA HA LAIV (Fig 2.3B). Plaque appearance, morphology and 
size was then assessed using MDCK cells at 32ºC. Both the WT and EA LAIV produced 
clear, distinct plaques (Fig 2.3C) of similar size (Fig 2.3D). However, the 2,3 EA LAIV 
produced significantly smaller plaques compared to the WT HA LAIV (FIG 2.3C, D). 
 Because MDCK cells do not accurately represent nasal epithelium where LAIV 
(FluMist) is administered, virus replication was then tested on primary hNEC cultures. 
We have previously shown that hNEC cultures are an excellent model of the normal 
nasal epithelium and allow phenotypes to show that aren’t found on MDCK cells [129, 
138, 145]. We studied viral replication at both 32ºC and 37º on hNECs. The WT HA 
LAIV yielded a significantly higher infectious virus compared to both the EA HA LAIV 
and the 2,3 EA HA LAIV at both 32ºC (Fig 2.4A) and 37ºC (Fig 2.4B). In addition to low 
MOI growth curves, basolateral supernatant from hNEC cultures was tested for 
presence of interferon lambda I/II/III (IFN-λ) every 24hrs post infection. Previous studies 
have shown that hNECs secrete IFN-λ during infection with IAVs [142]. Correlating with 
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infectious virus production, the WT HA LAIV induced the highest amount of IFN-λ at 
32oC (Fig 2.4C) and 37ºC (Fig 2.4D) compared to the EA HA LAIV and 2,3 EA HA LAIV.  
 Human nasal epithelial cell cultures are a heterogenous mixture of cells 
containing ciliated epithelial cells, mucus secreting goblet cells, basal cells and other 
supporting cells in a pseudostratified epithelium [146, 157-162]. There is a considerable 
amount of information about differential sialic acid receptor expression on the various 
cells in hNEC cultures. Ciliated cells tend to express more α2,6 sialic acid than α2,3 
sialic acid, and other cells in hNEC cultures tend to express more α2,3 sialic acid than 
α2,6 sialic acid [25, 75]. Using our different HA containing LAIVs with experimentally 
determined receptor differences, we next wanted to assess whether there was a 
difference in cellular tropism in hNEC culture and if this could explain the replication 
differences found. Human nasal epithelial cell cultures were infected with an equal 
amount of virus at a high MOI of 3 for 14 hours (Fig 2.5A) and then dissociated and 
stained for markers of cell lineage (Beta Tubulin IV, ciliated cells) and a marker of 
infection (H3 Anti-Serum) (Fig 2.5B). Gating strategy shown for one replicate (Fig 2.5C). 
We found that there was no extreme difference in cellular tropism due to receptor 
preference shifting. The WT HA LAIV infected a higher percentage of ciliated epithelial 
cells compared to both the EA HA LAIV and 2,3 EA HA LAIV (Fig 5B). However, the EA 
HA LAIV and WT HA LAIV infected a similar amount of non-ciliated epithelial cells 
suggesting that the EA amino acid changes reduce infectivity of the virus  without 
altering cellular tropism in hNEC cultures. Overall, the WT HA infected a higher 
percentage of cells compared to both the EA and 2,3 EA HA LAIV (Fig 5B), likely driven 
by consistently infecting more ciliated epithelial cells. As expected, based on the 
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previous results, the 2,3 EA HA LAIV showed the least infectivity across any cell type 
present in hNEC cultures. These results combined with poor replication seen in MDCKs 
(Fig 3A-B) and hNECs (Fig 4A-B), suggest that the 2,3 EA HA LAIV has a poor HA 
receptor and cannot efficiently infect or replicate in either MDCKs or hNECs in culture.  
Discussion 
 With the recent issues of the LAIV vaccine in the United States [163], this study 
was designed to understand how egg adaptation and the associated HA receptor amino 
acid mutations impact receptor specificity, viral fitness, innate immune induction and 
cellular tropism of an H3N2 LAIV vaccine strain. We demonstrated that egg adaptation 
during vaccine manufacturing significantly changes the function of the HA protein via a 
recombinant virus approach. Using three different HA proteins with varying amino acid 
mutations introduced to alter the receptor specificity (Fig 1), we tested the hypothesis 
that egg adaptation and altering receptor preference would decrease vaccine efficacy. 
Human H3N2 WT viruses typically bind to a high amount of the human α2,6 sialic acid 
receptor ligand [25, 75, 164-167]. There is still an appreciable α2,3 sialic acid binding of 
the WT HA used in this study, as many human viruses bind both α2,6 and α2,3 sialic 
acid [168, 169]. As expected, the EA HA receptor increased binding to the avian α2,3 
receptor. Using the EA HA protein and introducing two additional amino acid mutations 
to further reduce recognition of α2,6 sialic acid, we showed that this 2,3 EA HA virus 
preferred α2,3 sialic acid over the human α2,6 sialic acid receptor ligand (Fig 2). While 
these results were expected and back up previous glycan array studies using 
A/Victoria/361/2011, they verified our hypothesis that altering HA receptor binding site 
amino acids would alter receptor binding preferences [122]. In addition to α2,3 vs α2,6 
preference we found notable differences in the preference for penultimate sugars and 
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other sugar groups in the receptor ligands. Further studies into the significance of such 
findings is necessary, but these data suggest that HA receptor preference involves 
more than α2,3 or α2,6 sialic acid. We then took these viruses and conducted a number 
of virus fitness and cellular tropism studies to connect receptor preference differences 
with LAIV fitness. 
On immortalized MDCK cells, both the WT and EA virus produced a similar 
amount of infectious virus in a low MOI growth curve at 32ºC, while both were 
significantly better than the 2,3 EA HA LAIV (Fig 3). At 37ºC, the WT HA LAIV produced 
the highest amount of infectious virus titer compared to the EA HA LAIV and 2,3 EA HA 
LAIV, suggesting that HA egg associated amino acid changes were contributing to the 
attenuation phenotype of LAIV at 37ºC. In our hNEC studies we showed that egg 
adaptation of the A/Victoria/361/2011 HA decreased replication at both 32ºC and 37ºC 
(temperature of the upper and lower respiratory tract respectively) as well as 
significantly decreased IFN-λ production at both 32ºC and 37ºC (Fig 4). We then found 
that the WT HA LAIV infected more hNECs than either the EA HA or 2,3 EA HA LAIV 
(Fig 5). These results suggest that the receptor changes that resulted in differential 
recognition of sialic acid (Fig 2) impact the ability of EA and 2,3 EA HA LAIV to infect 
cells in hNEC cultures. A decreased ability to infect receptor binding differences can, in 
part, explain the lack of infectious virus production of the EA and 2,3 EA HA LAIV in low 
MOI growth curves. However, further studies into the glycan composition in hNEC 
cultures is necessary to prove this hypothesis. At the current time, it is unknown which 
ligands present in the CFG synthetic glycan array 5.3 are physiologically relevant in 
human infections and hNEC cultures. Taken together, these results suggest that egg 
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adapting the HA of LAIV further attenuates the LAIV and could significantly decrease 
vaccine effectiveness.  
 The LAIV vaccine has always been heralded as superior vaccine compared to 
the traditional IIV. This is in part due to the fact that the LAIV induces formation of 
mucosal IgG and IgA antibodies, a broad T cell response and significantly more 
heterologous protection compared to the IIV.  [170-173]. However, many H3N2 isolates 
that are passaged through eggs for vaccine manufacturing contain the G186V mutation, 
as seen in the A/Victoria/361/2011 strain used in this study [122, 124]. While this 
residue isn’t considered an important antigenic site, it likely assists HA recognition of 
α2,3 sialic acid and thus contributes to the phenotypes shown here in this study [174, 
175].  
 Because LAIV has been in use in the US and around the world, the “dogma” for 
IAV LAIV has always been any H3N2 or H1N1 HA and NA combination could be 
combined with the LAIV internal gene segment plasmids to produce an antigenic 
attenuated virus that protects recipients from that season’s circulating influenza viruses. 
In 2016, the Advisory Committee on Immunization Practices (ACIP) issued a statement 
which resulted in the LAIV not being used for the 2016-2017 season. This was due to 
an ineffective H1N1 component in the previous 2015-2016 season [163]. The H1N1 
component of LAIV was an antigenically similar but not identical strain to that used in 
the IIV. In 2015/16 IIV had much greater efficacy compared to LAIV indicating that the 
efficacy issues in LAIV were due to viral replication issues. Since then, the H1 HA used 
for the 2015/16 season has demonstrated very poor replication competency in MDCKs 
and human cell lines, suggesting that some aspect of egg adaptation or combining that 
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particular H1 HA with the LAIV internal segments is significantly decreasing viral fitness 
[176]. While the LAIV has been re-recommended by ACIP starting in the 2018/19 
season, it’s impossible to predict if a chosen vaccine strain could have the same 
replication issues as seen in 2015/16 H1N1 LAIV vaccine strain. LAIV is still an 
attractive vaccine platform even with many potential pitfalls of replication competency. 
Live, attenuated vaccines continue to be used to induce a robust and broadly effective 
immunity for many different viral infections. However, more focused research on 
stabilizing the HA protein during egg passaging or using an alternative substrate to grow 












































Figure 2.1: 3D modeling of A/Victoria/361/2011 HA proteins  
WT A/Victoria/361/2011 HA monomer protein adapted from Protein Data Bank 
A/Victoria/361/2011 HA (Code 4WE9). Sialic acid binding pocket residues highlighted 
[174, 175, 177-179] 190 Helix in pink, 130 loop in blue and 220 loop in green. (B) Model 
of EA A/Victoria/361/2011 HA. Egg adaptation of A/Victoria/361/2011 during vaccine 
manufacturing resulted in three amino acid changes, highlighted on the structure 
(H156Q, G186V and S219Y). (C) Model of 2,3 EA HA. Two additional amino acid 
changes were added to the EA HA to shift sialic acid binding preference to α2,3 sialic 
























































WT HA A/Victoria/361/2011  
EA HA A/Victoria/361/2011  





Figure 2.2: Glycan array analysis of recombinant LAIV’s with different HA proteins 
WT HA LAIV (A), EA HA (B) and 2,3 EA HA (C) were subjected to glycan array 
analysis. Y axis indicates raw RFU, X axis indicates specific glycan. See Tables 1-4 for 
information regarding chemical structure and glycan ID. α2,3 Sialic acid containing 
ligands in blue box (glycans 2-68) and α2,6 sialic acid containing glycans in off white 





































Figure 2.3: Replication of recombinant H3N2 LAIV viruses in MDCK cell cultures  
 
Low MOI growth curves with MDCK at 32ºC (A) or MDCK at 37ºC (B) with the indicated 
recombinant viruses. Hours post infection (HPI) on X axis, Log of TCID50/ml on Y axis.  
Data are pooled from 3 independent experiments with four replicates per virus per 
experiment (total n = 12 wells per virus timepoint). Data were analyzed with *p<.05 and 
two-way repeated measures ANOVA with Bonferroni multiple comparison posttest. The 
limit of detection (L.O.D.) is indicated with a dotted line at log 2.37 TCID50/ml. Error 
bars in A and B are SEM, error bars in D are SD. (C) Plaque assay performed with 
recombinant LAIV expressing WT, EA or 2,3 EA HA proteins. (D) Quantification of 
plaque area from 30-50 individual plaques per virus from 3 independent experiments. 








Figure 2.4: Replication of recombinant H3N2 LAIV viruses in hNEC cultures 
Low MOI growth curves with hNECs at 32ºC (A) or hNECs at 37ºC (B) with the 
indicated recombinant viruses. Hours post infection (HPI) on X axis, Log of TCID50/ml 
on Y axis.  Data are pooled from 2 independent experiments with four replicates per 
virus per experiment (total n = 8 wells per virus timepoint). Data were analyzed with 
*p<.05 and two-way repeated measures ANOVA with Bonferroni multiple comparison 
posttest. The limit of detection (L.O.D.) is indicated with a dotted line at log 2.37 
TCID50/ml. Error bars in A-D are SEM. (C) and (D) Quantification of IFN-λ I/II/III at 32ºC 
(C) and 37ºC (D) secreted in the basolateral media of hNEC cultures. Y axis pg/ml X 
axis hours post infection (HPI). Data were analyzed with *p<.05 and two-way repeated 





































Figure 2.5: Tropism of LAIV in hNEC Cultures 
hNEC infected with a high MOI of three and virus tropism was determined via flow 
cytometry.(A) TCID50 values of infection inoculum to verify similar titers used between 
three LAIVs. (B) Quantification of infection of total cells, Beta-Tubulin IV+ (ciliated 
epithelial cells) and Beta-Tubulin IV- (everything else in hNEC culture). (C) Gating 
strategy is shown for identifying lineages within heterogenous cell culture. Data are 
pooled from 3 independent experiments with 2 replicates per virus per experiment (total 
n = 6 hNEC wells tropism analysis). Data were analyzed with *p<.05 unpaired T test in 
B. Data was compared from WT HA LAIV percent infected to either EA or 2,3 EA HA. 
Mock is shown for background fluorescence in B and C. Error bars in B are SEM. 
Acquisition of data on BD LSR II flow cytometer and analysis done with FlowJo 10.5.3 




































Table 2.1: WT HA A/Victoria/361/2011 CFG synthetic glycan array binding data 
A/Victoria/361/2011 LAIV with WT HA used in CFG synthetic glycan array top 20 
values. Sialic acid orientation indicated (α2,3 vs α2,6). RFU average was calculated by 
taking the 4 highest RFU values (out of 6 technical replicates). Out of the top 20, 12 








Sample ID Average RFU 
α2,3 or  α2,6 
 SA 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0 44628 α2,6 
Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 41593 α2,6 




4GlcNAcb-Sp12 35455 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 34159 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 32877 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb-Sp8 31044 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb-Sp0 30317 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-
3)GalNAca-Sp14 20914 α2,6 
Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 15903 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 9754 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp21 8028 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 7644 α2,3 
Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-
4Glc-Sp21 4353 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 4184 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-
4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 4119 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb-Sp0 3734 α2,3 
Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 3214 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 3186 α2,3 










Table 2.2: EA HA A/Victoria/361/2011 CFG synthetic glycan array binding data 
A/Victoria/361/2011 LAIV with EA HA used in CFG synthetic glycan array top 20 values. 
Sialic acid orientation indicated (α2,3 vs α2,6). RFU average was calculated by taking 
the 4 highest RFU values (out of 6 technical replicates). Out of the top 20, 8 glycans 







Sample ID Average RFU 
2,3 or α2,6 
SA 
Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 43634 α2,6 
Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 
25436 α2,3 
Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 19376 α2,6 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 17094 α2,3 
Neu5Aca2-6Galb1-4GlcNAcb-Sp8 14351 α2,6 
Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 13421 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb-Sp0 12390 α2,6 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 12333 α2,3 
Neu5Aca2-6GalNAca-Sp8 10025 α2,6 
Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 10025 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 9878 α2,6 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 9869 α2,3 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0 9863 α2,6 
Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 9269 α2,3 
Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 8602 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb-Sp8 6823 α2,3 




4GlcNAcb-Sp21 4121 α2,3 






Table 2.3: 2,3 EA HA A/Victoria/361/2011 CFG synthetic glycan array binding data 
A/Victoria/361/2011 LAIV with 2,3 EA HA used in CFG synthetic glycan array top 20 
values. Sialic acid orientation indicated (α2,3 vs α2,6). RFU average was calculated by 
taking the 4 highest RFU values (out of 6 technical replicates). Out of the top 20, 7 












Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 21866 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 19281 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 15227 α2,3 
Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 11236 α2,3 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0 10638 α2,6 
Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 10557 α2,6 
Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 9451 α2,6 
Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 8016 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 7312 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-
Sp14 7025 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 6599 α2,3 
Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 6277 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 6234 α2,6 
Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 6220 α2,6 
Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 5952 α2,3 
Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 5725 α2,3 
Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 5359 α2,3 




3)GlcNAcb-Sp0 4836 α2,3 
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Table 2.4: Synthetic glycan array structure ID 
Chart ID on Table 1-3 glycan array data. Numbers on chart correspond to structure ID. 
Full structure information found on the CFG website [155]. Sp8 or Sp0 refers to 

































CHAPTER 3: Novel Neuraminidase glycosylation genotype in 
clade 3c.2a H3N2 2014-2015 isolates impacts viral growth on 
human nasal epithelial cells and neuraminidase function 
 
 














In the 2014-15 influenza season, clinical isolates generated from the Johns 
Hopkins Center of Excellence in Influenza Research and Surveillance sampling network 
contained a novel neuraminidase (NA) genotype. These isolates, which quickly 
emerged as the dominant genotype in the 3c.2a clade of H3N2 viruses, had a novel 
glycosylation site at position 245-247 in the NA protein. Addition of glycosylation sites 
can impact virus replication and enzymatic function. To verify the utilization of the 
glycosylation site at position 245 in the NA protein, the NA gene segments for the 
glycosylation positive and glycosylation negative genes were cloned into human 
expression vectors. After transient expression in HEK293T cells, utilization of the 
putative glycosylation site in the 245 NA Gly+ gene was verified via mobility shift SDS 
PAGE and western blotting. To test the effect this glycosylation had on replication, 
viruses containing either the NA glycosylation at residue 245 (245 NA Gly+) or viruses 
lacking the NA glycosylation at residue 245 (245 NA Gly-) were grown on Madin-Darby 
Canine Kidney Cells (MDCK), MDCK-SIAT1 cells and human nasal epithelial cells 
(hNEC). Viruses with the 245 NA Gly+ genotype grew to a significantly lower titer 
compared to viruses with the 245 NA Gly- genotype only in hNEC cultures. Additionally, 
viruses with the 245 NA Gly+ genotype had significantly less NA activity compared to 
245 NA Gly- viruses in two activity assays tested. Temperature had no significant effect 
on the difference in activity for the 245 NA Gly+ or 245 NA Gly- isolates. These results 
suggest that the addition of a new glycosylation site at position 245-247 in 
contemporary clade 3c.2a H3N2 NA proteins decreases viral replication in hNECs and 






Seasonal influenza virus infects millions of people and causes thousands of 
deaths worldwide each year [3, 136]. Influenza viruses that circulate in the human 
population routinely undergo genetic changes between influenza seasons as a result of 
host immune pressure [180-182]. This constant evolution, due to an error prone 
polymerase and immune pressure, results in the emergence of novel and unique 
variants that challenge our ability to protect individuals from infection [183, 184]. A small 
number of changes in the hemagglutinin (HA) protein can significantly alter 
immunogenicity of influenza A viruses and render the millions of influenza vaccine 
doses useless to a particular strain [183, 185-188]. In recent years, there has been an 
increased effort to study the genetic variation of influenza A viruses including all eight 
genomic segments and the 10-14 proteins these segments encode. Increased 
surveillance efforts can lead to identification and characterization of novel variants and 
how genetic variants lead to phenotypic differences between virus isolates. More 
importantly, routine surveillance and studying the fitness of variants is important for 
informing public health policy, influenza vaccine development and emerging threats 
[189-191]. 
One influenza A virus protein, the neuraminidase (NA) viral enzyme, has come into 
the spotlight in recent years as universal vaccine efforts increase. The NA protein is 
critical for both entry into cells and exit of progeny virus from cells. The well-studied HA 
protein, and variants that circulate in the human population, often dictate changes to the 
vaccine formulation by the World Health Organization (WHO). These minor variations in 
the HA protein sequence can lead to escape from neutralizing antibodies and changes 
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in HA receptor function [72, 108, 192, 193]. While variations in the NA protein are less 
frequently studied, understanding how these changes impact viral fitness and protein 
function are crucial to understanding influenza A virus evolution.  
 In the 2014-15 season a novel H3N2 NA genotype was sequenced through the 
Johns Hopkins Centers of Excellence for Influenza Research and Surveillance (JH 
CEIRS). This novel genotype, the addition of a new n-linked glycosylation site at 
position 245-247 in the NA protein, quickly became the dominant genotype the following 
year. After the introduction of this genotype in the human H3N2 population virtually all 
H3N2 isolates have gained this genotype. N-linked glycosylations are large post 
translationally added modifications that dramatically alter the antigenicity of viral 
proteins, and potentially the protein function. Based on the 3D protein structure this 
glycosylation is near the active site of the enzyme [109].  
Using clinical isolates that represent the two neuraminidase genotypes (245 NA 
Gly- and 245 NA Gly+ where “Gly” means n-glycosylation), we demonstrate that this 
glycosylation site is utilized and added to the viral protein.  Surprisingly, this 
glycosylation incurs a significant fitness cost to the virus. Viral replication on primary 
differentiated human nasal epithelial cells (hNEC) is significantly impacted and 











Materials and Methods 
Cell Lines and Primary Cells 
Madin-Darby Canine Kidney Cells (MDCK), MDCK-SIAT1 and human embryonic 
kidney cells 293T (HEK293T) were maintained in complete medium (CM) consisting of 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum, 100U/ml penicillin/streptomycin (Life Technologies) and 2mM Glutamax (Gibco). 
Human nasal epithelial cells (hNEC) were isolated from non-diseased donor tissue 
following endoscopic sinus surgery. Cells were grown, differentiated and maintained at 
the air liquid interface as previously described [129, 138, 145]. hNEC differentiation 
medium and maintenance medium was prepared as previously described [129, 132, 
138, 142]. hNEC cultures were used for low MOI growth curves only when fully 
differentiated. All cells were maintained at 37ºC in a humidified incubator supplemented 
with 5% CO2.  
Plasmids 
 The mammalian expression plasmid pCAGGS was used for transient expression 
of C-terminal flag-tagged neuraminidase proteins as previously described [129]. Briefly, 
vRNA was isolated from two representative clinical isolates A/Bethesda/55/2015 (245 
NA Gly+) and A/Columbia/41/2014 (245 NA Gly-) using a Qiagen mini-vRNA isolation 
kit. Gene specific primers with restriction sites were used to create cDNA via a one-step 
RT-PCR (SuperScript III Platinum Taq mix, ThermoFisher Scientific). The cDNA was cut 
with the appropriate enzymes and ligated into the plasmid pCAGGS.  C-terminal flag tag 
(DYKDDDDK) was added to pCAGGs-NA encoding plasmids via site directed 
mutagenesis (Agilent).  
Transient Transfection for NA-Flag expressing cells 
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 Transient transfection of HEK293T was performed with TransIT-LT1 per the 
manufacturers protocol. Briefly, cells were grown in complete medium until time of 
transfection to roughly 50% confluency. On the day of transfection, complete medium 
was removed and replaced with Opti-MEM serum free medium. Opti-MEM, TransIT-LT1 
and 2.5ug of plasmids encoding gene of interest were mixed then added to HEK293T 
cells. At 16hr post transfection wells were lysed with 1% sodium dodecyl sulfate (SDS) 
in phosphate buffer saline (PBS) for western blot and PNGase analysis. 
SDS-PAGE and Western Blotting 
Cell lysates prepared from HEK293T cells transiently expressing NA proteins of 
interest were used for western blotting. Cells were lysed in 1% SDS Page on ice then 
treated with 4X-Laemli buffer (Bio-Rad) containing 250mM dithiothreitol (DTT, 
ThermoFisher Scientific) and boiled at 100ºC for 5 minutes. Samples were run on 4-
20% Mini-PROTEAN TGX gels (Bio-Rad) with an All-Blue precision plus protein ladder 
(Bio-Rad) at 70v. Proteins were transferred onto an immobilon-FL membrane (Millipore) 
at 75v for 1hr. After transfer, membranes were blocked with blocking buffer (PBS 
containing .05% Tween-20 (Sigma) and 5% non-fat milk (Bio-Rad)) for 1 hour at room 
temp. Primary antibody (FLAG and Beta-Actin) was incubated overnight at 4ºC in 
blocking buffer. Membranes were washed in PBS with .05% Tween-20 (wash buffer). 
Secondary antibody was added for 1hr at room temperature (25ºC) in blocking buffer 
then washed again in wash buffer. Blots were imaged and analyzed with the FluorChem 
Q system (ProteinSimple).  
Immunoprecipitation and PNGase F treatment 
 FLAG-Tagged neuraminidase protein was immunoprecipitated from cell lysates 
per the manufacturer’s instruction (Abcam). Briefly, cell lysates were made using RIPA 
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buffer and allowed to lyse at 4ºC for 1 hour. After extended lysis step, lysates were 
clarified by centrifuging at 10,000g for 10 minutes to precipitate cellular debris. Clarified 
lysates were then incubated with mouse anti-FLAG antibody (Sigma, clone M2) over 
night at 4ºC. The next day, washed protein A/G coupled agarose beads were added to 
the cleared lysate and incubated with rocking for 2 hours at room temperature (25ºC). 
After, the beads and lysate mix was centrifuged at 3,000g for 3 minutes to pellet 
immunoprecipitation beads. The immunoprecipitation beads were washed three times 
with kit wash buffer. Next, 100ul of 1% SDS in PBS was added and mixture was boiled 
at 100ºC for 10 minutes. The mixture was centrifuged again at 3,000g for 3 minutes and 
the supernatant containing precipitated NA protein was used for PNGase treatment. 
PNGase F treatment was done according to the manufacturer’s instructions with no 
modifications to the provided protocol (NEB). After PNGase F treatment, product was 
used for western blotting as described above. 
Primary Antibodies 
 The primary antibody against the FLAG epitope (DYKDDDDK) was used at a 
concentration of 1ugl/ml for western blotting (Sigma clone M2). Beta-Actin (Abcam 
ab8227) was used at 1μg/ml for a loading control.  
Secondary Antibodies 
Secondary antibodies were used to detect binding of primary unconjugated 
monoclonal antibodies. Goat anti-Mouse IgG Alexa Fluor 488 and Goat anti-Rabbit IgG 
Alexa Fluor 488 were used at a concentration of 1μg/ml concentration in blocking buffer 
for Western blotting.  
Influenza H3N2 Database Sequence Analysis 
 Human H3N2 isolates were downloaded from the EpiFlu database from 
September of 2014 through March of 2018 during August of 2019. Neuraminidase 
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sequences were trimmed to the start codon (ATG) then analyzed for presence of a 
glycosylation (NXS/T) at amino acid positions 245-247. Any isolate without an NXS/T 
genotype was considered “245 glycosylation negative” for analysis purposes. No 
isolates contained a proline at position 246, which is unable to be glycosylated. 
Virus Isolation 
 hNEC cultures were washed twice with PBS- for 10 minutes and PBS aspirated 
after each wash. Then, 100ul of nasopharyngeal swab (NPS) from a PCR+ flu positive 
specimen was inoculated on the hNECs for 2 hours at 32ºC. After inoculation, NPS was 
aspirated and cells were washed three times in PBS. Cells were returned to 32ºC apical 
sample was taken every 24 hours, frozen at -70ºC, then used at a later timepoint to 
assess viral titer via TCID50. 
Virus Working Stock Generation 
 For generation of clinical isolate virus working stocks, a 95-100% confluent flask 
of MDCKs was infected at a multiplicity of infection (MOI) of 0.001 TCID50 units. Cells 
were washed twice with PBS containing 2mm calcium and magnesium. The inoculum 
was diluted infection medium (IM), consisting of DMEM with 0.3% BSA (Sigma), 
100U/ml pen/strep (Life Technologies), 2mM Glutamax (Gibco) and 5μg/ml N-acetyl 
trypsin((Sigma)). Inoculation was done at 32ºC for 1 hour with gentle rocking of the flask 
every 15 minutes. After infection, inoculum was removed and fresh IM was added. Cells 
were placed in a 32ºC incubator and monitored daily for CPE. Working stock was 
harvested between 3 and 5 days or when CPE reached approximately 75-80%. Viral 
working stocks were then Sanger sequenced with gene specific primers for all eight 
segments and infectious virus titer determined by TCID50 as described below. Neither 
isolate showed any tissue culture adaptation comparing the working stock to the original 
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NPS sequence with the exception of the HA protein. Both isolates had the amino acid 
mutation K160T in the HA protein, resulting in the loss of a putative glycosylation site in 
the sequence.  
Plaque Assay 
 MDCK cells were grown in CM to 95-100% confluency in 6-well plates. Complete 
medium was removed, cells were washed twice with PBS containing 2mm calcium and 
magnesium (PBS+). Virus stocks were serially 10-fold diluted and 250ul of the 
appropriate dilution was added. Cells and virus were incubated at 32ºC for 1hour with 
rocking every 15 minutes. After 1hr, the virus inoculum was removed and phenol-red 
free DMEM supplemented with 3% BSA (Sigma), 100U/ml pen/strep (Life 
Technologies), 2mM Glutamax (Gibco),5mM HEPES buffer (Gibco), 5μg/ml N-acetyl 
trypsin (Sigma) and 1% agarose was added. Cells were incubated at 32ºC for 3-5 days 
and then fixed with 4% formaldehyde. After removing the agarose, cells were stained 
with napthol-blue black. One image per well was collected using an Olympus OM-D E-
M5 Mark II digital camera. Plaque size was calculated in Image J [151]. 40-60 plaques 
were analyzed for each virus. 
Low-MOI Infections 
 Low-MOI growth curves were performed at a MOI of 0.001 in MDCK cells and 
0.01 in hNEC cultures. For MDCK cells and MDCK-SIAT1 cells infection took place at 
32ºC for 1 hour. After the infection, the inoculum was removed and the MDCK cells 
were washed three times with PBS+. After washing fresh IM was added and the cells 
were placed at 32ºC. At the indicated times post inoculation, IM was removed from the 
MDCK cells and frozen at -70ºC. Fresh IM was then added. In low-MOI hNEC growth 
curves, the apical surface was washed three times with PBS and the basolateral media 
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was changed at time of infection. hNEC cultures were inoculated at a MOI of 0.01. 
hNEC cultures were then placed in a 32ºC incubator for 2 hours. After inoculation, the 
hNECs were washed three times with PBS. At the indicated times, 100ul of IM without 
N-acetyl trypsin was added to the apical surface of the hNECs. The hNECs were then 
incubated for 5 minutes at 32ºC and the IM was harvested and frozen at -80ºC. 
Basolateral media was changed every 48hrs post infection for the duration of the 
experiment.  
TCID50 
 MDCK cells were seeded in a 96 well plate 2 days before assay and grown to 
100% confluence. Cells were washed twice with PBS+ then 180uL of IM was added to 
each well. Ten-fold serial dilutions of virus was created and then 20uL of the virus 
dilution was added to the MDCK cells. Cells were incubated for 6 days at 32ºC then 
fixed with 2% formaldehyde. After fixing, cells were stained with napthol blue-black, 
washed and virus titer was calculated [145, 150]. 
NA-Star Assay 
 NA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit 
assay was performed according to manufactures specifications (ThermoFisher 
Scientific). Briefly, virus titer was equalized via plaque assay. Serial two-fold dilutions of 
virus stock was prepared using NA-STAR assay buffer. Virus dilutions were placed in a 
96 well white opaque plate. 10ul of 1X NA-Star substrate was then added and the plates 
were incubated at room temp for 30 minutes while shaking. After adding substrate, 
accelerator was added, and plates were read immediately by measuring luminescence 
of the resulting enzymatic product on a FilterMax F5 multimode microplate reader.  
Enzyme Linked Lectin Assay 
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 Enzyme linked lectin assays (ELLA) were performed as previously. Flat-Bottom 
Nunc MaxiSorp plates (ThermoFisher Scientific) were coated with 100ul of fetuin 
(Sigma) at 25μg/ml. Plates were kept at 4ºC for at least 18 hours, up to 1 month before 
use. Virus stock was normalized via plaque assay. Virus stocks were serially two-fold 
diluted in Dulbecco’s phosphate buffered saline with calcium and magnesium 
(ThermoFisher Scientific) containing 1% BSA (Sigma) and 0.2% Tween-20 (referred to 
as sample buffer). Dilutions were performed in 60ul in duplicate on a Nunclon Delta 
Surface Round bottom 96 well plate. Fetuin coated plates were washed immediately 
before addition of 100ul virus dilutions. Plates were covered with a plastic lid then 
placed in 37ºC, 32ºC or 25ºC incubator with 5% C02 for 16-18 hours overnight. The 
following day, plates were washed six times with PBS containing 0.05% Tween 20 
(referred to as PBST). After the last wash, 100ul of biotinylated peanut agglutinin lectin 
at 1μg/ml was added to every well and incubated at room temperature for 2 hours. After 
peanut lectin addition, plates were washed three times with PBST. Next, 100ul of 
1μg/ml streptavidin-horse radish peroxidase (Millipore Sigma) was added to every well 
and plates were incubated at room temperature for 1 hour. Plates were then washed 3 
times with PBST before the addition of 100ul of 0.5mg/ml o-Phenylenediamine (Sigma) 
diluted in phosphate-citrate buffer with sodium perborate (Sigma). Plates were 
incubated for 10 minutes at room temperature and reactions were stopped and 
developed by addition of 100ul of 2N sulfuric acid diluted in water. Absorbance was 
read at 405nm on a FilterMax F5 multimode microplate reader (Molecular Devices). 




 Statistical analysis was performed using Graph Pad Prism Software (GraphPad 
v8.4.2). Viral growth was analyzed using two-way anova with a Bonferroni post test 
correction. Differences were considered significant if p <.05. Plaque size and enzyme 
activity was analyzed using an unpaired t-Test. Differences were considered significant 
if p <.05. 
Results 
 In the 2014-15 influenza season a novel NA genotype emerged within the human 
H3N2 population of viruses. The EpiFlu database was analyzed for isolates that 
contained either the 245 NA Gly- amino acid sequence (SAS genotype) or the 245 NA 
Gly+ amino acid sequence (NAS/T genotype). The 245 NA Gly+ genotype emerged in 
the 2014-15 season, and through the following seasons (2015 through 2018) the 
majority of isolates contained the putative NA glycosylation sequence at position 245 
(Fig 3.1A). The addition of N-linked glycosylation sites in influenza HA and NA can 
significantly impact the function of either protein as well as dramatically alter the 
antigenicity of the viral proteins. However, it’s important to verify utilization of the n-
linked glycosylation site before studying the phenotype of the added 245 NA 
glycosylation. N-linked glycans are added co-translationally as peptides are being 
translated in the endoplasmic reticulum. In order for the host cell oligosaccharyl 
transferase enzymes to add the core glycan to the asparagine residue, N-linked 
glycosylation sites must be exposed to these enzymes during protein translation [194]. 
To assess putative glycosylation site utilization, mammalian expression vectors for 
representative 245 NA Gly- and 245 NA Gly+ proteins were created and transfected into 
human embryonic kidney cells (HEK293T) then used for SDS-PAGE and western 
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blotting. N-linked glycans typically increase protein molecular weight by 2-4 kDa 
depending on the complexity of the added glycan [195]. When the NA proteins from 
A/Columbia/41/2014 (245 NA Gly-) and A/Bethesda/55/2015 (245 NA Gly+) were 
expressed in HEK293T cells and used for western blotting, A/Bethesda/55/2015 (245 
NA Gly+) was about 6 kDa heavier than the NA from A/Columbia/41/2014 (245 NA Gly-) 
(Fig 3.1B). This result, a size increase of 6 kDa, is larger than expected but it’s 
important to note that much is unknown about the size or complexity of this n-
glycosylation and the effect this glycan has on other n-glycans on the protein. To further 
verify glycan utilization, both NA proteins were immunoprecipitated and used for 
PNGase treatment. Treatment with PNGase F, an asparagine amidase, leaves native 
proteins without added n-linked glycosylations [195-197]. When the NA proteins from 
A/Bethesda/55/2015 (245 NA Gly+) and A/Columbia/41/2014 (245 NA Gly-) were 
immunoprecipitated and not treated with PNGase F, there was the expected 6 kDA 
difference in molecular weight due to the added N-glycan in A/Bethesda/55/2015 at 
position 245. However, when both proteins were treated with PNGase F, both proteins 
ran at the predicted molecular weight of NA at 49 kDa (Fig 3.1C). These assays confirm 
that the putative 245 N linked glycosylation site in A/Bethesda/55/2015 is in fact utilized, 
and any phenotypic differences between the isolates in viral replication and NA activity 
are likely due to the presence of this N-linked glycosylation at position 245 in the NA 
protein. 
The clinical isolates that represent each NA glycosylation genotype 
A/Bethesda/55/2015 (245 NA Gly+) and A/Columbia/41/2014 (245 NA Gly-) were used 
to assess viral growth. There are a number of amino acid differences in the polymerase 
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enzymes, however no amino acid differences in the HA and only the glycosylation site 
difference in the NA (Table 3.1). These viruses were first used for plaque size and 
morphology on MDCK cells (Figure 3.2A). Even though both isolates showed a 
decreased ability to produce clear and defined plaques, when quantifying plaque area 
both isolates produced similar sized plaques (Figure 3.2B). Next, the virus isolates were 
characterized with a low MOI growth curve on MDCK cells (Figure 3.2C). Both viruses 
had similar kinetics and showed no significant difference in peak virus titer. The isolates 
were then characterized on MDCK-SIAT1 cells, which overexpress the human enzyme 
CMP-N-acetylneuraminate:β-galactoside α-α2,6-sialyltransferase that results in these 
MDCK-SIAT1 cells producing more surface carbohydrates with terminal α-α2,6 sialic 
acid. Both isolates showed nearly identical kinetics of infectious virus production and 
peak infectious virus titer after a low MOI infection (Figure 3.2D). However, when using 
these isolates for a low MOI growth curve with hNEC cultures, the isolate with the 245 
NA Gly- genotype grew to a significantly higher titer compared to the isolate with the 
245 NA Gly+ genotype. Both viruses reached a similar peak titer of infectious virus 
production, but the 245 NA Gly+ isolate reached peak titer 24 hours after the 245 NA 
Gly- isolate. This data suggests that the 245 NA glycosylation does not impact 
replication on immortalized cells, but significantly decreases replication of 245 NA Gly+ 
isolates on primary differentiated hNEC cultures. 
 Because there was a replication difference on hNECs, but not immortalized cell 
cultures with clinical isolates that differed in 245 NA glycosylation status, we next 
assessed the enzymatic function of each isolate in two different enzymatic activity 
assays. Human nasal epithelial cells express membrane-bound mucins as well as 
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secrete mucins from the apical surface of the cells [198-200]. We hypothesized that a 
difference in NA activity could contribute to the difference in replication kinetics seen on 
hNEC cultures. Mucins are rich in o-linked glycosylations that contain a terminal sialic 
acid residue and serve as decoy receptors to protect the cells from influenza viruses 
and other viruses that use sialic acid as a receptor [198, 201, 202]. The NA protein from 
both clinical isolates used in this study have a nearly identical amino acid sequence, 
with the only difference being the 245-247 N-linked glycosylation sequence. Residues 
245-247 are not known to be involved in enzymatic function or coordinating ligands for 
the NA protein. Therefore, we assessed the ability of this glycan to impact enzymatic 
activity with a relatively small luminescent substrate with the NA-STAR assay and a 
large, more physiologically relevant, glycan as substrate in the ELLA assay. With viral 
content normalized via plaque forming units, A/Columbia/41/2014 with the 245 NA Gly- 
genotype had a significantly higher amount of enzymatic activity in the NA-STAR assay, 
suggesting that this glycan blocks the ability of even this small substrate to access the 
active site (Figure 3.3A). When comparing the activity of each NA protein at the highest 
concentration of virus, A/Bethesda/55/2015 (245 NA Gly+) had on average 62% of the 
activity of A/Columbia/41/2014 (245 NA Gly-) (Figure 3.3B). Using the ELLA assay, we 
found that at a broad range of temperatures tested (37ºC, 32ºC and 25ºC) the same 
trend held true, where A/Bethesda/55/2015 (245 NA Gly+) genotype had 25-30% of the 
activity of A/Columbia/41/2014 (245 NA Gly-) (Figure 3.3C-3G). This suggests that 
regardless of temperature the 245 NA Glycosylation significantly decreases enzymatic 
activity of isolates that carry the 245 NA glycosylation genotype. 
Discussion 
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 In this study we show that H3N2 clinical isolates that contain a putative 245 N-
linked glycosylation site quickly dominated the human H3N2 population. This putative 
glycosylation site is utilized when the NA proteins are expressed in human cells (Figure 
3.1). Within a year of seasonal circulation, this H3N2 virus became the dominant 
genotype, with the glycosylation site utilized. We next studied how this glycosylation 
impacted viral fitness. We found that the glycosylation did not impact virus replication in 
plaque assays, nor multi-step viral growth using immortalized MDCK or MDCK-SIAT1 
cells. However, this glycosylation had a significant impact on virus growth when primary 
differentiated hNEC cultures were used as a substrate for viral growth (Figure 3.2). We 
then studied the effect that this 245 NA glycosylation had on viral enzyme function in 
two different activity assays, the NA-STAR assay and the ELLA assay. In both assays, 
the isolate A/Columbia/41/2014 with the 245 NA Gly- genotype showed a significantly 
higher enzymatic activity compared to the isolate A/Bethesda/55/2015 with the 245 NA 
Gly+ genotype (Figure 3.3). The spectrum of temperatures used in the ELLA assays in 
Figure 3 was designed to assess enzymatic activity at temperatures present in areas of 
virus replication in the entire respiratory tract. The upper airway for humans averages 
32ºC as ambient or room-temperature (25ºC) air is drawn in through the nasal passage, 
and warmer air (core body temperature of 37ºC) is exhaled [203, 204]. Regardless of 
temperature (37ºC, 32ºC or 25ºC), enzymatic activity was decreased in the ELLA assay 
if the neuraminidase protein contained the 245 n-glycosylation. As expected, the activity 
of each neuraminidase protein decreased as the assay temperature decreased but the 
difference between 245 NA Gly- and 245 NA Gly+ activity remained roughly the same at 
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each temperature (Figure 3.3D, E, G). This suggests that at any physiological relevant 
temperature, the 245 n-linked glycan decreases enzymatic activity. 
Taken together, these results suggest that the addition of a large n-glycan near 
the active site of the enzyme incurs a significant fitness cost to the currently circulating 
H3N2 viruses. The 2014-15 season was a moderate to severe influenza season [205]. 
The vaccine efficacy during this season for H3N2 viruses was around 6% (95% CI -5% 
to 17%) in all age groups and thus offered no significant protection against H3N2 
infection [205, 206]. Poor vaccine efficacy in the 2014-15 season has been attributed to 
the emergence of a new HA clade, the H3N2 3c.2a clade, but it’s likely that the 
emergence of the 245 NA glycosylation genotype could further impact the ability of host 
antibodies to neutralize the virus [207]. Antibodies against NA are correlates of 
protection in many age groups and a drastic change in the antigenicity of the NA protein 
could impact the ability of individuals’ pre-existing immunity [208, 209]. The 245 N-
linked glycosylation has been shown to mask an important antigenic epitope near the 
active site of the enzyme and block inhibitory antibodies that target residues in and 
around the active site [109].  
One important note of this study is using the representative clinical isolates and 
not isogenic recombinant viruses. The clinical isolates have an identical HA sequence to 
each other, but importantly both isolates lost a glycosylation on the HA protein during 
isolation. The effect of this HA glycosylation is unknown at this time, especially 
considering the balance of HA and NA function and how glycosylations on both proteins 
play into this balance [97-99]. While not the focus of this study, A/Bethesda/55/2015 
(245 NA Gly+) had non-synonymous mutations in each polymerase segment compared 
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to A/Columbia/41/2014 (245 NA Gly-). Another mutation occurs in an alternate reading 
frame of PB1, the PB1-F2 protein [210]. The function of this PB1-F2 mutation, which 
has also fixed in the circulating human H3N2 population, is unknown at this time. It is 
also possible that one of the amino acid differences noted in Table 3.1 could 
compensate for the fitness cost of the 245 NA glycosylation in regard to transmission in 
the human population. 
This study, and others like it, highlight the necessity to study how variants in 
circulating human influenza viruses become dominant in the span of a few influenza 
seasons. Since the introduction of the 245 NA glycosylation site, nearly all circulating 
human H3N2 influenza viruses contain this glycosylation. While this glycosylation 
seemingly decreases virus fitness, it potentially gives an important fitness benefit by 





























































Figure 3.1: Emergence of 245 NA Gly+ genotype in human isolates and utilization 
of the putative 245 NA Glycosylation site.  
(A) EpiFlu data base human H3N2 NA sequence analysis from 2013 through 2018 
season. Sequences were pulled from EpiFlu database and analyzed for presence of 
either SAS amino acid sequence at positions 245-247 (NA Gly-) or NAS/T amino acid 
sequence at position 245-247 (245 NA Gly+). Data are representated as a percentage 
of all complete NA sequences that had either amino acid sequence present at 245-247 
in the NA protein. (B)The FLAG tagged NA protein from A/Bethesda/55/2015 (245 NA 
Gly+) and A/Columbia/41/2014 (245 NA Gly-) protein was transiently expressed in 








HEK293T cells and subjected to SDS-PAGE and western blotting. Numbers above 
protein bands indicate measured size in kilo Daltons (kDa). Beta-Actin was used as a 
loading control (39 kDa each lane). The NA from A/Bethesda/55/2015 was calculated to 
be 6 kDa heavier. (C) The FLAG tagged NA proteins treated with or without PNGase. 
Fully glycosylated proteins (lanes 1 and 2) have a 6 kDa difference in size whereas 
PNGase treated proteins (lanes 3 and 4) have the same size (49kDa). NA and Beta-
Actin protein size in A and B were determined using Bio-Rad software and via true-blue 





















































































Figure 3.2: Replication of clinical isolate H3N2 viruses with or without 245 NA 
glycosylation in MDCK, MDCK-SIAT1, or hNEC cultures 
 (A) Plaque assay performed with clinical isolates with 245 NA Gly + or 245 NA Gly - 
genotype on MDCK cells. (B) Quantification of plaque area from 40-60 individual 
plaques per virus from 3 independent experiments. *p<.05 unpaired T test. Error bars 
are SEM. Multi-step low MOI growth curves with MDCK (C) MDCK-SIAT1 cultures (D) 
or hNEC (E) with the indicated clinical isolates at 32ºC. Hours post infection (HPI) on X 
axis, Log of TCID50/ml on Y axis.  Data are pooled from 3 independent experiments 
with four replicates per virus per experiment (total n = 12 wells per virus timepoint). Data 
were analyzed with *p<.05 and two-way repeated measures ANOVA with Bonferroni 
multiple comparison posttest. The limit of detection (L.O.D.) is indicated with a dotted 
line at log 2.37 TCID50/ml. Error bars in A and B are SEM. Stats calculated in 










































































Figure 3.3: Neuraminidase activity of H3N2 clinical isolates that differ in 245 NA 
glycosylation status 
With viral content normalized via plaque assay, clinical isolates NA activity was tested 






separate temperatures in humidified incubators (C-G) to asses temperature effect on 
NA activity for each clinical isolate. In B, D, E, G A/Columbia41/2014 245 NA Gly- 
average activity for the highest virus concentration was set to 100%. The average 
activity for the highest virus concentration of A/Bethesda/55/2015 245 NA Gly+ is shown 
as a percentage of that activity. In Figures A, C, D, F numbers on x-axis are the dilution 
of virus, where for example “2” indicates a 1:2 dilution of the viral stock. * p < .05 













































Table 3.1: Amino acid differences between A/Bethesda/55/2015 (245 NA Gly+) and 
A/Columbia/41/2014 (245 NA Gly-) used for isolate characterization  
Differences are shown with standard single letter abbreviations for amino acid names. 



























number and residue 
A/Bethesda/55/2015 
number and residue 
HA - - 
NA 245S 247S 245N 247T 
PB1 525T 525M 
PB1-F2 75H 75P 
PB2 739N 739D 
PA 313M 313I 
NP - - 
NS1 - - 
NEP - - 
M1 - - 








CHAPTER 4: A neuraminidase glycosylation in H3N2 clade 3c.2a 
impacts virus growth on human nasal epithelial cells, 




















In the 2014-2015 influenza season a novel neuraminidase (NA) genotype 
emerged in the Johns Hopkins Center of Excellence for Influenza Research and 
Surveillance (JH CEIRS) surveillance network as well as globally. This novel genotype 
encoded a glycosylation site at position 245-247 in the NA protein from clade 3c.2a 
H3N2 viruses. In the years following the 2014-2015 season, this novel NA glycosylation 
genotype quickly dominated the human H3N2 population of viruses. To assess the 
effect this novel glycosylation has on virus fitness and antibody binding, recombinant 
viruses with (NA Gly+) or without (NA Gly-) the novel NA glycosylation were created. 
Viruses with the 245 NA Gly+ genotype grew to a significantly lower infectious virus titer 
on primary, differentiated human nasal epithelial cells (hNEC) compared to viruses with 
the 245 NA Gly- genotype, but growth was similar on immortalized cells. The 245 NA 
Gly+ blocked human and rabbit monoclonal antibodies that target the enzymatic site 
from binding to their epitope. Additionally, viruses with the 245 NA Gly+ genotype had 
significantly lower enzymatic activity compared to viruses with the 245 NA Gly- 
genotype. Human monoclonal antibodies that target residues near the 245 NA 
glycosylation were less effective at inhibiting NA enzymatic activity and virus replication 
of viruses encoding an NA Gly+ protein compared to ones encoding NA Gly- protein. 
Additionally, a recombinant H6N2 virus with the 245 NA Gly+ protein was more resistant 
to enzymatic inhibition from convalescent serum from H3N2-infected humans compared 
to viruses with the 245 NA Gly- genotype. Finally, the 245 NA Gly+ protected from NA 
antibody mediated virus neutralization. These results suggest that while the 245 NA 
Gly+ decreases virus replication in hNECs and decreases enzymatic activity, the 
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glycosylation blocks the binding of monoclonal and human serum NA specific antibodies 
that would otherwise inhibit enzymatic activity and virus replication. 
Introduction  
Each year seasonal influenza accounts for 3 to 5 million incidences of severe 
disease and up to 650,000 deaths [212]. Most influenza vaccines rely on the generation 
of antibodies against the hemagglutinin (HA) protein, one of the two major glycoproteins 
on the virion surface. The anti-HA protein antibodies inhibit virus entry into cells but also 
provide an immune pressure which leads to the emergence of virus strains with 
mutations in HA antigenic sites [213, 214]. This antigenic drift leads to escape from 
vaccine- and infection-induced immunity and results in the need to change influenza 
vaccine strains on a fairly frequent basis.  
There is renewed interest in generating influenza vaccines that provide broader 
and stronger protection against several virus strains [215-217] and the other major 
influenza surface glycoprotein, the NA protein, has emerged as a potential candidate for 
such a universal influenza vaccine [217]. The NA protein has a neuraminidase activity 
that is critical in two stages of the virus life cycle[60, 61, 218]. The NA protein cleaves 
sialic acid from mucins that coat airway epithelial cells which reduces HA protein 
binding to mucins and facilitates entry into respiratory epithelial cells[102]. The 
neuraminidase activity also removes sialic acid from host cell membrane bound proteins 
and viral HA and NA proteins at late times post infection, allowing viral particles to 
efficiently bud and spread to other respiratory epithelial cells[61, 219].  
Anti-NA antibodies can prevent or decrease the severity of influenza infection[94-
96, 220]. High titer anti-NA antibodies have been correlated with decreased disease 
severity and protection in adults[209, 221]. Seasonal influenza A and B viruses have a 
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conserved epitope in the NA protein which is necessary for enzymatic function[88, 89]. 
Antibodies that target this epitope inhibit neuraminidase function and virus replication. 
Neuraminidase antibodies can be potent and broadly reactive [95, 222]. Anti-NA 
antibodies increase in titer with age and are capable of recognizing influenza strains 
isolated in many different influenza seasons [89, 95, 222]. Additionally, a subset of anti-
NA antibodies raised in a human infection are broadly cross reactive and protective 
against influenza A and B virus strains [88, 89]. 
Neuraminidase antibodies can directly inhibit NA function as well as virus 
replication. Antibodies that bind neuraminidase can inhibit enzymatic activity, 
presumable through steric inhibition of substrate accessing the active site [94, 95]. 
Blocking NA activity prevents the virus from properly budding, leading to virions which 
aggregate at the cell surface [60, 95, 223]. Furthermore, escape mutants that decrease 
binding of certain active site targeting anti-NA antibodies incur a significant fitness 
disadvantage in virus replication and enzymatic activity [89]. This is due to mutating 
residues critical for the enzymatic function which these broadly reactive antibodies 
target. These studies indicate the NA protein has a highly conserved and critical epitope 
which can be targeted by neutralizing antibodies. Targeting the NA protein has recently 
become one strategy for generating a universal influenza vaccine [94, 208, 209, 222]. 
As such, a polyclonal antibody response to the NA protein assures inhibition of NA 
function as well as steric hindrance of the HA protein - effectively neutralizing virus entry 
and release. 
While the HA protein is the immunodominant antigen on the influenza virion, 
previous studies have shown the function and significance of anti-NA antibodies in 
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vaccination and natural infection [94, 95, 222, 224, 225]. However, this immune 
pressure can also lead to the selection of viruses that have accumulated mutations in 
NA protein antigenic sites. NA antigenic drift has been suggested to occur at lower 
frequency than HA antigenic drift but can have an impact on influenza spread and 
antibody recognition of NA [226-228]. 
In 2014-2015 a novel genotype emerged in the human H3N2 influenza viruses. 
This new genotype encoded an N-linked glycosylation at position 245-247 in the N2 NA 
protein. This glycosylation is located in close proximity to the NA active site and near a 
known antigenic site [229]. In chapter 3, we found that this glycosylation could impact 
virus replication, but that work was done using clinical isolates. Therefore, in this 
chapter we used recombinant isogenic viruses to study only the effect that the 245 NA 
glycosylation has on virus replication. Using infectious clone technology to assess viral 
fitness and enzymatic activity, we demonstrate that this NA glycosylation prevents 
binding of inhibitory antibodies but also reduces NA enzymatic activity and virus fitness 
in human nasal epithelial cell cultures. The fitness cost of this mutation is therefore 
balanced by the advantage provided through the escape of preexisting immunity, 
contributing to viruses with this NA genotype becoming the dominant global H3N2 
human virus strain.  
Materials and Methods 
Cell Lines and Primary Cells 
Madin-Darby Canine Kidney Cells (MDCK) and human embryonic kidney cells 
293T (HEK293T) were maintained in complete medium (CM) consisting of Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100U/ml 
penicillin/streptomycin (Life Technologies) and 2mM Glutamax (Gibco). Human nasal 
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epithelial cells (hNEC) were isolated from non-diseased donor tissue following 
endoscopic sinus surgery. Cells were grown, differentiated and maintained at the air 
liquid interface as previously described [129, 138, 145]. hNEC differentiation medium 
and maintenance medium was prepared as previously described [138, 142, 146]. hNEC 
cultures were used for low MOI growth curves only when fully differentiated. All cells 
were maintained at 37ºC in a humidified incubator supplemented with 5% CO2.  
Plasmids 
 The plasmid pHH21 was used to generate full length influenza hemagglutinin 
(HA) or neuraminidase (NA) plasmids for recombinant virus production.  Briefly, viral 
RNA was isolated from the clade 3c.2a H3N2 viruses A/Bethesda/P0055/2015 (NA Gly+ 
ID 253812) and A/Columbia/P0041/2014 (NA Gly- ID 253817) with a Qiagen mini-vRNA 
isolation kit. Gene specific primers with cloning sites for H3N2 neuraminidase or 
hemagglutinin were used to create cDNA via a one-step RT-PCR reaction (SuperScript 
III-Platinum Taq mix, ThermoFisher Scientific). The cDNA products were cut with 
appropriate restriction enzymes, column purified (QIAquick PCR Purification kit) and 
ligated with restriction enzyme cut-pHH21 using T4-ligase (New England Biolabs, NEB). 
Ligation products were transformed into DH5a (NEB) cells and colonies were mini-
prepped (QIAprep spin mini-prep) and Sanger sequence verified. Sequence verified 
colonies were maxi-prepped (ZymoPURE) and used for recombinant virus preparation. 
Since the HA amino acid sequence between A/Bethesda/55/2015 is identical to 
A/Columbia/41/2014, A/Bethesda/55/2015 HA-pHH21 plasmid was used for both H3N2 
viruses. The codon at amino acid position 160 in HA (H3 numbering, Threonine) was 
modified via site-directed mutagenesis (Agilent) from the wild type (ACA, Thr) to a new 
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codon (ACT, Thr) less likely to revert to a lysine codon- which occurred frequently 
during previous attempts to virus rescue.  
H6 hemagglutinin-pHH21 was synthesized by Genscript (www.genscript.com) in 
the pHH21 vector. The H6 HA coding sequence from A/Environment/Hubei-
Jinzhou/02/2010 [230] was inserted into pHH21 flanked by human H3 5’ 
(GCAAAAGCAGGGGATAATTCTATTAACC) and 3’ 
(TAAGAGTGCATTAATTAAAAACACCCTTGTTTCTACTAA) UTR sequences. After 
gene synthesis, two mutations (Q223L and G225S) were added in the HA coding 
sequence to increase HA protein binding to α2,6 sialic acid [150]. The gene product was 
transformed into DH5a (NEB) and maxi-prepped for recombinant virus production. 
pHH21 plasmids encoding the internal segments for A/Victoria/361/2011 (H3N2, rVic 
recombinant viruses) or A/WSN/33 (H6N2, rWSN recombinant viruses) were generated 
as previous described [148]. 
 The plasmid pCAGGS was used for transient expression of C-terminal flag-
tagged NA Gly+ or NA Gly- neuraminidase proteins. C-terminal flag tag (DYKDDDDK) 
was added to pHH21-NA encoding plasmids via site directed mutagenesis (Agilent). 
cDNA was generated from the pHH21-NA flag plasmids with Q5 Hot-Start PCR (NEB). 
This cDNA product was then cloned into the mammalian expression vector pCAGGS for 
transient transfection experiments as previously described [145]. 
Recombinant Virus Production 
 Recombinant H3N2 or H6N2 viruses were generated using the 12-plasmids 
reverse genetics system as previously described [148]. Briefly HEK293T cells were 
plated at 50% confluency 1 day before transfection in complete media. On the day of 
transfection, media was replaced with serum free Opti-MEM. HEK293Ts were then 
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transfected with eight plasmids encoding full length influenza segments in the pHH21 
vector (PB2, PB1, PA, HA, NP, NA, M, NS) and four plasmids encoding the influenza 
replication proteins in the pcDNA3.1 vector (PB2, PB1, PA and NP). At one day post 
transfection 5μg/ml N-acetyl trypsin was added to the transfection reaction. MDCK cells 
were over-laid four hours post trypsin treatment. Every 24 hours post MDCK-overlay 
virus containing supernatant was sampled for virus production. Fresh Opti-MEM with 
5μg/ml N-acetyl trypsin was added when a sample was taken. Virus from the 
transfected cell supernatants was plaque purified as described below, sequenced, and 
used to generate seed stocks by infecting MDCK cells at a MOI of 0.001. Working 
stocks were generated from sequence confirmed seed stocks by infecting MDCK cells 
at a MOI of .001 as described below. 
Plaque Assay 
 MDCK cells were grown in complete medium to 100% confluency in 6-well 
plates. Complete medium was removed, cells were washed twice with PBS containing 
2mm calcium magnesium (PBS+) and 400μL of inoculum was added. Cells were 
incubated at 32ºC for 1hr with rocking every 15 minutes. After 1hr, the virus inoculum 
was removed and phenol-red free DMEM supplemented with .3% BSA (Sigma), 
100U/ml pen/strep (Life Technologies), 2mM Glutamax (Gibco), 5mM HEPES buffer 
(Gibco) 5μg/ml N-acetyl trypsin (Sigma) and 1% agarose was added. Cells were 
incubated at 32ºC for 3-5 days and then fixed with 4% formaldehyde. After removing the 
agarose, cells were stained with napthol-blue black. Plaque size was analyzed in 
ImageJ [151]. For recombinant virus production, virus plaques were picked with a 
pipette instead of fixing with formaldehyde and placed in IM and stored at -80ºC for later 
seed stock generation. 
 90 
Virus Seed and Working Stocks 
 For generation of recombinant virus seed stocks, 400μl of plaque picked virus 
was added to confluent MDCK cells plated in 6 well plates and infected for 1hr as 
previously described [145, 150]. The plaque pick inoculum was removed and infection 
media (IM) was added. Infection medium (IM), consisted of DMEM with .3% BSA 
(Sigma), 100U/ml pen/strep (Life Technologies), 2mM Glutamax (Gibco) and 5μg/ml N-
acetyl trypsin((Sigma)). Cells were placed in a 32ºC incubator and monitored daily for 
CPE. Seed stock was harvested between 3 and 5 days or when CPE reached 
approximately 75-80%. Seed stocks were then sequenced, and infectious virus titer 
determined by TCID50. A working stock for each virus was generated by infecting 
confluent MDCK cells in a T75 flask at a MOI of .001 for 1 hour at 32ºC. The inoculum 
was removed, and IM was added. Cells were monitored daily for CPE and working 
stock harvested when CPE reached approximately 75-80%. Working stocks were 
sequenced verified and infectious virus determined via TCID50 as described below. 
Low-MOI Infections 
 Low-MOI growth curves were performed at a MOI of 0.001 in MDCK cells and 
0.01 in hNEC cultures. MDCK cell infections were performed as described above. After 
the infection, the inoculum was removed and the MDCK cells were washed three times 
with PBS+. After washing, IM was added and the cells were placed at 32ºC. At the 
indicated times post inoculation, IM was removed from the MDCK cells and frozen at -
80ºC. Fresh IM was then added. For low-MOI growth curves in the presence of 
monoclonal antibodies, the indicated antibodies were added to the IM after the virus 
was allowed to attach to cells.  In low-MOI hNEC growth curves, the apical surface was 
washed three times with PBS and the basolateral media was changed at time of 
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infection. hNEC cultures were inoculated at a MOI of 0.01. hNEC cultures were then 
placed in a 32ºC incubator for 2 hours. After inoculation, the hNECs were washed three 
times with PBS. At the indicated times, 100μl of IM without N-acetyl trypsin was added 
to the apical surface of the hNECs. The hNECs were then incubated for 5 minutes at 
32ºC and the IM was harvested and frozen at -80ºC. Basolateral media was changed 
every 48hrs post infection for the duration of the experiment.  
TCID50 
 MDCK cells were seeded in a 96 well plate 2 days before assay and grown to 
100% confluence. Cells were washed twice with PBS+ then 180μL of IM was added to 
each well. Ten-fold serial dilutions of virus was created and then 20μL of the virus 
dilution was added to the MDCK cells. Cells were incubated for 6 days at 32ºC then 
fixed with 2% formaldehyde. After fixing, cells were stained with napthol blue-black, 
washed and virus titer was calculated [145, 150]. 
Transient Transfection for NA-Flag expressing cells 
 Transient transfection of HEK293T was performed with TransIT-LT1 per the 
manufacturers protocol. Briefly, cells were grown in complete medium until time of 
transfection to roughly 50% confluency. On the day of transfection, complete medium 
was removed and replaced with Opti-MEM serum free medium. Opti-MEM, TransIT-LT1 
and 2.5ug of plasmids encoding gene of interest were mixed then added to HEK293T 
cells. At 16hr post transfection wells were used for flow cytometric analysis. 
NA Antibodies 
NA specific monoclonal antibodies 229-1G03, 235-1C02 and HCA2 were used to 
assess binding to NA proteins. 229-1G03 and 235-1C02 were provided by Patrick 
Wilson [222]. 235-1C02 binds to residues 249 and 428 on the NA protein as described 
and the 229-1G03 binds to an as yet uncharacterized epitope on the N2 NA protein. 
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HCA-2 monoclonal antibody was provided by Sean Li [88]. HCA-2 binds to a known, 
highly conserved epitope in the active site of the NA protein, residues 222-230 
ILRTQESEC.  To assess antibody binding to expressed NA proteins, all monoclonal 
antibodies were diluted to 1μg/ml 1X PBS (Quality Biologics) containing .1% BSA, 
(Sigma) was used throughout antibody staining protocol (FACS buffer). The antibodies 
were then serially diluted 1:2 in FACS buffer. Mouse anti-FLAG (clone M2, Sigma) was 
diluted in FACS buffer to 1μg/ml. For western blotting mouse anti-FLAG and anti-
influenza M1 antibody were diluted to 2μg/ml in blocking buffer. Antibodies were diluted 
in IM for virus neutralization assays. For low MOI growth curve viral inhibition, NA 
inhibitory antibodies were diluted in IM + 5ug N-Acetyl Trypsin. 229-1G03 was diluted to 
1.5nm, 235-1C02 1.3nm, and human IgG isotype clone IGHG1 diluted to 5nM. 
Secondary Antibodies 
Secondary antibodies were used to detect binding of primary unconjugated 
monoclonal antibodies. Goat anti-Mouse IgG Alexa Fluor 488, Goat anti-Rabbit IgG 
Alexa Fluor 647 and Goat anti-Human IgG Alexa Fluor 647 were used at 1μg/ml 
concentration in FACS buffer (ThermoFisher Scientific). For western blotting, all 
secondary antibodies were diluted in blocking buffer at a concentration of 1μg/ml. 
Human Serum 
 Convalescent human serum obtained through the JH-CEIRS study 
(HHSN272201400007C) were used in this study. Serum samples were treated with 
receptor destroying enzyme (Cosmos Biological) and heat treated according to the 
manufacturers protocol for use in ELLA studies. 
Flow Cytometry 
 HEK293T cells were detached with 0.05% Trypsin-EDTA (Life Technologies) and 
fixed with 2% paraformaldehyde (Affymetrix) at room temperature for 15 minutes. Cells 
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were washed with FACS buffer after fixation and stained with the indicated amounts of 
human or rabbit monoclonal antibody and anti-FLAG mouse monoclonal antibody. Cells 
were washed twice in FACS butter between each antibody incubation step. Cells were 
analyzed on a BD-FACS Calibur and data analyzed with FlowJo V10.5.3 software. 
Geometric mean was used to identify mean fluorescence intensity (MFI). 
Partially Purifying Virus Particles  
 Virus partially purified by ultracentrifugation over a sucrose cushion for SDS-
PAGE and western blotting. Clarified virus working stock supernatant was overlaid onto 
a 25% sucrose-NTE (100nM NaCl (ThermoFisher Scientific), 10mM Tris-HCl (Promega) 
and 1mM EDTA (Sigma)) buffer pH of 7.5. Virus was centrifuged at 27,000 RPM in a 
SW-28 rotor in a Beckman Coulter Optima L90-K UltraCentrifuge for 2 hours. After the 
first ultracentrifugation, the supernatant was removed. The virus pellet was re-
suspended in PBS. Pellet was further concentrated by ultracentrifugation in an SW-28ti 
rotor at 23,000 RPM for 1hr. The pellet was resuspended in PBS for use in NA activity, 
western blotting and PNGase assays. 
PNGase, SDS-PAGE and Western Blotting 
Partially purified virus particles were used for SDS-PAGE. For PNGase 
treatment, the PNGase kit from (NEB) was used per manufacturer’s instructions. After 
PNGase treatment, all samples were treated with 4X-Laemli buffer (Bio-Rad) containing 
250mM dithiothreitol (DTT, ThermoFisher Scientific) and boiled at 100ºC for 5 minutes. 
Samples were run on 4-20% Mini-PROTEAN TGX gels (Bio-Rad) with an All-Blue 
precision plus protein ladder (Bio-Rad) at 70v. Proteins were transferred onto an 
immobilon-FL membrane (Millipore) at 75v for 1hr. After transfer, membranes were 
blocked with blocking buffer (PBS containing 0.05% Tween-20 (Sigma) and 5% non-fat 
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milk (Bio-Rad)) for 1 hour at room temp. Primary antibody (HCA2 and anti-M1) was 
incubated overnight at 4ºC in blocking buffer. Membranes were washed in PBS with 
.05% Tween-20 (wash buffer). Secondary antibody was added for 1hr at room 
temperature (25ºC) in blocking buffer then washed again in wash buffer. Blots were 
imaged and analyzed with the FluorChem Q system (ProteinSimple).  
NA-Star Assay 
 NA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit 
assay was performed according to manufactures specifications (ThermoFisher 
Scientific). Briefly, serial two-fold dilutions of human serum or monoclonal antibodies 
were mixed in NA-STAR assay buffer. An equal volume of partially purified virus diluted 
in NA-Star assay buffer was added to the antibody dilutions. This mixture of virus and 
antibody was placed in a 96 well white opaque plate and incubated at room temp for 30 
minutes with gently horizontal shaking. After incubation, 10ul of 1X NA-Star substrate 
was added and the plates were incubated at room temp for an additional 30 minutes 
while shaking. After adding substrate, accelerator was added and plates were read 
immediately by measuring luminescence on a FilterMax F5 multimode microplate 
reader. To assess overall NA activity, no monoclonal antibody was added. Data was 
analyzed in Prism (GraphPad) and 50% inhibition was defined as antibody or serum 
concentration that resulted in at least 50% inhibition of NA activity compared to virus 
without antibody.  
Enzyme Linked Lectin Assay 
 Enzyme linked lectin assays (ELLA) were performed as previously [231, 232]. 
Flat-Bottom Nunc MaxiSorp plates (ThermoFisher Scientific) were coated with 100μl of 
fetuin (Sigma) at 25μg/ml. Plates were kept at 4ºC for at least 18 hours, up to 1 month 
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before use. Monoclonal antibodies, human serum or oseltamivir were serially two-fold 
diluted in Dulbecco’s phosphate buffered saline with calcium and magnesium 
(ThermoFisher Scientific) containing 1% BSA (Sigma) and .2% Tween-20 (referred to 
as sample buffer). Dilutions were performed in 60μl in duplicate on a Nunclon Delta 
Surface Round bottom 96 well plate. Virus was added to sample buffer, and 60μl of 
virus was added to the dilution plate. For monoclonal antibody and inhibitor experiments 
recombinant H3N2 virus was used. For human serum, recombinant H6N2 virus was 
used. NA content was equalized via western blotting for H3N2 or virus content 
equalized via plaque assay for H6N2. Fetuin coated plates were washed immediately 
before addition of 100μl virus premixed with antibody, serum or oseltamivir. Plates were 
covered with a plastic lid then placed in 37ºC incubator with 5% C02 for 16-18 hours 
overnight. The following day, plates were washed six times with PBS containing .05% 
Tween 20 (referred to as PBST). After the last wash, 100μl of biotinylated peanut 
agglutinin lectin at 1μg/ml was added to every well and incubated at room temperature 
for 2 hours. After peanut lectin addition, plates were washed three times with PBST. 
Next, 100μl of 1μg/ml streptavidin-horse radish peroxidase (Millipore Sigma) was added 
to every well and plates were incubated at room temperature for 1 hour. Plates were 
then washed 3 times with PBST before the addition of 100μl of .5mg/ml o-
Phenylenediamine (Sigma) diluted in phosphate-citrate buffer with sodium perborate 
(Sigma). Plates were incubated for 10 minutes at room temperature and reactions were 
stopped and developed by addition of 100μl of 2N sulfuric acid diluted in water. 
Absorbance was read at 405nm on a FilterMax F5 multimode microplate reader 
(Molecular Devices). To assess NA activity, no monoclonal antibody was added. Data 
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was analyzed in Prism (GraphPad8) and 50% inhibition was defined as antibody or 
serum concentration that resulted in at least 50% inhibition of NA activity compared to 
virus without antibody. 
NA-Fluor Assay 
 NA-Fluor Influenza Neuraminidase Assay was performed according to 
manufacturer’s specifications and enzyme kinetics experiments performed as previously 
reported [233]. For enzyme kinetics, MUNANA substrate was serially two-fold diluted in 
assay buffer on an opaque black 96 well plate. Virus was prepared in assay buffer then 
added to the plate containing MUNANA substrate dilutions. Fluorescence was 
measured every 60s for 1 hour after addition of virus on a FilterMax F5 multimode 
microplate reader (Molecular Devices). Enzyme Vmax and Km was calculated using 
Prism software (GraphPad). 
NA Neutralizing Antibody Assay 
To assess the ability of monoclonal antibodies ability to inhibit virus replication, a 
neutralizing assay was performed. MDCK cells were plated to 100% confluency on 96 
well plates and washed twice with PBS+. A two-fold serial dilution of monoclonal 
antibody was made in IM + 5μg/ml N-acetyl trypsin at a starting concentration of 100nm 
in a volume of 60μl in duplicate on round bottom Nunclon plates. Next, 60μl (total of 
2,000 PFU) of either 245 NA Gly+ or 245 NA Gly- H3N2 recombinant virus diluted in IM 
with 5μg/ml N-Acetyl Trypsin was added to the dilution plate and 100μl of the mixture of 
virus and antibody was then added to MDCK plates. After 6 days plates were fixed with 
4% formaldehyde and stained with napthol blue-black as described above. Wells were 
considered negative for virus replication if the entire monolayer was intact.  
NA Neutralizing Antibody Virus Replication Assay 
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To study monoclonal antibody inhibition of multistep viral growth, viral replication 
assays were conducted in the presence of NA monoclonal antibodies or human IgG 
isotype. Confluent MDCKs were infected with a MOI of 0.001 as described above. After 
infection, viral inoculum was removed, the cells washed twice with PBS+ and 
monoclonal antibodies (235-1C02, 229-1G03 or human IgG isotype clone IGHG1) were 
added at the indicated concentration in IM containing 5μg/ml n-Acetyl trypsin. Infected 
cells were incubated at 32ºC. At each timepoint post infection, supernatant was 
removed and stored at -80C. Fresh IM with 5μg/ml N-acetyl trypsin and the indicated 
antibody was added. Viral titer was determined via TCID50. 
Statistical Analysis 
 Statistical analysis was performed using Graph Pad Prism Software (GraphPad 
v8.4.2). Viral growth with or without NA neutralizing antibodies was analyzed using two-
way anova with a Bonferroni post test correction. Differences were considered 
significant if p <.05. Plaque size, enzyme activity, virus inhibition and infectivity was 
analyzed using an unpaired t-Test. Differences were considered significant if p <.05. 
Results 
We previously showed that human H3N2 clinical isolates with an NA protein 
containing a glycosylation at position 245 had decreased replication on primary human 
nasal epithelial cell (hNEC) cultures, but not immortalized Madin-Darby Canine Kidney 
(MDCK) cells [234]. To further study the effect that 245 NA glycosylation has on virus 
replication and enzymatic activity, recombinant viruses were generated which encoded 
either the 2014/15 N2 NA proteins with (245 NA Gly+) or without (245 NA Gly-) the NA 
245 glycosylation and an 2014/2015 HA protein. The remaining six influenza virus 
segments from A/Victoria/361/2011 (H3N2) were used as the virus genetic backbone. 
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These viruses were first characterized on MDCK-SIAT1 cells, which overexpress the 
human enzyme CMP-N-acetylneuraminate:β-galactoside α-α2,6-sialyltransferase 
producing more cell surface carbohydrates with terminal α-α2,6 sialic acid [235]. Both 
viruses showed similar kinetics of infectious virus production and peak infectious virus 
amounts after a low MOI infection (Figure 4.1A). In contrast, infection of hNEC cultures 
at a low MOI with the 245 NA Gly- virus yielded significantly higher amounts of 
infectious virus for a prolonged period of time when compared to the 245 NA Gly+ virus 
(Figure 4.1B). Plaque appearance, morphology and size was then assessed using 
MDCK cells. Both viruses produced clear, distinct plaques (Figure 4.1C) of similar size 
(Figure 4.1D). This data indicates that while the 245 NA glycosylation does not impact 
virus replication on immortalized MDCK-SIAT1 or MDCK cells, it has an adverse effect 
on virus replication in hNEC cultures.  
To understand how the additional of a N-linked glycosylation could impact virus 
replication, a model of the N2 neuraminidase monomer was generated with UCSF 
Chimera 3D modeling software. A similar N2 NA strain (A/Tanzania/2010) was used to 
highlight key residues and add a complex N-linked glycan at position 245 (Figure 4.2A) 
via the online program Glyprot. From the model, it is clear that the 245 N-linked Glycan 
is uniquely situated near the active site of the protein. To assess whether this N-linked 
glycan could interfere with the binding of antibodies that target epitopes close to the NA 
enzymatic active site, the coding sequences for both the 245 NA Gly+ and 245 NA Gly- 
gene were inserted into a mammalian cDNA expression vector (pCAGGS), with an C-
terminal FLAG epitope tag before the stop codon (C-terminus). The NA-FLAG plasmids 
were transfected into HEK293T cells and the reactivity of the proteins assessed using 
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monoclonal antibodies specific for the NA protein or the FLAG epitope. Three different 
anti-NA monoclonal antibodies were used. HCA-2 is a rabbit IgG that recognizes a 
highly conserved 9 amino acid sequence (ILRTQESEC) in the active site of most 
influenza A and B virus NA proteins. [88, 89]. This antibody was unable to bind to the 
245 NA Gly+ protein but showed robust binding of the 245 NA Gly- protein (Figure 
4.2B). The human monoclonal antibodies (235-1C02 and 229-1G02) were also used to 
study epitope masking. The binding of these antibodies to N2 NA proteins have been 
described previously [222]. NA proteins encoding amino acid changes at 248 and 429 
[222] allow for escape from binding with 235-1C02, suggesting that glycosylation at 245 
could inhibit antibody binding to its epitope. Binding of the 235-1C02 to the 245 NA Gly+ 
protein was not detected but the antibody recognized the 245 NA Gly- protein (Figure 
4.2C).  The monoclonal antibody 229-1G03 was previously shown to robustly bind to 
245 NA Gly- proteins, but its binding epitope has not been mapped. This antibody can 
inhibit NA enzymatic activity, suggesting it binds near the NA active site [222]. We found 
that this antibody recognizes both 245 NA Gly- and 245 NA Gly+ proteins but shows 
decreased binding to the 245 NA Gly+ protein, suggesting that the 245 NA glycan 
partially disrupts 229-1G03 antibody epitope recognition (Figure 4.2D). Taken together 
these results indicate that the 245 NA glycan masks epitopes in and around the active 
site of the protein as well as multiple epitopes recognized by human monoclonal 
antibodies, some of which are potent, broadly reactive inhibitory antibodies. Similar 
results have recently been reported using the NA protein of the A/Hong 
Kong/4801/2014 vaccine strain [229]. 
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 To understand how 245 NA glycosylation impacted NA function a variety of 
enzymatic and kinetic activity assays were performed. To standardize NA content, we 
chose to partially purify virus particles using ultracentrifugation over a sucrose cushion 
then normalize for NA content using Western blotting with the HCA-2 monoclonal 
antibody. While the HCA-2 antibody binding to conformationally intact 245 NA Gly+ 
protein is inhibited, when the protein is denatured, the HCA-2 linear epitope [88, 89] is 
recognized in both the 245 NA Gly- and Gly+ proteins (Figure 4.3A). The NA enzymatic 
activity was measured using three different NA assays. The Enzyme Linked Lectin 
Assay (ELLA) uses fetuin (Figure 4.3B) as a complex carbohydrate substrate which 
mimics the natural ligands seen by the NA protein during natural infection [231, 232]. 
The NA-STAR (Figure 3C) and NA-Fluor assays (Figure 4.3D) utilize smaller sialic acid 
mimics that release luminescent or fluorescent molecules after cleavage. Using all three 
substrates, the enzymatic activity of 245 NA Gly- was significantly higher than that of 
the 245 NA Gly+, suggesting that the 245 glycosylation was adversely affecting NA 
enzymatic activity.  This NA activity difference was highest in the ELLA assay, 
suggesting that the 245 N-linked glycan sterically blocks the full carbohydrate substrate 
in this assay from the active site. However, the relatively smaller NA-STAR and NA 
Fluor substrates were still utilized less efficiently by the 245 NA Gly+ protein, suggesting 
this glycosylation may have more extensive structural effects on the NA active site.  
In addition to bulk activity assays, we performed an enzyme kinetic assay to 
determine enzyme velocity and affinity for substrate (Figure 4.3E). As expected, the 245 
NA Gly+ protein has lower enzyme velocity and a lower affinity for substrate (Figure 
4.3E, Table 4.1). All of these findings indicate that the 245 NA glycan significantly 
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decreases NA enzymatic activity by decreasing substrate access to the active site of the 
protein.  
 Since the 245 NA glycosylation blocked or decreased binding of the two human 
monoclonal antibodies 235-1C02 and 229-1G03 and we tested the ability of these 
antibodies to inhibit viral enzymatic activity. First, viral stocks of 245 NA Gly+ and 245 
NA Gly- were equalized via NA content and virus was incubated with a dilution series of 
the human monoclonal antibodies or oseltamivir. Vehicle (assay buffer) was used for a 
control and used to subtract background. As expected from the antibody binding 
studies, the monoclonal antibody 235-1C02 was unable to inhibit the NA enzymatic 
activity of the 245 NA Gly+ in the NA star assay even at the highest concentration 
tested (100nM) but inhibited the 245 NA Gly- virus at a concentration of 0.8nm (Figure 
4A). The 229-1G03 inhibited both the 245 NA Gly+ and 245 NA Gly- at a concentration 
of 4.7nm and 1.1nm respectively, suggesting a partial inhibition of inhibitory activity 
(Figure 4.4A) via the 245 NA glycan. The same trend is seen in the ELLA assay (4.4B) 
with 235-1C02 unable to inhibit the neuraminidase activity of the 245 NA Gly+ virus and 
229-G03 showing reduced inhibitory activity. Importantly, in both assays oseltamivir 
inhibition was clearly observed and not different between viruses, suggesting that the 
drug was fully capable of inhibiting NA enzymatic activity irrespective of 245 NA 
glycosylation status. These results confirm that 245 NA glycosylation can result in 
reduced inhibitory activity of antibodies that bind near the NA active site.  In addition to 
monoclonal antibody studies we investigated how human convalescent serum from the 
2014 through 2016 influenza seasons could inhibit enzymatic activity of the 245 NA 
Gly+ and 245 NA Gly- protein. We generated H6N2 viruses to avoid the confounding 
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effect that anti-HA antibodies in human serum can have on NA enzymatic activity [231, 
236]. Twenty serum samples taken from individuals approximately 28 days after 
confirmed H3N2 infection were used. Ten serum samples were from patients infected 
with a 245 NA Gly- virus and 10 from patients infected with a 245 NA Gly+ virus (Table 
4.2). Regardless of the source of serum, the 245 NA Gly+ protein was more resistant to 
serum based enzymatic inhibition, indicated by a higher concentration of serum needed 
to inhibit 50% of the enzymatic activity (Figure 4.4C-E, Table 2) when compared to the 
245 NA Gly- virus. In 18 of the 20 serum samples tested, two to three-fold more serum 
was necessary to inhibit the 245 NA Gly+ protein compared to the 245 NA Gly- protein 
(Figure 4F). Together these results demonstrate that the 245 NA glycosylation 
sequence reduces the recognition of serum NA antibodies consistent with antigenic drift 
of the NA protein. 
Neuraminidase inhibitory antibodies have previously been shown to inhibit virus 
replication by inhibiting enzymatic activity of the protein or by inducing a cellular immune 
response through antibody dependent cellular cytotoxicity (ADCC) [95, 222, 231, 237] 
or a combination of both. With two recombinant viruses only differing in the 245 NA 
glycosylation sequence, we sought to understand how this glycan would impact the 
ability of 229-1G03 and 235-1C02 to neutralize virus infectivity. Using the two 
recombinant viruses we found that the antibody 235-1C02 was unable to neutralize the 
245 NA Gly+ virus, but effectively neutralized the 245 NA Gly- virus at an average 
concentration of 1.3nm (Figure 4.5A). Using 229-1G03, we found this antibody was able 
to neutralize both 245 NA Gly+ and 245 NA Gly- viruses, with an average concentration 
of 6.4nm and 1.5nm respectively, indicating somewhat reduced neutralizing activity 
 103 
against the 245 NA Gly+ virus (Figure 4.5B). Using the experimentally determined 50% 
neutralizing antibody concentration with the 245 NA Gly- virus in Figure 4.5 and 5.5B, a 
multistep growth curve in the presence or absence of these antibodies was performed. 
Figure 54.5C demonstrates that the 245 NA Gly+ virus was not impacted with the 235-
1C02 antibody, as no significant difference was found in infectious virus production 
comparing human IgG isotype (clone IGHG1) and 235-1C02. However, antibody 229-
1G03 did significantly decrease infectious virus production of the 245 NA Gly+ virus, 
showing a partial ability to neutralize infectious virus, consistent with the binding (Figure 
4.2) and enzymatic inhibition results (Figure 4.3). This suggests that the epitope this 
antibody binds is partially accessible on the 245 NA Gly+ protein. In Figure 4.5D, both 
human monoclonal antibodies significantly decreased infectious virus production of the 
245 NA Gly- virus to near undetectable levels, suggesting potent neutralizing activity. 
These results confirm our previous findings with protein binding (Figure 4.2) and 
enzymatic inhibition (Figure 4.3). The 245 NA glycan prevents NA active site-specific 
antibodies from binding and inhibiting the NA protein, and significantly decreases 
antibody mediated neutralization of other NA-specific neutralizing antibodies. 
Discussion 
In this study, we demonstrated that the recently acquired 245 N-linked 
glycosylation site in the NA protein of currently circulating human H3N2 viruses 
significantly alters the function and antigenicity of the NA protein. The 245 NA glycan 
decreased in vitro replication on primary hNECs but did not decrease replication on 
immortalized MDCK cells nor decrease plaque area of isogenic viruses (Figure 4.1). 
These data suggest that some aspect of primary hNECs, likely the presence of 
respiratory mucins, decreases virus replication. Neuraminidase is necessary for virus 
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motility through mucins [100, 102] and decreasing NA enzymatic activity likely 
decreases the ability of the virus to move through mucus. The decrease in NA activity 
found in three separate activity assays (Figure 4.3) but was most pronounced when 
fetuin was used as a substrate, indicating recognition of sialic acid on longer 
carbohydrate chains is especially affected by 245 NA glycosylation. We conclude that 
the 245 NA glycan likely blocks substrate access to the active site and decreases 
enzymatic activity. Decreasing enzymatic activity is likely tied to a decrease in 
replication seen in mucin secreting hNECs but not seen in immortalized MDCK cells, 
which to this point have not been shown to secrete mucins. 
 The presence of a glycosylation site at NA 245 did not affect NA sensitivity to the 
antiviral drug oseltamivir. While oseltamivir access to the NA active site may be reduced 
due to the 245 NA glycosylation in a manner similar to that seen with the other enzyme 
substrates used, subsequent release of oseltamivir is most likely not effected, resulting 
in efficient inhibition of NA enzymatic activity. Further studies of the kinetics of 
oseltamivir inhibition of 245 NA Gly+ and 245 NA Gly- viruses could provide additional 
insights into this observation.   
Recently there have been attempts to map the antigenic regions of the NA 
protein. The 245 NA glycan is located near the enzymatic active site ([229], Figure 4.2) 
and is poised to mask this region of the NA protein. We sought to understand how this 
glycosylation, which incurs a significant fitness disadvantage as judged by virus 
replication in hNEC cultures, could still fix in the human H3N2 virus population in such a 
short timeframe. Through multiple assays we found this glycan has an important role in 
masking NA antigenic sites. This glycan blocks NA active site-specific antibodies from 
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binding (Figure 4.2), prevents NA active site-specific antibodies from inhibiting enzyme 
function (Figure 4.4), and blocks the ability of active site antibodies to neutralizing virus 
replication (Figure 4.5). Additionally, another NA specific monoclonal (229-1G03) 
antibody with an as yet undefined binding epitope is partially blocked from binding to 
their epitope by this glycan (Figure 4.2, 4.4, 4.5), suggesting that the 245 NA glycan 
masks multiple epitopes on the NA protein.  This inhibition of NA inhibitory antibody 
activity was shown with specific monoclonal antibodies and with polyclonal serum from 
H3N2 infected individuals. The ability to escape from preexisting NA immunity therefore 
provides a significant fitness advantage for the virus. While we used serum antibody 
levels to show reduced activity towards 245 NA Gly+ viruses, assessing escape from 
NA antibody in respiratory tract secretions would be more relevant. This antibody 
evasion presumably counters the reduced replication of 245 NA Gly+ viruses in hNEC 
cultures, resulting in a virus whose overall fitness for infecting humans is increased 
compared to 245 NA Gly- viruses. Since the virus replication fitness deficits were only 
observed in hNEC cultures while the antibody inhibition of virus replication was evident 
in immortalized cell lines, our use of hNEC cultures has allowed for a more complete 
understanding of the effects of 245 NA glycosylation on virus fitness.  
Neuraminidase works in conjunction with the HA receptor of influenza A viruses 
to infect and spread virus effectively [98, 99]. As such, studying the NA and HA proteins 
together is crucial to understanding viral evolution. Both the HA and the NA protein 
interact with the same ligand, sialic acid, and thus balancing each proteins’ affinity for 
this ligand is critical to the influenza cycle [97-99, 104]. Both proteins are necessary for 
in vivo replication, but the nuance of their interaction is important as well. Too strong of 
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an HA-sialic acid interaction compared to NA activity results in the HA protein being 
trapped in respiratory mucins or not being able to release progeny virions from the 
infected cell [238, 239]. On the other side of the spectrum, too weak of an HA-sialic acid 
interaction compared to NA activity results in removal of sialic acid receptors before the 
HA protein can engage its ligand and initiate infection. This fine balance between affinity 
for sialic acid impacts virus fitness [99, 104]. Whether the adverse effects of 245 NA 
Gly+ are observed with more contemporary H3 HA proteins should be investigated to 
determine whether HA mutations that compensate for the reduced 245 NA Gly+ 
enzymatic activity have fixed in human H3N2 viruses.  
In recent years, the NA protein has had renewed interest as a relatively 
conserved protein that’s an attractive vaccine target [95, 208, 240]. In some respects, 
the NA protein is an excellent candidate for a universal vaccine. A single monoclonal 
antibody can neutralize decades of influenza virus isolates regardless of strain at 
nanomolar amounts. Neuraminidase inhibitory antibodies can inhibit viral spread, and 
replication at multiple stages of the virus life cycle [241]. Finally, many different studies 
show that NA inhibitory antibodies can decrease disease severity and virus 
transmission as well as provide sterilizing immunity [88, 89, 96, 216, 222, 225].  
Antibody responses to NA are not induced effectively in all age groups by current 
influenza vaccines because the amount of NA is not standardized in vaccine 
preparations and the NA protein conformation is more sensitive to the current vaccine 
production methods than the HA protein [95, 222, 242, 243]. While other methods for 
inducing NA immunity are being developed, our data show that two amino acid changes 
in N2 NA can lead to escape from antibodies that bind to one of the most universal 
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antigenic sites of the protein. It is important that future studies of universal influenza 
vaccines utilize a multi-epitope vaccine that would require multiple mutations from the 
virus to escape the vaccine-induced immunity.   
This study highlights the necessity to consider multiple aspects of the NA protein 
in regard to vaccine production and virus evolution. Decades of influenza research have 
focused on the HA protein for vaccine development, viral evolution and pandemic 
potential. As the interest in NA protein as a vaccine increases, many of the lessons 
learned studying influenza HA may also be applied to NA. The NA protein is 
immunogenic and can provide protection against many strains of influenza viruses[240]. 
However, like the HA protein, the NA protein can undergo antigenic drift and evade the 
humoral immune response. As immune pressure mounts due to a renewed vaccination 
effort at targeting NA protein, the NA protein will likely also become a “moving target” for 
vaccine development, in a manner similar to what has already been documented for the 
























Figure 4.1: Replication of recombinant H3N2 viruses in MDCK-SIAT1, MDCK or 
hNEC cultures with or without 245 NA glycosylation 
Low MOI growth curves with MDCK-SIAT1 (A) or hNEC cultures (B) with the indicated 
recombinant viruses at 32ºC. Hours post infection (HPI) on X axis, Log of TCID50/ml on 
Y axis.  Data are pooled from 3 independent experiments with four replicates per virus 
per experiment (total n = 12 wells per virus timepoint). Data were analyzed with *p<.05 
and two-way repeated measures ANOVA with Bonferroni multiple comparison posttest. 
The limit of detection (L.O.D.) is indicated with a dotted line at log 2.37 TCID50/ml. Error 
bars in A and B are SEM. (C) Plaque assay performed with recombinant 245 NA Gly + 
and 245 NA Gly - viruses on MDCK cells. (D) Quantification of plaque area from 30-50 













Figure 4.2: Binding of neuraminidase inhibitory antibodies to cells expressing NA 
Gly+/- proteins 
(A) 3D model of N2 NA with (Left, 245 NA Gly+) or without (Right, 245 NA Gly-) the 
predicted 245 N-glycan. Catalytic and framework residues are highlighted in cyan. 
Residues 245-247 are highlighted in red. Protein structure modeled and modified via 
UCSF Chimera, Protein Data Bank ID code 4GZP (Tanzania/2010 N2 NA). A typical 
complex style N-glycan was added via the Glyprot program. (B-D) 245 NA Gly+ (blue 
dots) or 245 NA Gly- (red dots) FLAG-tagged proteins expressed in HEK293T cells. NA 
expressing cells were incubated with dilutions of monoclonal antibodies HCA2 (B), 235-
1C02 (C) or 229-1G03 (D) in addition to a mouse monoclonal antibody recognizing the 
FLAG epitope (to measure overall NA expression). Red lines indicate mAb binding to 
cells expressing 245 NA Gly- protein. Blue lines indicate mAb binding to cells 
expressing 245 NA Gly+ protein. Representative data from 3 experiments. * p <.05 two-





















Figure 4.3: Effect of 245 NA glycosylation on neuraminidase activity 
 The NA content in partially purified influenza virus particles was measured via SDS-
PAGE and western blot (A) using HCA-2 mAb to detect NA and M1 antibody 
GTX125928 to detect M1. Numbers below protein bands indicate measured intensity. 
NA content was normalized to the M1 content of the same virus sample. With NA 
content normalized, the NA activity in the partially purified virus preparations was 
measured in the enzyme linked lectin assay (ELLA) (B), NA-STAR assay (C) and NA-
Fluor MUNANA based assay (D). In B, C, and D, 245 NA Gly- enzymatic activity was 
set to 100. X axis label is viral NA genotype 245 NA Gly+ activity is graphed as a 
percentage of that activity. (E) To assess enzyme kinetics, 245 NA Gly- and 245 NA 
Gly+ viruses were incubated with a dilution of MUNANA substrate and fluorescence was 
measured every 60s for 1 hour. Initial velocity plotted as uM product generated per 
minute. Non-linear regression plotted (line) with individual values (points). * p < .05 
unpaired T test. NA and M1 protein content in A were determined using ImageJ 
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software. Enzyme kinetics was determined using a non-linear curve fit Michaelis-














































Figure 4.4: Effect of inhibitory antibodies and human serum on NA enzymatic 
function ELLA and NA Star.  
Concentration of N2 monoclonal antibody needed to inhibit 50% of NA activity of 245 
NA Gly+ and 245 NA Gly- viruses in NA-STAR (A) or ELLA (B) NA activity assays using 
partially purified H3N2 viruses. Upper limit of detection shown with a dotted line in A and 
B, indicating the highest concentration of inhibitory antibody used (100nM). (C-E) NA 
inhibition (NAI) ELLA assay performed with human convalescent serum from patients 
with confirmed H3N2 infection using H6N2 recombinant viruses. Virus content equalized 
via plaque assay. Convalescent serum NAI assay from all patients with confirmed H3N2 
infection with NA Gly- virus (C), and NA Gly+ virus (D) and all serum samples 
regardless of NA genotype (E). X axis label indicates virus NA genotype. All patient 
serum samples with connecting lines between matched serum samples (F). Serum 
samples from the same individual are connected to indicate relative activity to the 245 
NA Gly+ and 245 NA Gly- viruses. Dotted line shown is lower limit of detection in C-F, 































































Figure 4.5: Effect of neuraminidase activity inhibiting antibodies on virus growth 
The concentration of anti-neuraminidase monoclonal antibody 235-1C02 (A) and 229-
1G03 (B) needed to neutralize 50% of the infectivity of 245 NA Gly – or 245 NA Gly+ 
viruses was determined on MDCK cells.  Low MOI growth curve with recombinant 
viruses on MDCK cells (C-D). Hours post infection (HPI) on X axis, Log of TCID50/ml on 
Y axis. MDCK cells were infected with an MOI of .001 with either 245 NA Gly+ virus (C) 
or 245 NA Gly- virus (D). After 1hr of inculation, viruses were treated with either human 
IgG isotype control (clone IGHG1), mAb 235-1C02 or mAb 229-1G03. Dotted line in A 
and B indicated upper limit of detection, highest concentration of mAb used (100nM). .* 
p< .05 unpaired T test A and B. Dotted line in C and D indicated lower limit of detection, 
2.37 TCID50/ml. Data are pooled from 3 independent experiments with four replicates 
per virus per experiment (total n = 12 wells per virus timepoint) in C and D Error bars in 
C and D is SEM.  * p<.05 two way repeated measures ANOVA with Bonferroni multiple 






Table 4.1: Enzyme kinetics of 245 NA Gly- and 245 NA Gly+ viruses 
 NA-Flour assay conducted in triplicate, representative of two biological replicates. 
Values calculated with Graph Pad prism 8 with Michaelis-Menten non-linear regression. 


































Test Virus vMAX (95% CI) Km (95% CI) R squared of line 
245 NA Gly- .6645 (0.6305 to 
0.7001) 
61.55 (50.59 to 
74.76) 
.9942 
245 NA Gly+ .4680 (0.4551 to 
0.4813) 





Table 4.2: Serum samples and 50% NAI values in ELLA Assay 
 Serum samples taken from CEIRS study. Serum genotype, 50% NAI (NAI50) titer and 
fold difference shown. Twenty convalescent serum samples taken approximately 28 
days after confirmed H3N2 infection used. Ten from 245 NA Gly+ infected patients, 10 
from individuals infected with a 245 NA Gly- virus. NAI50 values are the highest titer that 
resulted in at least 50% inhibition of enzyme activity in ELLA assay using H6N2 viruses 
expressing either 245 NA Gly+ or 245 NA Gly- protein. Data shown from one biological 










245 NA Gly+ 
NAI50 Titer 
245 NA Gly- 
NAI50 Titer 
Fold NA Gly+ / 
NA Gly- 
01-23-A-0081 NA Gly Positive 80 80 1 
01-23-A-0023 NA Gly Positive 160 640 4 
01-23-A-0051 NA Gly Positive 160 320 2 
01-11-A-0262 NA Gly Positive 1280 2560 2 
01-21-A-0268 NA Gly Positive 1280 2560 2 
02-11-Pro-0003 NA Gly Positive 80 80 1 
02-11-Pro-0005 NA Gly Positive 160 320 2 
02-11-Pro-0023 NA Gly Positive 320 1280 4 
02-11-Pro-0029 NA Gly Positive <40 320 8 
02-11-Pro-0101 NA Gly Positive 160 2560 8 
01-11-A-0148 NA Gly Negative 40 80 2 
01-11-A-0256 NA Gly Negative 1280 5120 4 
01-11-A-0307 NA Gly Negative 640 1280 2 
02-11-Pro-0006 NA Gly Negative 1280 1280 1 
01-21-A-0192 NA Gly Negative 320 640 2 
02-11-Pro-0030 NA Gly Negative <40 <40 1 
02-11-Pro-0036 NA Gly Negative <40 160 4 
02-11-Pro-0056 NA Gly Negative 160 320 2 
02-11-Pro-0057 NA Gly Negative 160 320 2 








CHAPTER 5: Novel HA and NA Glycosylations of H3N2 viruses 























In the 2013-15 North Hemisphere influenza seasons, the H3N2 virus underwent 
significant changes to both the hemagglutinin (HA) and neuraminidase (NA) proteins. 
These changes included the addition of an n-linked glycosylation site to position 158-
160 on the HA protein and an n-linked glycosylation site to the NA protein. Since the 
emergence of this variant, nearly all H3N2 viruses in the 3c.2a clade and subclades 
contain this double glycosylation genotype. To assess the effect that these glycosylation 
events had on HA receptor binding and viral fitness, recombinant viruses with or without 
the HA 158 glycosylation and with or without the NA glycosylation were created. Using 
this panel of four recombinant viruses, we found that the 158 HA glycosylation 
dramatically increased the receptor binding specificity for the HA protein. In in vitro 
replication studies, the 158 HA glycosylation decreased viral replication on both 
immortalized and primary hNEC cultures. There was no significant effect that either 
protein glycosylation had on HA and NA balance. Taken together, these data suggest 
that while both of the recent HA and NA glycosylation events decrease viral replication 
and there is no obvious change in the HA and NA balance, the ability to evade 
preexisting immunity likely provide a strong fitness advantage to allow emergence, or 














The 2013-14 season marked the beginning of significant changes to both the HA 
and NA proteins of H3N2 viruses. The HA protein is under constant immune pressure 
and as a result there are numerous amino acid changes in the HA head yearly [108, 
179, 193]. Many of these changes occur in antigenic sites and some of which are near 
the receptor binding site (RBS) of the protein. During in the 2013-14 season, H3N2 
clade 3c.2a viruses emerged and quickly dominated the circulating H3N2 virus 
population. This novel HA clade, highlighted by a novel n-linked glycosylation at position 
158-160 in the HA protein (H3 numbering), decreased the effectiveness of the northern 
hemisphere seasonal influenza vaccine that season [205, 206, 244-246]. The position of 
this HA glycan at residue 158 is directly near the RBS of the HA protein based on 3D in 
silico modeling, and could impact receptor binding and recognition as seen in previous 
isolates [81, 244, 247]. This glycan also effectively blocks antibodies targeted to 
antigenic site B on the H3 HA near the receptor binding site [27, 64, 72, 248].  
The following 2014-15 influenza season a small percentage circulating H3N2 
isolates encoded a novel n-linked glycosylation at position 245-247 on the NA protein in 
addition to the recently added HA 158 glycosylation. This novel NA glycosylation masks 
an important antigenic epitope near the active site of the protein and significantly 
reduces enzymatic activity [109]. In the influenza seasons since, the majority of 
circulating H3N2 isolates encode the HA 158 Gly+ and 245 NA Gly+ protein. Based on 
the relatively quick and significant evolutionary changes to the HA and NA proteins of 
circulating H3N2 influenza viruses, we believe that the addition of an NA n-linked glycan 
next to the active site of the protein could play an important role in re-balancing the HA 
and NA balance of circulating H3N2 viruses. Pairing an HA protein with a decreased 
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affinity for certain sialic acid ligands with an NA protein with a proven decreased 
enzymatic rate would effectively rebalance the HA and NA interaction in the human 
H3N2 population [93, 104, 249-251]. Rebalancing HA and NA activity, in combination 
with an increased ability to evade humoral immunity targeting antigenic site B in the HA 
protein and the active site of the NA protein, could explain the dominance of the HA 158 
Gly+ 245 NA Gly+ genotype of circulating H3N2 influenza viruses. 
Using a panel of four recombinant viruses expressing a 158 HA Gly +/- protein 
and a 245 NA Gly +/- protein we found that HA and NA balance is not perceptibly 
altered in any of the four recombinant viruses. While the 158 HA Gly+ protein binds a 
broader amount of synthetic sialic acid containing ligands, viruses expressing the HA 
158 Gly+ protein replicate significantly worse than the HA 158 Gly- viruses. The fitness 
cost of the HA 158 Gly+ protein is likely offset by the ability to evade pre-existing 
immunity which likely leads to the dominance of this HA genotype in the circulating 
H3N2 population of viruses. 
Materials and Methods 
Structural Analysis 
 To analyze the 3D structures of 158 Gly+/- HAs, the Protein Data Bank (PDB) 
structure ID 4WE9 from A/Victoria/361/2011 was used. The amino acid sequence was 
modified using UCSF Chimera to create the 158 HA Gly+ or 158 HA Gly- structure. 
Glycosylation was added via the online program Glyprot (Glycosciences.de).  
Cell Lines and Primary Cells 
Madin-Darby Canine Kidney Cells (MDCK) and human embryonic kidney cells 
293T (HEK293T) were maintained in complete medium (CM) consisting of Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100U/ml 
penicillin/streptomycin (Life Technologies) and 2mM Glutamax (Gibco). Human nasal 
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epithelial cells (hNEC) were isolated from non-diseased donor tissue following 
endoscopic sinus surgery. Cells were grown, differentiated and maintained at the air 
liquid interface as previously described [129, 138, 145]. hNEC differentiation medium 
and maintenance medium was prepared as previously described [138, 142, 146]. hNEC 
cultures were used for low MOI growth curves only when fully differentiated. All cells 
were maintained at 37ºC in a humidified incubator supplemented with 5% CO2.  
Plasmids 
 The plasmid pHH21 was used to generate full length influenza hemagglutinin 
(HA) or neuraminidase (NA) plasmids for recombinant virus production. Briefly, viral 
RNA was isolated from the clade 3c.2a H3N2 viruses A/Bethesda/P0055/2015 (NA Gly+ 
EpiFlu DB ID 253812) and A/Columbia/P0041/2014 (NA Gly- EpiFlu DB ID 253817) with 
a Qiagen mini-vRNA isolation kit. Gene specific primers with cloning sites for H3N2 
neuraminidase or hemagglutinin were used to create cDNA via a one-step RT-PCR 
reaction (SuperScript III-Platinum Taq mix, ThermoFisher Scientific). The cDNA 
products were cut with appropriate restriction enzymes, column purified (QIAquick PCR 
Purification kit) and ligated with restriction enzyme cut-pHH21 using T4-ligase (New 
England Biolabs, NEB). Ligation products were transformed into DH5a (NEB) cells and 
colonies were mini-prepped (QIAprep spin mini-prep) and Sanger sequence verified. 
Sequence verified colonies were maxi-prepped (ZymoPURE) and used for recombinant 
virus preparation. Since the HA amino acid sequence between A/Bethesda/55/2015 is 
identical to A/Columbia/41/2014, A/Bethesda/55/2015 HA-pHH21 plasmid was used for 
all of the H3N2 viruses in this study. The codon at amino acid position 160 in HA (H3 
numbering, Threonine) was modified via site-directed mutagenesis (Agilent) from the 
wild type (ACA, Thr) to a new codon (ACT, Thr) less likely to revert to a lysine codon- 
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which occurred frequently during previous attempts to virus rescue. To create the HA 
158 Gly- pHH21 plasmid, site directed mutagenesis was performed to alter the HA 160 
codon from a Thr (WT) to a Lysine (Lys, K). Lysine was chosen as this residue appears 
in many clinical isolates at this position before the introduction of the 3c.2a clade. 
Recombinant Virus Production 
 Recombinant H3N2 viruses were generated using the 12-plasmids reverse 
genetics system as previously described [148]. Briefly, HEK293T cells were plated at 
50% confluency 1 day before transfection in complete media. On the day of 
transfection, media was replaced with serum free Opti-MEM. HEK293Ts were then 
transfected with eight plasmids encoding full length influenza segments in the pHH21 
vector (PB2, PB1, PA, HA, NP, NA, M, NS) and four plasmids encoding the influenza 
replication proteins in the pcDNA3.1 vector (PB2, PB1, PA and NP). At one day post 
transfection 5μg/ml N-acetyl trypsin was added to the transfection reaction. MDCK cells 
were over-laid four hours post trypsin treatment. Every 24 hours post MDCK-overlay 
virus containing supernatant was sampled for virus production. Fresh Opti-MEM with 
5μg/ml N-acetyl trypsin was added when a sample was taken. Virus from the 
transfected cell supernatants was plaque purified as described below, sequenced, and 
used to generate seed stocks by infecting MDCK cells at a MOI of 0.001. Working 
stocks were generated from sequence confirmed seed stocks by infecting MDCK cells 
at a MOI of .001 as described below. 
Virus Working Stock Generation 
 For generation of recombinant virus working stocks, a 95-100% confluent flask of 
MDCKs was infected at a multiplicity of infection (MOI) of .001 TCID50 units. Cells were 
washed twice with PBS containing 2mm calcium and magnesium (PBS+). The inoculum 
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was diluted infection medium (IM), consisting of DMEM with .3% BSA (Sigma), 100U/ml 
pen/strep (Life Technologies), 2mM Glutamax (Gibco) and 5μg/ml N-acetyl 
trypsin((Sigma)). Inoculation was done at 32ºC for 1 hour with gentle rocking of the flask 
every 15 minutes. After infection, inoculum was removed and fresh IM was added. Cells 
were placed in a 32ºC incubator and monitored daily for CPE. Working stock was 
harvested between 3 and 5 days or when CPE reached approximately 75-80%. Viral 
working stocks were then sanger sequenced with gene specific primers for all eight 
segments and infectious virus titer determined by TCID50 as described below.  
Partially Purifying Virus Particles  
 Virus partially purified by ultracentrifugation over a sucrose cushion for SDS-
PAGE and western blotting. Clarified virus working stock supernatant was overlaid onto 
a 25% sucrose-NTE (100nM NaCl (ThermoFisher Scientific), 10mM Tris (Promega) and 
1mM EDTA (Sigma)) buffer. Virus was centrifuged at 27,000 RPM in a SW-28 rotor in a 
Beckman Coulter Optima L90-K UltraCentrifuge for 2 hours. After the first 
ultracentrifugation, the supernatant was removed. The virus pellet was re-suspended in 
PBS. Pellet was further concentrated by ultracentrifugation in an SW-28ti rotor at 23,000 
RPM for 1hr. The pellet was resuspended in PBS for use in glycan array. 
Labeling Partially Purified Virus Particles 
 Partially purified virus particles were labeled with Alexa Fluor 488 Succinimidyl 
Ester per the manufacturer’s instructions (Thermofisher Scientific).  
Consortium for Functional Glycomics Glycan Array  
 To assess HA receptor specificity partially purified, whole virus particle labeled 
with fluorescent dye was allowed to bind to Consortium for Functional Glycomics Array 
version 5.3 synthetic glycan chip as previously described [79-82]. Labeled virus was 
allowed to bind to array chip for 1 hr. at room temperature, then excess was aspirated. 
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Slides were washed three times before fluorescence analysis. Array chip was scanned 
with GenePix 4300A Microarray scanner then data was analyzed with GenePix Pro 
Microarray Analysis Software and processed via Excel spreadsheets as previously 
described [79-82]. Only sialic acid containing ligands were considered for analysis.  
Low-MOI Infections 
 Low-MOI growth curves were performed at a MOI of 0.001 in MDCK cells and 
0.01 in hNEC cultures. Infection of MDCK cells took place at 32ºC for 1 hour. After the 
infection, the inoculum was removed and the MDCK cells were washed three times with 
PBS+. After washing, fresh IM was added and the cells were placed at 32ºC. At the 
indicated times post inoculation, IM was removed from the MDCK cells and frozen at -
70ºC. Fresh IM was then added. In low-MOI hNEC growth curves, the apical surface 
was washed three times with PBS and the basolateral media was changed at time of 
infection. hNEC cultures were inoculated at a MOI of 0.01. hNEC cultures were then 
placed in a 32ºC incubator for 2 hours. After inoculation, the hNECs were washed three 
times with PBS. At the indicated times, 100ul of IM without N-acetyl trypsin was added 
to the apical surface of the hNECs. The hNECs were then incubated for 5 minutes at 
32ºC and the IM was harvested and frozen at -80ºC. Basolateral media was changed 
every 48hrs post infection for the duration of the experiment. All samples from growth 
curves were used for infectious virus quantification via TCID50. 
TCID50 
 MDCK cells were seeded in a 96 well plate 2 days before assay and grown to 
100% confluence. Cells were washed twice with PBS+ then 180uL of IM was added to 
each well. Ten-fold serial dilutions of virus was created and then 20uL of the virus 
dilution was added to the MDCK cells. Cells were incubated for 6 days at 32ºC then 
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fixed with 2% formaldehyde. After fixing, cells were stained with napthol blue-black, 
washed and virus titer was calculated. 
Plaque Assay 
 MDCK cells were grown in CM to 95-100% confluency in 6-well plates. Complete 
medium was removed, cells were washed twice with PBS+. Virus stocks were serially 
10-fold diluted and 250ul of the appropriate dilution was added. Cells and virus were 
incubated at 32ºC for 1hour with rocking every 15 minutes. After 1hr, the virus inoculum 
was removed and phenol-red free DMEM supplemented with 3% BSA (Sigma), 100U/ml 
pen/strep (Life Technologies), 2mM Glutamax (Gibco),5mM HEPES buffer (Gibco), 
5μg/ml N-acetyl trypsin (Sigma) and 1% agarose was added. Cells were incubated at 
32ºC for 3-5 days and then fixed with 4% formaldehyde. After removing the agarose, 
cells were stained with napthol-blue black. One image per well was collected using an 
Olympus OM-D E-M5 Mark II digital camera. Plaque size was calculated in Image J 
[151]. 40-60 plaques were analyzed for each virus. 
Statistical Analysis 
 Statistical analysis was performed using Graph Pad Prism Software (GraphPad 
v8.4.2). Viral growth was analyzed using two-way anova with a Bonferroni post test 
correction. Differences were considered significant if p <.05. Plaque was analyzed using 
an unpaired t-Test. Differences were considered significant if p <.05. 
Results 
To study the effect that HA and NA glycosylation has on virus fitness, a panel of 
viruses based off of the prototypic 3c.2a viruses A/Bethesda/0055/2015 and 
A/Columbia/0041/2014 were created. While both of these isolates have the same HA 
glycosylation genotype (158 HA Gly+), they differ in their NA glycosylation status at 
position 245-247. Recombinant viruses were generated with the four possible HA and 
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NA glycosylation genotypes to study this hypothesis. Two viruses with the HA 
glycosylation and only differing in NA glycosylation were rescued. These viruses are 
designated as 245 NA Gly+ 158 HA Gly+ and 245 NA Gly- 158 HA Gly+. Two additional 
recombinant viruses were produced with an HA missing the n-linked glycosylation site. 
These viruses, 245 NA Gly+ 158 HA Gly- and 245 NA Gly- 158 HA Gly-, differ in NA 
glycosylation but lack the HA glycosylation at position 158-160. All four recombinant 
viruses were created using the contemporary H3N2 A/Victoria/361/2011 internal 
segments and only differ in the amino acids involved in HA n-linked glycosylation 
(position 158-160) or NA glycosylation (position 245-247) The HA glycosylation is 
predicted to cover antigenic site B of the protein. A 3D model of both the HA 158 Gly+ 
(Figure 5.1A) and HA 158 Gly- (Figure 5.1B) reveals that this glycosylation site is near 
the sialic binding pocket of the HA protein.  
 N-linked glycans can dramatically alter the function of a protein, especially viral 
HA and NA proteins [252, 253]. Previous work has shown that the HA 158 glycosylation 
now present in many circulating H3N2 viruses masks an important antigenic epitope on 
the HA protein and protects the HA protein from antibody mediated neutralization [81, 
254, 255]. We hypothesized that the addition of an n-linked glycan would have an 
additional effect of altering the glycan specificity of the HA protein, due to its proximity to 
the receptor binding pocket.  We used two recombinant viruses (HA 158 Gly+ 245 NA 
Gly+ and HA 158 Gly- 245 NA Gly+) in a glycan array to assess sialic acid binding 
preference. The HA 158 Gly- virus bound to a few synthetic glycans and strongly 
preferred glycans with a α2,6 sialic acid linkage (Figure 5.2A, Table 5.1). Furthermore, a 
number of the highest binding ligands for the HA 158 Gly- virus were single chain and 
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short glycans (Table 5.1). The majority (18/20) of the synthetic ligands contained 
galactose as the penultimate sugar. Conversely, the HA 158 Gly+ virus displayed strong 
binding to α2,3 sialic acid and had much broader preference for on the glycan array 
(Figure 5.2B, Table 5.2). Many of the highest binding glycans for this virus were 
complex, multi-antennary glycans (Table 5.1) and all of them contained galactose as the 
penultimate sugar. Additionally, while not canonically considered influenza receptors, 
the HA 158 Gly+ protein bound to a number of non-traditional sialic acid linkage (2,8 
linkage). Influenza A viruses have been shown bind 2,8 sialic acid in other glycan array 
studies, but their biological relevance to virus replication remains to be elucidated [75, 
256, 257]. The difference in glycan array binding between these two viruses is striking. 
The addition of the 158 glycosylation on the HA protein appears to broaden the receptor 
preference, which is somewhat of a surprise as we hypothesized that a large bulky 
glycan would limit the ability of ligands to enter the receptor binding pocket of the HA 
protein. However, we did not see a dramatic change in preference for the penultimate 
sugar in the chain, suggesting that the 158 glycan does not play a role in recognition of 
other molecules in the sialic acid containing ligands. While microarray analysis cannot 
give a quantitative analysis of binding preferences between viruses, there is clearly a 
qualitative difference in receptor binding specificity.  
 Because there was a striking difference in receptor binding between viruses 
differing in HA 158 glycosylation, and we have previously shown that NA 245 
glycosylation status dramatically impacts virus fitness, we decided to assess the viral 
fitness of the four recombinant viruses with different HA and NA proteins. We first 
characterized the four recombinant viruses (158 HA Gly +/- and 245 NA Gly +/-) with a 
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low MOI growth curve on immortalized Madin-Darby Canine Kidney epithelial cells. The 
viruses with the 158 HA Gly- protein replicated better than viruses with the 158 HA Gly+ 
protein, regardless of NA genotype (Figure 5.3A). Suggesting that the HA protein 
dictated replication fitness, and no combination of HA or NA was significantly better than 
the rest on MDCK cells. We next characterized the panel of viruses on primary hNEC 
cultures. Previously, we showed that the 245 NA glycosylation significantly impacts 
virus replication on hNECs when paired with a HA 158 Gly+ protein [211]. Within the 
pair of 158 HA Gly+ viruses, the virus with the 245 NA Gly- genotype replicated 
significantly better than the virus with the 245 NA Gly+ genotype, replicating previous 
results (Figure 5.3B). With the other pair of viruses (HA 158- 245 NA +/-) the same trend 
holds true, where 245 NA Gly+ decreases viral replication. Overall, in hNEC cultures the 
combination of HA 158 Gly- 245 NA Gly- replicated to the highest titer out of all four 
viruses. Plaque size and morphology was assessed via plaque assay on MDCK cells. 
All four viruses produced distinct plaques (Figure 5.3C) with no significant difference in 
plaque area (Figure 5.3D). However, viruses with the 158 HA Gly+ genotype had a 
visibly different plaque morphology and did not produce plaques as clear as the 158 HA 
Gly- viruses.  
Discussion 
In this study we demonstrated that the H3N2 158 HA glycosylation present in all 
circulating 3c.2a clade and all subclades does change receptor binding of the H3N2 
3c.2a HA 158 Gly+ virus (Figure 5.1, 5.2) and virus replication (Figure 5.3). We aimed to 
study how this HA 158 glycosylation and associated HA receptor binding changes 
would impact virus replication in both immortalized MDCKs and human primary nasal 
epithelial cells. In immortalized MDCK cells, regardless of NA genotype, recombinant 
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viruses expressing the HA 158 Gly+ protein replicated worse than the HA 158 Gly- 
recombinant viruses (Figure 5.3A). NA genotype had no perceptible fitness effect in 
immortalized MDCK cells. This suggests that the HA 158 glycosylation is impacting viral 
fitness in this cell culture system. When using a physiologically relevant cell culture 
system of hNECs the same trend holds true. All four recombinant viruses used in these 
assays have different growth kinetics. First, the pair of the recombinant HA 158 Gly- 
viruses, the virus with the HA 158 Gly- 245 NA Gly- genotype replicated to a higher titer 
than the HA 158 Gly- 245 NA Gly+ virus (Figure 5.3B). In the pair of HA 158 Gly+ 
viruses, a similar trend holds where the HA 158 Gly+ 245 NA Gly+ protein replicates to 
a significantly lower titer compared to the HA 158 Gly- 245 NA Gly- recombinant virus. 
Taken together, these results suggest that suggesting that the NA protein genotype 
drives the replication phenotype in hNEC cells, regardless of HA protein. 
In our hNEC studies, the HA 158 Gly- 245 NA Gly- virus replicated the best on 
hNECs, suggesting this virus would be the most fit in the human population. However, 
currently circulating strains all contain the 245 NA Gly+ gene and many have the HA 
158 Gly+ protein. This indicates that regardless of increased replication fitness in in vitro 
models, evading host immune pressure via n-linked glycosylation is the major 
determinant of virus fitness and the ability of a virus to persist. Highlighting this is the 
fact that the HA 158 Gly+ 245 NA Gly+ virus was the dominant circulating strain at the 
end of the 2015 influenza season but showed the lowest growth on hNEC cultures in 
this study. While there is a significant replication fitness disadvantage, it’s likely the 
ability to evade pre-existing HA and NA antibodies in the population far outweighed the 
loss of viral replication fitness in hNEC cultures and human hosts. 
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While we showed that the HA 158 Gly+ protein bound to a broader array of 
synthetic ligands it’s worth noting a few caveats to this finding. At this point there have 
been no studies demonstrating presence of the synthetic ligands in the CFG synthetic 
glycan array version 5.3 in MDCKs and other tissue culture systems. Therefore, it’s 
possible that the HA 158 Gly+ receptor has an enhanced binding to ligands that aren’t 
physiologically relevant in either cell culture system tested. Influenza HA and NA 
proteins have a balanced interaction to the viral receptor, sialic acid. Both proteins are 
necessary for in vivo replication, but the nuance of their interaction is important as well. 
Too strong of an HA-sialic acid interaction compared to NA activity results in the HA 
protein being trapped in respiratory mucins or not being able to release progeny virions 
from the infected cell [98, 99, 258]. On the other side of the spectrum, too weak of an 
HA-sialic acid interaction compared to NA activity results in removal of sialic acid 
receptors before the HA protein can engage its ligand and initiate infection. This fine 
balance between affinity for sialic acid impacts virus fitness. It’s possible that binding to 
a broader array of ligands disrupts the HA NA balance in viruses with the HA 158 Gly+ 
genotype, regardless of NA function, as shown by our results. However, more studies 
are necessary to prove this hypothesis. 
This study highlights the necessity to study multiple aspects of viral fitness when 
considering influenza virus evolution. While both the 158 HA and 245 NA n-linked 
glycosylations impacted protein function, there is no obvious replication fitness 
advantage to encoding both of these n-linked glycosylations on their respective 
proteins. In the years since the introduction of the H3N2 3c.2a clade, numerous 
subclades such as the 3c.2a1 and 3c.2a2 have evolved and replaced the parental 3c.2a 
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clade. Future studies into how these subclades and the associated amino acid changes 
impact HA receptor binding and replication fitness are necessary to further understand 

















































Figure 5.1: Structure of A/Bethesda/55/2015 HA trimer with or without 158-160 
glycosylation used in recombinant virus preparation 
 (A) A/Bethesda/55/2015 HA (158 HA Gly+) with added simple glycosylation added at 
amino acid 158. (B) A/Bethesda/55/2015 HA (158 HA Gly-) without glycosylation due to 
removal of putative glycosylation sequence via site directed mutation of HA segment 
(T160K, H3 numbering). Figures prepared using HA trimer structure from 
A/Victoria/361/2011 (PDB 4WE8) via UCSF Chimera software. Glycosylation added via 







Figure 5.2: Glycan array analysis of two recombinant H3N2 viruses with different 
HA proteins 
158 HA Gly- (A) 158 HA Gly+ (B) were subjected to glycan array analysis. Y axis 
indicates raw RFU, X axis indicates specific glycan ID. α2,3 Sialic acid containing 
ligands in blue box (glycans 2-68), α2,6 sialic acid containing glycans in off white box 
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Table 2.4 in Chapter 2 for glycan ID and chemical structure. See Table 5.1 and 5.2 for 































































Figure 5.3: Replication of recombinant H3N2 viruses in MDCK cell cultures 
 Low MOI growth curves using MDCK at (A) or hNEC (B) with the indicated 
recombinant viruses. Hours post infection (HPI) on X axis, Log of TCID50/ml on Y axis.  
Data were analyzed with *p<.05 and two-way repeated measures ANOVA with 
Bonferroni multiple comparison posttest. The limit of detection (L.O.D.) is indicated with 
a dotted line at log 2.37 TCID50/ml. Error bars in A and B are SEM, error bars in D are 
SD. (C) Plaque assay performed with indicated recombinant viruses. (D) Quantification 
of plaque area from 20-30 individual plaques per virus from 2 independent experiments. 
*p<.05 unpaired T test.  
A B 
C D 
245 NA Gly- 
HA 158 Gly+ 
245 NA Gly+ 
HA 158 Gly+ 
245 NA Gly+ 
HA 158 Gly- 
245 NA Gly- 
HA 158 Gly- 
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Table 5.1: HA 158 Gly- CFG synthetic glycan array binding data 
A/Bethesda/55/2015 HA158 Gly- used in CFG synthetic glycan array top 20 values. 
Sialic acid orientation indicated (α2,3 vs α2,6). RFU average was calculated by taking 
the 4 highest RFU values (out of 6 technical replicates). Out of the top 20, 11 glycans 
contain α2,6 sialic acid (SA) linkages and 9 contains α2,3 SA. 






4GlcNAcb-Sp0 38440 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-
3Galb1-4(Fuca1-3)GlcNAcb-Sp0 36956 α2,6 




4GlcNAcb-Sp12 23608 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb-Sp8 21033 α2,6 
Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 19416 α2,6 
Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 17384 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-
3)GalNAca-Sp14 12822 α2,6 
Neu5Aca2-6Galb1-4GlcNAcb-Sp0 12036 α2,6 
Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 10215 α2,6 
Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-
Sp21 2923 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 1531 α2,3 
Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 1339 α2,3 
Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 1330 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 1122 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 1043 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-
4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-
4GlcNAcb-Sp21 1033 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 907 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 622 α2,3 
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Table 5.2: 158 Gly+ HA CFG synthetic glycan array binding data 
A/Bethesda/55/2015 HA158 Gly+ used in CFG synthetic glycan array top 20 values. 
Sialic acid orientation indicated (α2,3 vs α2,6). RFU average was calculated by taking 
the 4 highest RFU values (out of 6 technical replicates). Out of the top 20, 8 glycans 
contain α2,6 SA linkages and 12 contains α2,3 SA. 






3Galb1-4(Fuca1-3)GlcNAcb-Sp0 54486 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-
3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 41319 α2,3 
Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 39017 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 38168 α2,3 




4GlcNAcb-Sp12 36718 α2,6 




4GlcNAcb-Sp21 35713 α2,3 
Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0        35059 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-
2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-
3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 34130 α2,3 
Neu5Aca2-3Galb1-3GalNAca-Sp8 33454 α2,3 
Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-
3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 31563 α2,3 
Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-
Sp14 30540 α2,3 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-
4GlcNAcb-Sp0 29887 α2,6 
Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 29466 α2,3 
Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 29191 α2,6 
Neu5Aca2-6Galb-Sp8 28754 α2,6 
Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 28666 α2,6 






















This dissertation improves the understanding of how the HA protein impacts LAIV 
vaccine effectiveness and how the NA protein impacts virus replication. By studying 
how egg adaptation of the LAIV vaccine strains increases viral attenuation, I showed 
that the current method of manufacturing the LAIV vaccine dramatically impacts HA 
receptor function and LAIV fitness. In my studies with the NA protein of recent H3N2 
viruses, I was able to show how an n-linked glycosylation sequence on the H3N2 NA 
significantly decreased enzymatic function of the protein, virus replication, but ultimately 
provided a significant benefit in blocking the ability of neutralizing antibodies to bind and 
inhibit the protein. While recent N-linked glycosylation sites added to the H3N2 HA 
protein impact receptor function and decrease viral replication, there is no significant 
change in the balanced activity of the H3N2 HA and NA proteins. Taken together, this 
work has progressed our understanding of the LAIV attenuation phenotype, how 
evolution of the NA impacts virus fitness and antigenicity, and how glycosylations to the 
HA protein dramatically impact HA protein function and virus fitness. The research 
within this dissertation highlights the need to continuously assess the effects that 
evolution of viral proteins other than HA has on virus fitness and antigenicity. 
Advisory Committee on Immunization Practices Has Recently Reversed Ruling in 
2016-17 Which Advised Against LAIV Vaccination 
 During the 2014-2016 influenza seasons, the LAIV had little or no protection 
against circulating H1N1 strains in vaccinated children [163, 170, 171]. LAIV has 
historically been shown to offer greater protection for children between 2 and 17 years 
of age, compared to the IIV “flu shot” vaccine formulation [170, 171]. LAIV induces a 
systemic IgG response and a mucosal IgA and IgG response. Furthermore, LAIV 
induces a cytotoxic and helper T cell response, with reports of influenza-specific 
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follicular helper T cells being induced in the tonsils shortly after vaccination [259, 260]. 
For these reasons, a multi-armed and robust immune response, LAIV is theoretically an 
excellent vaccine. Multiple studies indicate that LAIV induces a broad, cross reactive T 
cell response to conserved epitopes between the LAIV strain and circulating isolates, 
even if the vaccine is considered a mismatch [261-264]. These cross reactive T cells 
theoretically make LAIV a better vaccine platform than the IIV, which does not 
consistently induce a cellular immune response [265, 266]. However, during the 2014 
through 2016 seasons the effectiveness of the H1N1 component was significantly lower 
than the IIV, suggesting that the lack of effectiveness was due to LAIV viral replication 
and not an antigenic mismatch. There have been a number of hypothesis as to why this 
happened, but most have been disproved. Some hypothesized that because this H1N1 
LAIV deficiency occurred in a similar timeframe as the CDC recommending that both 
the IIV and LAIV become four strain vaccines, adding an additional influenza B strain, 
that the added vaccine strain could be interfering with H1N1 LAIV in some manner [267-
269]. However, data suggests that both the LAIV 3 (H1N1, H3N2 and one influenza B 
strain) has similar H1N1 issues as the LAIV 4 (LAIV 3 with an additional influenza B 
strain) [267]. Another hypothesis was that previous vaccination history could interfere 
with LAIV effectiveness. This hypothesis suggests that pre-existing antibodies are 
neutralizing the H1N1 component of the LAIV before the virus can infect respiratory 
epithelial cells, mainly because the H1N1 component had not been dramatically 
changed since the emergence of the 2009 pandemic H1N1. The results are not clear 
cut as some studies suggest that naïve children have a higher rate of LAIV vaccine 
response and other studies suggest that vaccination and infection history do not 
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significantly impact vaccine efficacy. [270, 271]. Thermo stability of the H1N1 vaccine 
component was one potential issue with the LAIV effectiveness but this has also been 
ruled out. The updated H1N1 LAIV strain used between 2014 and 2016 
(A/Bolivia/559/2013) was proven to be thermostable [272, 273]. The most compelling 
reason of H1N1 LAIV ineffectiveness came from the manufacturer, MedImmune. 
 Since the introduction of 2009 pandemic swine-H1N1 into the human population, 
a number of viral replication deficiencies have been noted [274-277]. In general, when 
novel viruses emerge in the human population mutations in the HA, NA and/or multiple 
polymerase genes need to occur for a replication competent virus in human patients. 
This is due to HA receptor preferences, HA/NA balance, and the ability of the 
polymerase and non-structural genes to interact with host cell components and 
efficiently replicate in different species cell types [275]. These “species jump” issues are 
likely the root of the pandemic H1N1 LAIV replication issues. Historically, MedImmune 
has routinely screened LAIV vaccine strains for the ability to infect MDCK cells, with the 
fluorescent focus assay. While this assay tests the ability for LAIV to infect immortalized 
cells, it does not assess the ability of the vaccine virus to carry out multiple rounds of 
replication, nor the ability to infect more physiologically relevant hNECs [176]. During 
the two year period in which the Advisory Committee on Immunization Practices (ACIP) 
did not recommend LAIV in the United States, MedImmune revamped the protocol for 
testing LAIV vaccine strains [176]. They found that while the H1N1 component of LAIV 
from 2014-2016 (A/Bolivia/559/2013) was able to infect MDCKs, the virus showed a 
decreased ability to carry out multiple rounds of replication and had a significantly 
decreased ability to infect hNECs [176]. These new tests that MedImmune and other 
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members of the Pekosz Lab conducted suggest that the HA of the H1N1 LAIV 
component was significantly impairing viral replication competence. The new strain of 
H1N1 LAIV, A/Slovenia/2903/2015, has shown enhanced replication competency in 
both immortalized and primary hNECs, and the new strain showed similar vaccine 
effectiveness to the IIV formulation in studies in the UK [274, 278, 279]. Even though 
the H1N1 LAIV appears to once again be a functional component, the underlying issues 
of LAIV and viral replication competency still exist. 
LAIV Replication Deficiencies Impact Vaccine Effectiveness 
 Historically, LAIV and to a greater extent other live attenuated vaccine are the 
gold standard of vaccines. These replication competent viruses antigenically mimic 
virulent circulating strains, but do not cause the level of disease associated with a 
natural infection. As discussed in Chapter 2, the dogma of LAIV has always been to use 
any H1N1 or H3N2 HA and NA proteins and create a temperature sensitive attenuated 
vaccine with the LAIV backbone [280-285]. The resulting virus will induce antibodies 
which should neutralize wild type viruses but not be able to cause significant disease. 
The recent issues with the H1N1 LAIV component should be cause for concern. The 
problem is twofold.  
For one, it appears that certain strains of H1N1 IAV have an HA that, when 
combined with the LAIV backbone, will produce a replication deficient virus. This 
suggests that not all HA proteins from any circulating IAVs will be suitable for LAIV 
production. There are five amino acid differences in the HA protein between the poor 
H1N1 LAIV component from 2014-2016 (A/Bolivia/559/2013) and the updated H1N1 
LAIV component for 2018-2020 (A/Slovenia/2903/2015). These amino acid changes 
(A39T, S101N, S179N, I233T, P288Q) are not in any canonical functional sites of the 
 144 
HA protein, but it’s important to note that S179N results in a putative n-linked 
glycosylation site [286-289]. How these amino acids change HA function remains to be 
studied, but the important point is that these amino acid changes completely change the 
effectiveness of the LAIV vaccine without significantly altering antigenicity of the protein. 
Moving forward, this problem of amino acid differences dramatically and unexpectedly 
impacting function could continue to cause issues with LAIV effectiveness. If we 
extrapolate this issue to a worst-case scenario, a potential animal reservoir pandemic 
influenza virus could also be incompatible with our current LAIV platform. Some studies 
with an avian influenza H7N9 LAIV virus show the H7N9 based LAIV is safe and 
effective in humans and ferrets, but it’s impossible to know for every potential pandemic 
virus and the potential HA proteins [290-292].  
 The second issue with LAIV, as discussed in Chapter 2, relates to egg adaptation 
of all LAIV and IIV vaccine strains. The issue of egg adaptation is an unfortunate side 
effect of mass-producing vaccine antigen [76, 117, 121, 124]. Circulating viruses 
isolated form humans are passaged in eggs multiple times create a high growth 
reassortment that’s used for vaccine testing and manufacturing [293-295]. Many amino 
acid changes occur in or around the receptor binding site, dramatically altering the 
receptor function of the HA protein. As studied in Chapter 2, I found that three amino 
acid changes that occurred in the H3N2 component of the LAIV in 2012/13 reduced 
replication of the LAIV strain in both immortalized and primary hNECs. Furthermore, 
these egg associated HA mutations led to a decreased innate immune response at both 
32ºC and 37ºC.  
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 There are both studies and currently licensed technologies for overcoming the 
egg associated mutations. Balancing high growth in eggs and maintaining genetic 
integrity of the HA protein is likely a non-possible outcome due to the differences 
between avian eggs and human nasal epithelium. However, one study looked at the 
incompatibility of two common egg associated mutations in the H3N2 LAIV strains, 
L294P and G186V, based on database sequence analysis. Their research showed that 
L294P significantly alters antigenicity of the protein, but it is incompatible with G186V. 
The G186V mutation does not dramatically alter the antigenicity of the protein and 
prevents the antigenic change of L294P [296-298]. Inducing the G186V mutation could 
create a vaccine virus capable of growing in eggs, but not dramatically changing the 
antigenicity of the protein. Taking these results, the next step would be to create a panel 
of H3N2 vaccine viruses and creating the G186V mutation before egg adaptation. This 
specific mutation, or others like it, could stabilize the rest of the HA protein and allow 
human isolates to grow to high titers in eggs. Using G186V egg adapted viruses, a 
rational next step would be to test their antigenicity, their ability to replicate on hNECs, 
and the ability to induce an innate immune response. While my work in Chapter 2 used 
a virus with the G186V egg associated mutation, it’s unknown how this mutation 
impacts viral fitness of both historic and contemporary vaccine strains. This method 
could be an attractive solution balancing the need of an antigenically stable LAIV 
capable of replicating in both eggs and hNECs. While this would be a “stop-gap” 
measure of using an egg adapted LAIV vaccine, it could increase the replication 
deficiencies seen with some H3N2 LAIV vaccines. 
Utilizing a Dual HA LAIV to Balance Egg Growth and Antigenic Stability 
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 Influenza viruses acquire egg associated mutations in a somewhat random 
fashion, and it’s impossible to predict how these mutations impact vaccine efficacy in 
humans. One group has published studies using a recombinant virus that expresses 
two HA proteins. This “dual HA” virus expresses the wild type HA protein and an egg 
adapted HA protein on the same virus particle [299]. This system removes the 
adaptation pressure for the wild type HA, allows the egg adapted HA protein to drive 
virus infection in eggs, which prevents wild type HA protein mutations. The virus 
replicates sufficiently in both eggs and cell culture, and still maintains the genetic 
integrity of the wild type HA protein after many passages. This approach is important 
because single amino acid changes in HA proteins can dramatically reduce vaccine 
efficacy, and this approach theoretically addresses that issue  [113, 153, 300, 301]. One 
approach to take with this recombinant virus platform is to assess the ability of this dual 
HA system with the LAIV vaccine. Applying this idea with the LAIV platform and 
assessing the ability of this virus to replicate efficiently on hNECs would be the first step 
in validating this dual HA LAIV. Additionally, assessing the dominant immune response 
to the vaccine virus would be necessary. It’s possible that, due to the phenomenon of 
antigenic sin, that the host immune response will focus on the egg adapted protein and 
not develop new antibodies to the wild type HA protein [302-314]. Technological 
breakthroughs like this study are primarily focused on bettering the IIV vaccine platform, 
but they should be assessed in the context of the LAIV vaccine. 
Utilizing a Cell Based Approach to Manufacturing LAIV  
 In addition to changing the input virus to prevent egg associated mutations, 
another approach to avoiding egg associated HA mutations is to change the substrate 
on which the virus is grown. Novartis is currently licensed to produce Flucelvax, an 
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inactivated influenza vaccine using cell culture [315]. Flucelvax is unlike traditional 
inactivated influenza vaccines because it is entirely cell grown, completely avoiding 
using eggs as a substrate. Many studies have shown that Flucelvax is at least as good 
or better than the standard egg grown influenza vaccine [316-319], showing that no 
significant antigenic differences occur when growing vaccine virus on cells. Considering 
that MedImmune is now licensed to produce LAIV via a reverse genetics approach that 
utilizes mammalian cells, growing the LAIV in cells could be straightforward and prevent 
these common egg associated mutations. There are some caveats to this approach that 
need to be considered. As reported by others, some N-linked glycosylations on the HA 
protein (specifically site 158-160 on the H3 HA) will be lost during cell or egg culture 
[247, 320-323]. The presence of n-linked glycosylations on the HA protein dramatically 
alter the antigenicity of the protein and developing antibodies against a vaccine without 
specific HA glycosylations will not efficiently neutralize viruses with specific HA 
glycosylations [324-330]. There are also other cell culture associated mutations that 
occurring during cell passage [108, 193, 330, 331]. Furthermore, the cells used to 
manufacture Flucelvax are MDCK cells. MDCK cells express the avian like α2,3 linked 
sialic acid so the issue of receptor switching could still occur when passaging human 
isolates into either cells or eggs [156]. A potential solution to the MDCK cell receptor 
issue would be to use MDCK-SIAT 1 cells, which over express the human receptor α2,6 
sialic acid [235]. Following my work in Chapter 2, it is also necessary to test how both a 
WT HA and EA HA can protect against influenza infection in either humans or ferrets. 
The WT HA protein replicated better on hNECs and induced a stronger IFN-λ immune 
response, but these two factors don’t guarantee there will be an appreciable difference 
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in efficacy between WT and EA HA LAIV vaccine strains. Following my work in chapter 
2 and utilizing a cell-based vaccine manufacturing process, I would test whether or not 
the WT HA (which maintains genetic integrity on cells) is a more effective vaccine than 
an EA HA LAIV. I would set up a study to test serum neutralizing antibody in humans 
before and after vaccination (with the appropriate placebo group). Furthermore, testing 
the ability of WT and EA HA LAIV’s to induce protection with ferrets would be another 
appropriate test. Assuming that the WT HA is a better and safe vaccine platform than 
the EA HA in these suggested experiments it would be beneficial to adjust how we 
manufacture LAIV. Combining LAIV with a cell-based approach could alleviate the 
issues of receptor switching that results in deficiencies of virus growth, innate immune 
induction, cell tropism and ultimately vaccine effectiveness.  
Temperature Sensitivity of Egg Adapted HA protein 
In Chapter 2 I demonstrated that regardless of cell type the EA HA LAIV showed 
significant attenuation at 37ºC compared to the WT HA LAIV at 37ºC. The mutations 
between this EA HA and this WT HA, H156Q, G186V and S219Y, are in known receptor 
binding or antigenic sites of the HA protein. However, the mechanism of which they 
reduce viral fitness at higher temperature (37ºC) is unclear. Many studies in the 
thermostability of the HA protein are focused on H1N1 viruses, but none of the amino 
acids pertaining to H1 HA thermostability align with either of the three egg adapted 
mutations in this H3 HA [332-334]. Furthermore, studies into protein dynamics in the ER 
suggest that there are many ER components (chaperones, calnexin and calreticulin) 
that bind to the HA protein and assist in folding and stability [333, 335, 336]. All of these 
studies are done using an H1 HA and none of the amino acid residues noted as being 
important in stability and folding align with the A/Victoria/361/2011 EA HA used in this 
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study. Therefore, the next step would be to create a panel of viruses and assess how 
the individual egg associated amino acid changes impact viral growth. This panel of six 
recombinant viruses with either single or double mutations for the EA HA amino acid 
changes would indicate which pair or single mutations causes the phenotype of 
temperature attenuation. It’s also possible that only the three amino changes together 
(H156Q, G186V, S219Y) create this phenotype however that still allow me to conduct 
experiments to determine how these amino acids impact temperature attenuation. 
Based on the amino acid(s) discovered in the viral screen the next step would be to 
identify which step in the viral life cycle is being impacted by the HA mutations. It could 
be attachment, and I would look at the infectivity of the virus at high temperatures. It 
could be protein stability or trafficking in the cell, and I would fractionate infected cells 
and see where the HA protein is localizing or if it’s being degraded. It could also be 
interaction with specific ER components, and I would test this with immunoprecipitation 
assays and determine the extent of chaperones or other ER proteins interacting with the 
HA protein. With this line of questions, I propose that discovering the mechanism behind 
this temperature-based attenuation is an important step for vaccine development in 
general. With these findings it would allow vaccine developers to understand which egg 
associated amino acid changes have a high likelihood of impacting viral fitness as well 
as increase our understanding of how the HA protein impacts viral fitness of LAIV. 
PB1-F2 Protein Emergence with 245 NA Gly+ Isolates 
 Human H3N2 viruses encode the PB1-F2 protein, a 2nd protein generated from 
the PB1 vRNA. PB1-F2 is known to be involved in modulating the host immune 
response as well as modulating aspects of viral polymerase function [210, 337]. PB1-F2 
antagonizes interferon production by interfering with the apoptotic pathway as well as 
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suppressing the mitochondrial anti-viral response (MAVS) pathway [338-344]. While not 
the focus of Chapter 3, H3N2 isolates with the 245 NA Gly+ genotype also had a 
mutation in PB1-F2 protein (H75P) during the 2014/15 season. Sequence analysis 
shows that the PB1-F2 H75P mutation fixed in the human H3N2 when the 245 NA Gly+ 
genotype emerged and fixed. All of the 3c.2a isolates from 2014/15 fell into two 
categories, 245 NA Gly- PB1-F2 75H or 245 NA Gly+ PB1-F2 75P, suggesting that 
these genes grouped together [234]. The combination of these genes should be further 
studied to understand the effect that the PB1-F2 75H genotype or PB1-F2 75P 
genotype has on viral replication. The 75th amino acid in PB1-F2 is involved in 
mitochondrial targeting and some reports suggest that a Histidine residue at position 75 
of the PB1-F2 protein decreases cellular inflammation [345, 346]. Interestingly, the 
H75P mutation found in recent isolates could increase inflammation and response to 
viral infection. The significance of such remains to be studied. To address how PB1-F2 
75 H/P impact virus fitness, I would assess how this protein impacts innate immune 
induction, viral RNA transcription, viral polymerase localization, and viral replication. 
Creating reverse genetics viruses with either PB1-F2 gene and then assessing markers 
of innate immune induction as well as host transcriptional response would address 
questions relating innate immune induction [347-350]. Levels of secreted IFN-λ as well 
as other cytokines and chemokines would be assessed in our hNEC model. Using these 
same recombinant viruses, I could assess the level of viral transcripts present in the cell 
and localization of viral polymerase components. PB1-F2 modulates viral polymerase 
activity and localization through direct interaction with the PB1 protein and this would be 
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a relatively straight forward way of understanding how this mutation impacts polymerase 
activity [344]. 
 Additionally, while the previous suggested studies would uncover the mechanistic 
role of the PB1-F2 mutation, a panel of recombinant viruses differing in both 245 NA 
glycosylation and PB1-F2 genotype should be created. These four viruses (245 NA 
Gly+/- and PB1-F2 75 H/P) could illustrate how the PB1-F2 mutation impacts virus 
replication and potentially how this mutation works in synergy with the 245 NA 
glycosylation. For example, if the 245 NA Gly+ PB1-F2 75H virus is significantly 
attenuated compared to the 245 NA Gly+ PB1-F2 75P virus it would indicate that the 
PB1-F2 75P protein was a key factor in allowing this 245 NA Gly+ virus to emerge and 
dominate the population. On the other hand, if the PB1-F2 75P decreased replication of 
the 245 NA Gly- virus, it would suggest that only the combination of 245 NA Gly+ and 
PB1-F2P would create a virus fit enough emerge in the human H3N2 population. Taken 
together, this set of experiments would lead to a greater understanding of the interplay 
of different mutations and segments with the influenza genome. These experiments 
would either uncover the functional benefit that PB1-F2 75P gives to H3N2 viruses, or it 
would indicate that the PB1-F2 mutation was a passenger and the 245 NA Gly+ drove 
the dominance of that strain that descendants of which still circulate to this day. 
Identifying the Mechanism that 245 NA Glycosylation Impacts Viral Replication 
 Neuraminidase removes sialic acid from respiratory mucins and removes sialic 
acid from both host and viral proteins when the virus is budding. In Chapter 3, I showed 
that the 245 NA Gly+ virus had a significantly decreased replication fitness on hNECs 
but not immortalized MDCK cells. Based on these findings we hypothesized that the 
presence of respiratory mucins is the driving cellular factor inhibiting virus replication.  
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 To support this hypothesis, the first step would be to assess the ability of 245 NA 
Gly +/- to infect cells with or without respiratory mucins. Respiratory mucins would be 
collected from our hNEC cultures then applied to MDCK cultures. While theoretically 
possible, using hNECs devoid of respiratory mucins through genetic modification or 
another respiratory epithelial cell line without respiratory mucins would add additional 
variables. Removing secreted mucins from hNEC cultures and adding them to MDCK 
cultures would indicate if viral replication is inhibited by the presence of soluble mucins, 
without the presence of other host cell factors of cell membrane anchored mucins 
present in hNEC cultures. If soluble respiratory mucins were not substantially impacting 
virus replication in these studies, the next step would be to test whether or not anchored 
respiratory mucins or other secreted host cell factors are inhibiting virus replication for 
the 245 NA Gly+ virus. Some groups have looked at how viruses migrate through 
respiratory mucins, showing that NA is polarized to the forward part of the virion particle 
as it moves through the respiratory epithelial cell mucin layer. Influenza HA and NA act 
as viral motors and propel the virus through mucins to the target cell. [238, 351]. 
Conducting similar experiments and tracking viral movement through mucins would be 
an important experiment to understand how the 245 NA glycosylation impacts the entry 
phase of the viral life cycle as well as viral motility. This would highlight key points in the 
viral life cycle the 245 NA glycosylation impacts replication.  
Addressing the Ability of 245 NA Gly +/- Proteins to Cleave Sialic Acid from 
Respiratory Mucins 
In a similar vein, assessing how 245 NA Gly +/- proteins interact with respiratory 
mucins would uncover how this glycosylation directly impacts physiologically relevant 
NA function. In Chapter 3 and 4, I showed that the 245 NA Gly+ NA protein had a 
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decreased reactivity towards both soluble (NA-STAR) and fixed (ELLA) substrate. 
Additionally, the 245 NA glycosylation decreases maximum velocity and affinity for 
soluble substrate. Fetuin, the substrate for the ELLA assay, contains both α2,6 and α2,3 
sialic acid and all n and o-linked sites utilize sialic in the glycan [352-355]. The o-linked 
glycans containing α2,3 sialic acid present in fetuin is not representative of the topology 
of respiratory mucins and the o-linked glycosylations on mucin proteins. Mucins in 
general contain numerous o-linked glycosylation sites adjacent to one another, which 
results in a highly glycosylated protein covered in a glycan shell [195, 198-201, 356, 
357]. Respiratory mucins can be as much as 85% by weight o-linked glycosylations 
[195, 358, 359]. Fetuin contains sporadic o-linked glycosylation sites throughout the 
protein sequence [352, 353, 355]. Utilizing a similar enzymatic substrate, either whole 
respiratory mucins or o-linked glycans in an array-like format could address how the 245 
NA Gly +/- proteins interact with physiologically relevant ligands oriented in a 
physiological relevant manner. This set of assays would highlight how the recent human 
H3N2 NA proteins interact with respiratory mucins and o-linked glycans.  
Addressing Recent NA Protein Specificity for Sialic Acid Containing Ligands  
 Following the work in Chapters 3 and 4, one important question remaining is to 
address is the specificity of recent H3N2 NA proteins with the added 245 NA 
glycosylation. Glycosylations change the HA protein preference for different 
carbohydrates present in sialic acid containing receptors and this has implications of 
altering cell tropism and receptor activity [81, 82]. In recent years the composition of the 
ligand and not just α2,6 vs α2,3 sialic acid has becoming increasingly relevant in HA 
receptor function. At this time, little is known if the NA protein has a similar preference 
for the penultimate sugar in sialic acid containing molecules or the complexity of the 
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glycan that contains sialic acid moieties. Based on the glycan array data in Chapter 2 
and 5, assessing the ability of these NA proteins to remove sialic acid from an array of 
sialic acid containing ligands could offer insight to the specificity of the 245 NA Gly+ and 
245 NA Gly- proteins. These assays would likely have to be optimized to rule out the HA 
protein interfering with results, such as using virus like particles or a functionally 
defective HA protein. With this set of experiments, I could determine whether certain 
ligands are preferentially targeted for NA activity and whether or not the 245 NA 
glycosylation impacts the recognition of different sugars in a glycan chain. For example, 
I could determine if H3N2 NA proteins preferentially bind to single chain sialic acid 
containing ligands or multi-antennary ligands, and how glycosylations impact this 
preference. General characteristics of the complexity and composition of ligands 
preferred by recent human H3N2 NA proteins would be valuable information to 
determine how the 245 n-linked glycan changes the interaction between viral protein 
and substrate.  
Neuraminidase Immunity Can Still be Utilized as a Universal Vaccine 
Before the 245 NA glycosylation event that swept the circulating human H3N2 
viruses, many groups had suggested the possibility of targeting the active site as a 
potent universal vaccine [88, 89, 241]. While this is likely no longer possible for H3N2 
viruses, it is still possible for all H1N1 viruses and Influenza B viruses that circulate in 
the human population. Universal vaccines should be developed to target as many 
influenza strains as possible [215, 217, 360]. Comparing other influenza virus NA 
sequences to that of currently circulating H3N2 viruses, shows that no other isolates 
appear to have a putative n-linked glycosylation site near the active site of the NA 
enzyme. Therefore, targeting the active site of the highly conserved NA protein is still an 
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attractive candidate for a nearly universal influenza vaccine. As discussed in Chapter 3 
the epitope targeted by the HCA-2 mAb inhibits all influenza A and B viruses, with the 
notable exception of post 2015 human H3N2 isolates. The ability of this antibody and 
others like it to be a quick line of defense against newly emerging zoonotic influenza 
viruses should not be overlooked, and in my opinion should be developed as part of the 
influenza pandemic threat preparedness [361, 362]. Since there is little to no immune 
pressure in animal reservoirs of influenza viruses, there will be no pressure on these 
animal reservoir influenza viruses to add glycosylations that would block anti-NA active 
site antibodies. The swine flu pandemic of 2009 originated from the human Spanish flu 
of 1918. In the nearly 100 years this virus was in swine the antigenicity of the strain 
changed very little. This highlights the fact that the antigenicity of influenza viruses, 
specifically the HA protein, changes significantly only under immune pressure [363]. 
Therefore, utilizing an immunization strategy that targets virtually all the animal reservoir 
influenza viruses is an attractive candidate for vaccine development. With this 
knowledge, the ability of whole NA protein or specific epitopes from the active site could 
be evaluated for inducing a broad nearly universal vaccine in mice or ferrets. The HCA-
2 Ab, used in Chapter 4, recognizes a linear epitope. This antibody was first developed 
by immunizing rabbits and could be utilized in a similar manner to induce broad 
immunity in ferrets and mice. 
Identifying Antigenic Epitopes of H3N2 neuraminidase protein and NA Immunity 
Previous work has shown that treating mice with serum raised against a 245 NA 
Gly- virus could not protect against challenge with a 245 NA Gly+ virus, they did not 
look at an appropriate transmission model nor a vaccination challenge model [109]. At 
this point we don’t know how antibodies against the NA protein impact transmission of 
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the virus, we only know that they correlate with decreased disease severity in humans 
[89, 209, 240, 364]. Many studies have looked at using monoclonal NA specific 
antibodies in preventing viral infection but assessing the polyclonal response to NA is a 
logical next step. Questions such as age and sex differences in NA antibodies affinity, 
quantity or specific NA immune epitopes should be investigated as they have been with 
the HA protein. Neutralizing antibodies that target the HA protein have been well 
documented to decline based on age and sex and these same questions need to be 
addressed with NA antibodies [365-369]. The question remains how recent changes in 
the NA protein affect antigenicity. The HA protein regularly mutates antigenic sites in an 
effort to evade humoral immunity, and even minor point mutations in the HA protein can 
reduce neutralizing antibody reactivity [365]. Neuraminidase antigenic mutation can be 
addressed using human serum samples from numerous years and a panel of NA 
proteins. Assessing NA antibody binding and neutralization of virus infection would 
indicate how the human immune response recognizes various NA proteins and how 
viral evolution changes this response. Additionally, neuraminidase antibodies in nasal 
swab or nasal pharyngeal washes are correlates of protection against influenza [221]. 
The specificity and affinity of these neuraminidase mucosal antibodies (IgA and IgG) 
has yet to be determined and could be done with infected patients nasal wash samples 
or animal models. For example, do mucosal IgA antibodies target conserved regions of 
the NA protein (such as the enzymatic pocket) or are they broader and more diverse in 
recognition? There are numerous questions needed to be answered about how the 
antigenicity of the evolving NA protein can be utilized to effectively vaccinate individuals, 
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and these experiments would further our understanding of the systemic and local 
immune response to neuraminidase. 
Neuraminidase Immunity and Antigenic Sin 
Antigenic sin refers to the phenomenon where conserved epitopes within an 
antigen are boosted instead of developing a novel response [303, 308, 310, 311]. For 
example, patients that receive their first influenza vaccine or natural infection are more 
likely to repeatedly boost the response specific epitopes first encountered and not 
develop antibodies towards recently changed epitopes. For the NA protein, one would 
ask if antigenic sin has occurred in the human population and that is what drove the 
emergence of the 245 NA glycosylation genotype. Virtually all influenza A and B viruses 
that circulate in humans share a linear epitope within the NA protein active site as well 
as many other shared 3D epitopes on the NA protein [88, 89, 241]. The ability of 
patients to recognize these shared epitopes would indicate that humans have a 
tendency to focus on highly conserved epitopes across all influenza viruses, thus 
proving a version of NA antigenic sin. To test this, repeated infection in animal models 
with different HA/NA proteins would show the ability of the host immune system to boost 
the immune response to a specific NA epitope- and potentially develop a novel almost 
universal vaccine strategy. There are certain studies designed to induce HA stem 
antibodies by sequential vaccination with H1, H7, H9 and H11 proteins. These HA 
proteins all share similar epitopes on the stem of the molecule and not the head [370, 
371]. This study could be redesigned by sequential vaccination with N1, N2, N3 (etc.) 
and then screen the resulting serum for epitopes that are recognized in the NA protein. 
The screen could be done with whole NA protein or a phage display experiment. While 
a phage display assay only tests linear epitopes, it would be a valuable tool to rapidly 
 158 
screen many patients’ serum for presence of conserved recognized epitopes [372-374]. 
I hypothesize that the enzymatic pocket would be the immunodominant epitope after 
such a study, and it would suggest that repeated infection with influenza predisposes 
people to boost the humoral immune response to this common epitope. Studies like this 
would show how the immune response to NA can be targeted at only specific epitopes 
and ignore other antigenic regions of the NA protein and would offer new insights into 
the immunodominant epitopes in the NA protein. Alternatively, if only the enzymatic site 
of the NA protein is targeted, it would suggest that this epitope is immunodominant and 
targeting other regions of the NA protein does not result in neutralizing protein function 
of virus infectivity. Additionally, it would offer evidence that continuous immune pressure 
lead to the emergence of the H3N2 245 NA glycosylation.  
Evaluate NA Antibodies Contribution to Antibody Dependent Cellular Cytotoxicity 
(ADCC) 
 Neutralizing antibodies that target and neutralizing the influenza HA protein are 
the largest contributor to preventing infection and decreasing disease severity [375]. 
However, the ability of non-neutralizing antibodies to aid in viral clearance and bolster 
the immune response are an often-overlooked aspect of protective immunity [376]. The 
ability of NA specific antibodies to stimulate a non-neutralizing immune response 
pathway is largely unstudied. In this dissertation the NA immunity work was focused 
largely on monoclonal antibodies and specific epitopes. However, the immune response 
to the HA and NA of influenza A viruses is polyclonal in nature. Therefore, testing the 
ability of human serum samples from taken from patients with contemporary influenza 
infections to stimulate the ADCC pathway and assess the polyclonal non-neutralizing 
response to influenza NA would be an important experiment to fill this gap in our 
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understanding of influenza immunity. Many groups infect immortalized MDCK cells then 
use human serum and effector cells (e.g., Jurkat immortalized T cells) to test ADCC 
antibodies against HA proteins [376-379]. I would focus on NA specific antibodies by 
expressing NA proteins in the absence of any other influenza proteins. Studying how 
the 245 NA glycosylation impacts the ADCC response with human serum would further 
expand our knowledge how this NA glycosylation impacts another facet of the immune 
response. This experimental plan would add to our knowledge of how NA protein 
evolution evades non-neutralizing antibodies, and if NA specific non-neutralizing 
antibodies play a major role in the immune response to influenza infection.  
Conclusion 
Traditional influenza vaccines rely on a decades old manufacturing process, one 
which routinely leads to severe seasons and underperforming vaccine components. 
Current vaccination formulation procedures have been insufficient to respond quickly to 
a rapidly changing virus under constant immune pressure, and even when the correct 
strain is chosen the reliance on growing most influenza vaccines in eggs can lead to 
complete failure of a vaccine component. Even though the LAIV vaccine is a relatively 
new influenza vaccine, only being approved in the United States in September of 2003, 
there have been numerous documented issues with antigenicity and efficacy. While the 
work in this dissertation focused on one vaccine component in one influenza season, 
the same findings can apply to each year’s LAIV vaccine. Egg adaptation and the 
unknown result of combining certain HA proteins with the LAIV vaccine platform can 
result in an over-attenuated low efficacy LAIV vaccine. The idea that HA protein plays a 
role in attenuation is not a novel concept, but the improvements outlined in the 
dissertation could alleviate the unpredictable efficacy of each years LAIV strain. 
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A common theme in studying influenza is the rapid evolution of each segment in 
response to a variety of host pressures. When glycosylation changes occur within the 
influenza HA protein, the vaccine has been shown to fail due to dramatic antigenicity 
changes. The finding that glycosylation changes that happen to the NA protein and 
dramatically impact humoral immunity and virus fitness is a novel finding presented in 
this dissertation. This dissertation shows that the influenza virus will incur a significant 
fitness advantage at the benefit of blocking the activity of NA specific neutralizing 
antibodies. Since nearly all H3N2 viruses have undergone this cost-benefit process, it 
suggests that NA immunity plays a large role in the human immune response and 
deserves further attention. NA immunity is not a recent finding in the influenza 
community however NA immunity deserves an equal consideration when developing 
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